ICPE 2009
25TH ANNIVERSARY

International Conference
On Pharmacoepidemiology & Therapeutic Risk Management

Final Program
August 16-19, 2009
Rhode Island Convention Center
Providence, RI

Jointly sponsored by
• International Society for Pharmacoepidemiology
• Program in Pharmacoepidemiology and Pharmacoeconomics, College of Pharmacy, University of Rhode Island
• School of Medicine and College of Pharmacy, Virginia Commonwealth University
• The Brown University Program in Public Health

Photo credit: Providence/Warwick Convention & Visitors Bureau
You will notice that the “ICPE 25th Anniversary” logo has been appended to selected sessions. These sessions have been selected because the topics are broad and reach into the future of our field.
Ana Afonso
Kadir Alam
Anna Birna Almarsdóttir
Keith Altman
Daniel Ankrah
Ariel E. Arias
Ali Artaman
Darren Ashcroft
Annlouise Assaf
Kathleen Beach
Begler Begovic
Paul Benninger
Dimitri Bennett
Bhajish Bharathan
Pipasha Biswas
William Blumentals
Rhonda Bohn, FISPE
Nancy Brandenburg
M. Miles Braun, FISPE
Kimberly Brodovicz
M. Alan Brookhart
Jeffrey Brown
Bin Cai
Herve Caspard
Jordi Castellsague
Yan Chen
Jennifer Christian
Barton Cobert
Alexander Cole
Lyn Colvin
Michael Cook
Deborah Covington
Suellen Curkendall
Wanju Dai, FISPE
Johan De Haes
Carl de Moor
Frank de Vries
Corinne de Vries
Rachael DiSantostefano
David Dore
Sascha Dublin
Tomasz Dyszynski
Stanley Edlavitch
Monique Elseviers
Sybil Eng
Germano Ferreira
Donnie Funch
Kari Furu
Joshua Gagne
David Gagnon
Christiane Gasse
Tobias Gerhard
Dina Gifkins
Andrew Gilbert
Earl Goehring
Jean-Pierre Gregoire, FISPE
Patricia Grossman
Jose Pedro Guerreiro
Jeff Guo
Lia Gutierrez
Gillian Hall, FISPE
Joseph Hanlon
Spencer Harpe
Kevin Haynes
Eibert Heerdink
Sean Hennessy, FISPE
Sonia Hernandez-Diaz, FISPE
Richard Hill
Michie Hisada
Alan Hochberg
Laura Home
Amalia Issa
Jessica Jalbert
Yonghua Jing
Catherine Johannes
Judith K. Jones, FISPE
Judith Kelly
Mirjam-Colette Kempf
Farhad Ali Khan
Alena Khromava
Victor Kiri
Olaf Klungel
Scott Kom
Kate L. Lapane, FISPE
Tamar Lasky
Deborah Layton
Charles Leonard
James D. Lewis, FISPE
Geoffrey Liu
Sandra Lopez Leon
Jeanne Loughlin
Kimberly Lowe
Marie-Josee Martel
Ramona Mateos-Campos
Jay McDonald
Anita McGrogan
Hans-Ulrich Melcher
Dominique Milea
Daniel Mines
Eileen Ming
Allen Mitchell, FISPE
Jingping Mo
Nicholas Moore, FISPE
Elaine Morrato
Jonathan Morris
Cristiano Moura
Pavel Napalkov
C. Ineke Neutel, FISPE
Herbert Noack
Niklas Noren
Mette Norgaard
Anthony Nunes
Jude Nwokike
Fredrik Nyberg
Susan Oliveria
Sallie Pearson
Susana Perez Gutthann, FISPE
Ingemar Persson
Jennifer Polinski
Brian J. Quilliam
Jeremy Rassen
Joe Reilly
Margaret (Meg) Richards
Roelof Risselada
Elena Rivero, FISPE
Lewis Roht, FISPE
Annalisa Rubino
Stefan Russmann
Susan Sacks, FISPE
Patricia Saddier
Maribel Salas
Nancy Santanello
Delphine Saragoussi
Bill Saunders
Hedi Schellemann
Sebastian Schneeweiss, FISPE
Marike Schoonen
Glenn Schumock
John Seeger
Harry Seifert
Sarah Sellers
Soko Setoguchi
Gloria Shalviri
Mary Lou Skovron
Emily Somers
Paul Stang, FISPE
Michael Steinbuch
Monika Stender
Til Stürmer, FISPE
Bharat Thakrar
Paula Thompson
Thierry Trenque
Gianluca Trifiro
Ilse Truter
Jerzy Tyczynski
Marianne Ulcickas Yood
Cristina Varas
Zdravko Vassilev
Priscilla Velentgas
Patrice Verpillat
Steven Vlad
Vera Vlahovic-Palcevski
Peter Wahl
Alexander M. Walker, FISPE
Alex Ward
Li Wei
Michael Wess
Sue L. West, FISPE
Jim Wilson
Fei Xue
Yu Yan
Rong-Yuan Zheng
Wei Zhou
26th ICPE
International Conference on Pharmacoepidemiology & Therapeutic Risk Management
The online abstract site will be operational by mid-December 2009.
Abstract Submission Deadline: February 10, 2010
Meeting information will be posted at www.pharmacoepi.org
### Saturday, August 15, 2009

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>11:30am - 6:00pm Registration Open</td>
</tr>
<tr>
<td>8:00am</td>
<td>1.00 - 5:00pm Introduction to Pharmacoepidemiology</td>
</tr>
<tr>
<td></td>
<td>555AB</td>
</tr>
<tr>
<td></td>
<td>6:15 - 6:30pm Journal Club</td>
</tr>
<tr>
<td></td>
<td>555AB</td>
</tr>
<tr>
<td>9:00am</td>
<td>1.00 - 5:00pm Introduction to Pharmacogenetics — Part 1</td>
</tr>
<tr>
<td></td>
<td>554AB</td>
</tr>
<tr>
<td>10:00am</td>
<td>5:00 - 7:00pm Student Meet &amp; Greet</td>
</tr>
<tr>
<td></td>
<td>Cuban Revolution Grill</td>
</tr>
<tr>
<td>11:30am</td>
<td>ISPE Board of Directors Meeting</td>
</tr>
<tr>
<td></td>
<td>Bristol/Kent - Westin</td>
</tr>
<tr>
<td>12:00pm</td>
<td>1.00 - 1:00pm B.O.D. Lunch</td>
</tr>
<tr>
<td></td>
<td>South County - Westin</td>
</tr>
<tr>
<td>1:00pm</td>
<td>1.00 - 5:00pm ISPE Board of Directors Meeting</td>
</tr>
<tr>
<td></td>
<td>Bristol/Kent - Westin</td>
</tr>
</tbody>
</table>

### Sunday, August 16, 2009

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>8:30am - 12:00pm Educational Sessions:</td>
</tr>
<tr>
<td></td>
<td>Regulatory Epidemiology/Public Health Decision Making</td>
</tr>
<tr>
<td></td>
<td>555B</td>
</tr>
<tr>
<td></td>
<td>Introduction to Drug Utilization/Health Services Research</td>
</tr>
<tr>
<td></td>
<td>555A</td>
</tr>
<tr>
<td></td>
<td>Comparative Effectiveness Review</td>
</tr>
<tr>
<td></td>
<td>556B</td>
</tr>
<tr>
<td></td>
<td>Introduction to Pharmacogenetics-Part 2</td>
</tr>
<tr>
<td></td>
<td>556A</td>
</tr>
<tr>
<td></td>
<td>Special Skills Workshop (Students Only)</td>
</tr>
<tr>
<td></td>
<td>554A</td>
</tr>
<tr>
<td>8:00am</td>
<td>12:00 - 1:30pm New Members Lunch</td>
</tr>
<tr>
<td></td>
<td>Westin Waterplace Ballroom</td>
</tr>
<tr>
<td>10:00am</td>
<td>1.30 - 6:00pm Educational Sessions: Introduction to Risk Management</td>
</tr>
<tr>
<td></td>
<td>557</td>
</tr>
<tr>
<td></td>
<td>Advanced Topics in Pharmacoepidemiology</td>
</tr>
<tr>
<td></td>
<td>Ballroom D</td>
</tr>
<tr>
<td>11:30am</td>
<td>8:00 - 7:30pm Welcome Reception/</td>
</tr>
<tr>
<td></td>
<td>Academic Showcase</td>
</tr>
<tr>
<td></td>
<td>Rhode Island State House</td>
</tr>
<tr>
<td>12:00pm</td>
<td>ISPE Committee/ Council Meetings</td>
</tr>
<tr>
<td></td>
<td>Student Council</td>
</tr>
<tr>
<td></td>
<td>Ballroom E</td>
</tr>
<tr>
<td>12:00pm</td>
<td>Fellowship &amp; Awards</td>
</tr>
<tr>
<td></td>
<td>558A</td>
</tr>
<tr>
<td>1:00pm</td>
<td>3:30 - 5:30pm Symposia &amp; Workshops</td>
</tr>
<tr>
<td></td>
<td>Automated Data Sources for Pharmacoepidemiology</td>
</tr>
<tr>
<td></td>
<td>556AB</td>
</tr>
<tr>
<td></td>
<td>Can Registries Deliver?</td>
</tr>
<tr>
<td></td>
<td>555AB</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Confounding by Indication—Epoetin</td>
</tr>
<tr>
<td></td>
<td>Ballroom B</td>
</tr>
<tr>
<td></td>
<td>Evaluating Study Designs for Drug Exposure</td>
</tr>
<tr>
<td></td>
<td>Ballroom B</td>
</tr>
<tr>
<td>3:00pm</td>
<td>Gastrointestinal Drugs: Going Beyond the Intestines</td>
</tr>
<tr>
<td></td>
<td>556AB</td>
</tr>
<tr>
<td>4:00pm</td>
<td>Improving Linking Databases</td>
</tr>
<tr>
<td></td>
<td>556AB</td>
</tr>
<tr>
<td>5:00pm</td>
<td>Personalized Medicine: Molecular and Genetic Biomarkers of Efficacy and</td>
</tr>
<tr>
<td></td>
<td>Toxicity</td>
</tr>
<tr>
<td></td>
<td>554AB</td>
</tr>
<tr>
<td>6:00pm</td>
<td>Past, Present &amp; Future of Pharmacovigilance</td>
</tr>
<tr>
<td></td>
<td>556AB</td>
</tr>
<tr>
<td>7:00pm</td>
<td>ISPE Council Meetings (Westin)</td>
</tr>
<tr>
<td></td>
<td>Academic Narragansett C</td>
</tr>
<tr>
<td></td>
<td>Government/Regulatory Narragansett B</td>
</tr>
<tr>
<td></td>
<td>Manufacturing/Service Providers Narragansett A</td>
</tr>
<tr>
<td>8:00pm</td>
<td>Student Social Event</td>
</tr>
<tr>
<td></td>
<td>Bravo Brasserie</td>
</tr>
</tbody>
</table>

### Monday, August 17, 2009

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>8:00am - 5:00pm Speaker Ready Room</td>
</tr>
<tr>
<td></td>
<td>555B</td>
</tr>
<tr>
<td>8:00am</td>
<td>8:00 - 7:30pm PDS Editorial Board (By invitation)</td>
</tr>
<tr>
<td></td>
<td>Bristol Room - Westin</td>
</tr>
<tr>
<td>9:00am</td>
<td>8:00 - 10:00am Opening General Session</td>
</tr>
<tr>
<td></td>
<td>Hall B</td>
</tr>
<tr>
<td>10:00am</td>
<td>12:00 - 1:00pm Lunch/Poster Walks/Poster Session A/Exhibits</td>
</tr>
<tr>
<td></td>
<td>Sponsored by UBC</td>
</tr>
<tr>
<td></td>
<td>Hall B</td>
</tr>
<tr>
<td>11:00am</td>
<td>10:00 - 11:00am Drug Utilization-I</td>
</tr>
<tr>
<td></td>
<td>555AB</td>
</tr>
<tr>
<td>1:00pm</td>
<td>12:00 - 1:00pm Lunch/Poster Walks/Poster Session A/Exhibits</td>
</tr>
<tr>
<td></td>
<td>Sponsored by UBC</td>
</tr>
<tr>
<td></td>
<td>Hall B</td>
</tr>
<tr>
<td>1:00pm</td>
<td>12:00 - 1:30pm Analysis Methods I</td>
</tr>
<tr>
<td></td>
<td>Ballroom B</td>
</tr>
<tr>
<td>2:00pm</td>
<td>1:30 - 3:30pm Gastrointestinal Drugs: Going Beyond the Intestines</td>
</tr>
<tr>
<td></td>
<td>556AB</td>
</tr>
<tr>
<td>3:00pm</td>
<td>ISPE Committee/ Council Meetings</td>
</tr>
<tr>
<td></td>
<td>Student Council</td>
</tr>
<tr>
<td></td>
<td>Ballroom E</td>
</tr>
<tr>
<td>4:00pm</td>
<td>3:30 - 5:30pm Symposia &amp; Workshops</td>
</tr>
<tr>
<td></td>
<td>Automated Data Sources for Pharmacoepidemiology</td>
</tr>
<tr>
<td></td>
<td>556AB</td>
</tr>
<tr>
<td>5:00pm</td>
<td>Confounding by Indication—Epoetin</td>
</tr>
<tr>
<td></td>
<td>Ballroom B</td>
</tr>
<tr>
<td>6:00pm</td>
<td>Evaluating Study Designs for Drug Exposure</td>
</tr>
<tr>
<td></td>
<td>Ballroom B</td>
</tr>
<tr>
<td>7:00pm</td>
<td>Gastrointestinal Drugs: Going Beyond the Intestines</td>
</tr>
<tr>
<td></td>
<td>556AB</td>
</tr>
<tr>
<td>8:00pm</td>
<td>Personalized Medicine: Molecular and Genetic Biomarkers of Efficacy and</td>
</tr>
<tr>
<td></td>
<td>Toxicity</td>
</tr>
<tr>
<td></td>
<td>554AB</td>
</tr>
<tr>
<td>9:00pm</td>
<td>Past, Present &amp; Future of Pharmacovigilance</td>
</tr>
<tr>
<td></td>
<td>556AB</td>
</tr>
<tr>
<td>10:00am</td>
<td>ISPE Council Meetings (Westin)</td>
</tr>
<tr>
<td></td>
<td>Academic Narragansett C</td>
</tr>
<tr>
<td></td>
<td>Government/Regulatory Narragansett B</td>
</tr>
<tr>
<td></td>
<td>Manufacturing/Service Providers Narragansett A</td>
</tr>
<tr>
<td>11:00am</td>
<td>5:00 - 6:00pm ISPE Council Meetings</td>
</tr>
<tr>
<td></td>
<td>Bristol Room - Westin</td>
</tr>
<tr>
<td>12:00am</td>
<td>6:00 - 7:30pm Student Social Event</td>
</tr>
<tr>
<td></td>
<td>Bravo Brasserie</td>
</tr>
</tbody>
</table>
### Meeting At-A-Glance

#### Tuesday, August 18, 2009

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Registration Open</td>
</tr>
<tr>
<td>7:30am</td>
<td>3rd Floor Foyer</td>
</tr>
<tr>
<td>7:30am</td>
<td>Speaker Ready Room</td>
</tr>
<tr>
<td>7:00am - 5:00pm</td>
<td>Plenary Session B, National Pharmacy, Imperial, Policies, Awards &amp; Ceremonies</td>
</tr>
<tr>
<td>7:30am - 11:00am</td>
<td>Poster Session B, Break/Posters/Exhibits Hall B</td>
</tr>
<tr>
<td>8:00am - 6:00pm</td>
<td>Exhibitors/Poster Session B, Hall B</td>
</tr>
<tr>
<td>8:00am - 9:15am</td>
<td>Annual Meeting of ISPE Members &amp; Awards Ceremony, Hall A</td>
</tr>
<tr>
<td>9:15am - 10:30am</td>
<td>Anti-Infectives</td>
</tr>
<tr>
<td>10:00am - 12:30pm</td>
<td>Information as a Basis for Risk Mgmt.</td>
</tr>
<tr>
<td>11:00am - 12:30pm</td>
<td>Measurement Methods</td>
</tr>
<tr>
<td>12:30pm - 2:00pm</td>
<td>Lunch/Poster Walks, Poster Session B/Exhibits, Hall B</td>
</tr>
<tr>
<td>2:00pm - 3:30pm</td>
<td>Cancer All Over the Place</td>
</tr>
<tr>
<td>3:30pm - 4:30pm</td>
<td>Break/Hot Topics Session: Clopidogrel: Has the Pharmacogenetics Era Arrived?</td>
</tr>
<tr>
<td>4:00pm - 5:00pm</td>
<td>Plenary Session A: Global Development, Risk Factors, Surveillance, and Comorbidities</td>
</tr>
<tr>
<td>5:30pm - 6:30pm</td>
<td>SIGs, Biologics, Drug Utilization/Health Services Research, Ballroom B</td>
</tr>
<tr>
<td>6:00pm - 7:00pm</td>
<td>Medications in Pregnancy, Molecular Epidemiology/Pharmacogenetics, Hall B</td>
</tr>
</tbody>
</table>

#### Wednesday, August 19, 2009

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Registration Open</td>
</tr>
<tr>
<td>7:30am</td>
<td>3rd Floor Foyer</td>
</tr>
<tr>
<td>8:00am - 9:15am</td>
<td>Plenary Session C, Exhibitors/Poster Session C, Hall B</td>
</tr>
<tr>
<td>9:15am - 10:30am</td>
<td>Analysis Methods II, Ballroom B</td>
</tr>
<tr>
<td>10:00am - 11:00am</td>
<td>Assessment of Prenatal Exposure to Medications, Hall B</td>
</tr>
<tr>
<td>10:30am - Noon</td>
<td>Symposium &amp; Workshops</td>
</tr>
<tr>
<td>11:00am - 12:30pm</td>
<td>RiskMAP, REMS, Challenges of Epidemiology, Ballroom D</td>
</tr>
<tr>
<td>12:00pm - 1:30pm</td>
<td>Invited Plenary, Hall A</td>
</tr>
<tr>
<td>1:30pm - 2:30pm</td>
<td>Hot Topics Session: Clorpropamide Has the Pharmacogenetics Era Arrived?</td>
</tr>
<tr>
<td>2:30pm - 3:30pm</td>
<td>The Final Word: Poster Awards, ICPE 2010 Adjournment</td>
</tr>
<tr>
<td>3:30pm - 5:00pm</td>
<td>The Future of Epidemiology, Ballroom A</td>
</tr>
<tr>
<td>5:30pm - 6:30pm</td>
<td>Using Databases for Hypothesis Generating and Hypothesis Confirmation</td>
</tr>
</tbody>
</table>

---

**Meeting At-A-Glance**

Tuesday, August 18, 2009

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Registration Open</td>
</tr>
<tr>
<td>7:30am</td>
<td>3rd Floor Foyer</td>
</tr>
<tr>
<td>7:30am</td>
<td>Speaker Ready Room</td>
</tr>
<tr>
<td>8:00am - 6:00pm</td>
<td>Plenary Session B, National Pharmacy, Imperial, Policies, Awards &amp; Ceremonies</td>
</tr>
<tr>
<td>7:30am - 11:00am</td>
<td>Poster Session B, Break/Posters/Exhibits Hall B</td>
</tr>
<tr>
<td>8:00am - 9:15am</td>
<td>Annual Meeting of ISPE Members &amp; Awards Ceremony, Hall A</td>
</tr>
<tr>
<td>9:15am - 10:30am</td>
<td>Anti-Infectives</td>
</tr>
<tr>
<td>10:00am - 12:30pm</td>
<td>Information as a Basis for Risk Mgmt.</td>
</tr>
<tr>
<td>11:00am - 12:30pm</td>
<td>Measurement Methods</td>
</tr>
<tr>
<td>12:30pm - 2:00pm</td>
<td>Lunch/Poster Walks, Poster Session B/Exhibits, Hall B</td>
</tr>
<tr>
<td>2:00pm - 3:30pm</td>
<td>Cancer All Over the Place</td>
</tr>
<tr>
<td>3:30pm - 4:30pm</td>
<td>Break/Hot Topics Session: Clopidogrel: Has the Pharmacogenetics Era Arrived?</td>
</tr>
<tr>
<td>4:00pm - 5:00pm</td>
<td>Plenary Session A: Global Development, Risk Factors, Surveillance, and Comorbidities</td>
</tr>
<tr>
<td>5:30pm - 6:30pm</td>
<td>SIGs, Biologics, Drug Utilization/Health Services Research, Ballroom B</td>
</tr>
<tr>
<td>6:00pm - 7:00pm</td>
<td>Medications in Pregnancy, Molecular Epidemiology/Pharmacogenetics, Hall B</td>
</tr>
</tbody>
</table>

---

**Meeting At-A-Glance**

Wednesday, August 19, 2009

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Registration Open</td>
</tr>
<tr>
<td>7:30am</td>
<td>3rd Floor Foyer</td>
</tr>
<tr>
<td>8:00am - 1:30pm</td>
<td>Plenary Session C, Exhibitors/Poster Session C, Hall B</td>
</tr>
<tr>
<td>9:15am - 10:30am</td>
<td>Analysis Methods II, Ballroom B</td>
</tr>
<tr>
<td>10:00am - 11:00am</td>
<td>Assessment of Prenatal Exposure to Medications, Hall B</td>
</tr>
<tr>
<td>10:30am - Noon</td>
<td>Symposium &amp; Workshops</td>
</tr>
<tr>
<td>11:00am - 12:30pm</td>
<td>RiskMAP, REMS, Challenges of Epidemiology, Ballroom D</td>
</tr>
<tr>
<td>12:00pm - 1:30pm</td>
<td>Invited Plenary, Hall A</td>
</tr>
<tr>
<td>1:30pm - 2:30pm</td>
<td>Hot Topics Session: Clorpropamide Has the Pharmacogenetics Era Arrived?</td>
</tr>
<tr>
<td>2:30pm - 3:30pm</td>
<td>The Final Word: Poster Awards, ICPE 2010 Adjournment</td>
</tr>
<tr>
<td>3:30pm - 5:00pm</td>
<td>The Future of Epidemiology, Ballroom A</td>
</tr>
<tr>
<td>5:30pm - 6:30pm</td>
<td>Using Databases for Hypothesis Generating and Hypothesis Confirmation</td>
</tr>
</tbody>
</table>

---

**ICPE 2009**

August 16-19, 2009 Providence, RI
ISPE Exhibitors & Sponsors

ISPE gratefully acknowledges the generous support of the following organizations and institutions. Their contributions helped to enhance the scientific program content and increase attendance at the ICPE 2009. Thank you.

Exhibitors

- Analysis Group
- APCER Pharma Solutions
- Aris Global
- Covance
- DrugLogic
- Exponent
- GPRD/MHRA
- HealthCore
- i3 Drug Safety
- IMS Health
- Kendle
- LA-SER
- Lovelace Respiratory Research Institute
- MedMining, a Geisinger System Business
- National Death Index, NCHS
- Outcome
- Phase Forward
- Premier Inc.
- PPD
- ProSanos
- REGISTRAT-MAPI
- RTI Health Solutions
- The Degge Group
- The Mattson Jack Group
- The Uppsala Monitoring Centre
- Thomson Reuters
- TCC llc
- United BioSource Corporation
- Wiley-Blackwell
- Wolters Kluwer Health

ISPE Sponsors

Corporate Benefactor
- Astra Zeneca R & D
- Pfizer

Annual Meeting Sponsor

Platinum: $12,500
- Pfizer
- Wiley-Blackwell

Gold: $6,500
- Amgen
- Celgene Corporation
- Cephalon, Inc.
- Covance
- Eli Lilly & Company
- GlaxoSmithKline
- Genentech
- HealthCore
- i3 Drug Safety
- IMS Health
- Outcome
- Phase Forward
- PPD
- ProSanos
- REGISTRAT-MAPI
- Roche
- RTI Health Solutions
- The Degge Group
- The Mattson Jack Group
- United BioSource Corporation
- Analysis Group
- CSD-EPIC
- EpiSource
- PharmIdeas
- WHISCON

Bronze: $1,500
- Analysis Group, Inc.
- Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine
- Center for Drug Safety, School of Pharmacy, University of Maryland
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida
- Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University
- Program in Pharmacoepidemiology and Pharmacoeconomics, College of Pharmacy, University of Rhode Island
- Program in Pharmacoepidemiology, Department of Epidemiology, UNC Gillings School of Global Public Health University of North Carolina at Chapel Hill
- IMS Health
- National Death Index, NCHS
- Pharmaceutical Solutions
- Aris Global
- DrugLogic
- Exponent
- GPRD/MHRA
- HealthCore
- i3 Drug Safety
- IMS Health
- Kendle
- LA-SER
- Lovelace Respiratory Research Institute
- MedMining, a Geisinger System Business
- National Death Index, NCHS
- Outcome
- Phase Forward
- Premier Inc.
- PPD
- ProSanos
- REGISTRAT-MAPI
- RTI Health Solutions
- The Degge Group
- The Mattson Jack Group
- The Uppsala Monitoring Centre
- Thomson Reuters
- TCC llc
- United BioSource Corporation
- Wiley-Blackwell
- Wolters Kluwer Health

Academic Showcase/Welcome Reception

- Analysis Group
- APCER Pharma Solutions
- Aris Global
- Covance
- DrugLogic
- Exponent
- GPRD/MHRA
- HealthCore
- i3 Drug Safety
- IMS Health
- Kendle
- LA-SER
- Lovelace Respiratory Research Institute
- MedMining, a Geisinger System Business
- National Death Index, NCHS
- Outcome
- Phase Forward
- Premier Inc.
- PPD
- ProSanos
- REGISTRAT-MAPI
- RTI Health Solutions
- The Degge Group
- The Mattson Jack Group
- The Uppsala Monitoring Centre
- Thomson Reuters
- TCC llc
- United BioSource Corporation
- Wiley-Blackwell
- Wolters Kluwer Health

8 August 16-19, 2009 Providence, RI ICPE 2009
ISPE Supporters

Organizational & Institutional Members

Corporate Benefactors
(10-year membership)
- Astra Zeneca R & D
- Pfizer

Members

Pharmaceuticals
- Roche
- Sanofi-Aventis

Service Provider
- RTI Health Solutions

Academic Programs
- Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine
- Center for Drug Safety, School of Pharmacy, University of Maryland
- College of Pharmacy, University of Texas at Austin
- Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University
- Harvard School of Public Health
- McGill Pharmacoeconomics & Research Unit, McGill University
- Program in Pharmacoeconomics and Pharmaceutical Economics, College of Pharmacy, University of Rhode Island
- Program in Pharmacoeconomics, Department of Epidemiology, UNC Gillings School of Global Public Health University of North Carolina at Chapel Hill
- Slone Epidemiology Center, Boston University

$25 for 25th (ICPE) Campaign (as of July 30, 2009)

The Society expresses its sincere appreciation to those supporters listed below for their contribution in honor of ISPE’s 25th Annual Meeting (ICPE).

- Edgar Adams
- Michael Adena
- Anna Birna Almarsdottir
- Susan Andrade
- Daniel Ankrath
- Mauritís Arbouw
- Felix Arellano, FISPE
- Janet Arrowsmith
- Annlousie Assaf
- Anita Assmann
- Elenie Bartzokis
- Keith Beard, FISPE
- Ulf Bergman, FISPE
- Harshvinder Bhullar
- Sebastien Bineau
- Stella Blackburn, FISPE
- William Blumentals
- Rhonda Bohn, FISPE
- Alison Bourke
- Elliot Brown
- Rudolf Bruppacher, FISPE
- Claudia Cabrera-Moksnes
- Suzanne Cadarette
- Stella Chang
- Robert Chen, FISPE
- Lyn Collin
- Anne Costello
- Suellen Curkendall
- Marie-Christine Cyr
- Andrzej Czamecki, FISPE
- Hilda de Jong
- Lotke de Jong-van den Berg
- Frank De Vries
- Dabashish Dey
- Nancy Dreyer, FISPE
- David Dore
- William Eastmann
- Carol Fairchild
- Sarah Frise
- Genevive Gabb
- Helga Gardarsdottir
- Chun-Shiouh Gau
- Brian Godman
- Jean-Pierre Gregoire, FISPE
- Lamiae Grimaldi-Bensouda
- Zhenchao Guo
- Flora Haaijer-Ruskamp
- James Haddock
- Gillian Hall, FISPE
- Jesper Hallas
- Kjell Hermann Halvorsen
- Abraham Hartzema
- Klaas Heinemann
- Deborah Hennessey
- David Henry
- Ishan Hirji
- Zhiping Huang
- Jacqueline Hugtenburg
- Anders Hvid
- Michael Iskedjian
- Betsey Jackson
- Derek Johnson
- Eric Johnson
- Jo-young Kim
- Stephen Kimmel, FISPE
- Brice Kito Schrass
- Olaf Klungel
- James Kotsanos, FISPE
- Gottfried Kreutz
- Kyoshi Kubota
- Ana Lasisi
- Nancy Lass
- Deborah Layton
- Joongyub Lee
- Linda Levesque
- James D. Lewis, FISPE
- Michael Lewis, FISPE
- Jeanne Loughlin
- Malcolm Maclure
- Milada Mahic
- William Maior
- Marie-Josee Martel
- Colleen Maxwell
- Frank May, FISPE
- Giampiero Mazza
- Andrew McAfee
- Anita McGrogan
- Joseph McLaughlin
- Dominique Mlea
- David Miller
- Allen Mitchell, FISPE
- Jocelyne Moisan, FISPE
- Yola Moride, FISPE
- C. Ineke Neutel, FISPE
- Anthony Nunes
- Axel Olsen
- Byung-Joo Park, FISPE
- Inger Nordin Olsson
- Hans Petri
- Cynthia Phillips
- Richard Platt
- Mary Prince Panaccio
- Brian J. Quilliam
- June Raine
- Joe Reilly
- Maria Elena Rivero
- Ferrar, FISPE
- Noah Robinson
- Daniel Rosenberg
- Annalisa Rubino
- Ken Rothman, FISPE
- Leo Russo
- Susan Sacks, FISPE
- Deborah Saltman
- Lloyd Sansom
- Cees Scheep, FISPE
- Robert Schirmer
- Markus Schuerch
- Harry Seifert
- Saad Shikr, FISPE
- Gloria Shalviri
- Rosemarie Sitar Carter
- Daniel Solomon
- Patrick Souverain
- Tommasco Stanisica
- Miriam C. M. Sturkenboom
- Shinji Suzuki
- Martina Teichert
- Bharat Thakrar
- Sengwee Toh
- Marianne Ulcickas Yood
- John Urquhart, FISPE
- Carla Van Bennenk
- Zdravko Vassilev
- Patrice Verpillat
- Peter Wahl
- Alexander M. Walker, FISPE
- Mari-Ann Wallander, FISPE
- Douglas Watson
- Sue L. West, FISPE
- James Wilson
- Almut Winterstein
- Fenglong Xie
- Songlin Xue, FISPE
- Shu-ju Yang

In This Program

25th ICPE Agenda
Saturday, August 15 ............................................. 9
Sunday, August 16 ................................................. 10
Monday, August 17 ................................................ 12
Tuesday, August 18 ................................................. 22
Wednesday, August 19 ......................................... 32

25th ICPE Posters
Poster-Presentation Guidelines ........................................ 38
Poster Session A .................................................... 40
Poster Session B .................................................... 48
Poster Session C .................................................... 57

Abstract Index ...................................................... 64
Advertisers Index ................................................ 70
Badges
All attendees at ICPE 2009 must wear their name badges to all events.

A badge will be needed for admission to meeting related functions, such as the scientific sessions, the exhibit/poster hall, and social events. Badges will be included in the registration packet material. In some cases, tickets for admission will be required.

Badge Legend
- Student – YELLOW
- One Day Attendee – RED
- New Member – BLUE
- Local Host Comm. – GREEN

Rhode Island Convention Center (RICC)
All Pre-ICPE courses, the ICPE 2009, and ISPE Committee, Council and SIG meetings will be held at the Rhode Island Convention Center, One Sabin Street, Providence, RI, except otherwise listed. Food/beverage will be available at all committee meetings.

Future Meetings

ISPE’s Fourth Asian Meeting
(Asian Conference on Pharmacoepidemiology)
Convened in conjunction with the Pharmaceutical Society of Taiwan
- October 23-25, 2009
- National Cheng Kung University, Tainan, Taiwan

ISPE Mid-Year Meeting
- April 10-12, 2010
- Marriott Raleigh City Center, Raleigh, North Carolina

26th International Conference on
Pharmacoepidemiology & Therapeutic
Risk Management
- August 19-22, 2010
- Hilton Brighton Metropole, Brighton, England, UK

5th Asian Conference on Pharmacoepidemiology
- October 29-31, 2010
- Tokyo, Japan

ISPE Mid-Year Meeting
- April TBD, 2010
- Florence, Italy
8:30am-5:00pm
ISPE Board of Directors Meeting
(Westin Providence-Bristol/Kent)
(Open to ISPE members; notify staff if you plan to attend)

11:30-5:00pm
Registration
(Third Floor Foyer)

1:00-5:00pm
Introduction to Pharmacoepidemiology
(Room 555AB)

*On Saturday afternoon (Day 1), there will be didactic teaching. On Sunday morning (Day 2) participation is optional, but there will be a small group workshop that will use real pharmacogenetic case studies catering to both novice and advanced participants.

[Note: There is no separate registration for Part 2 only; you must register for Part 1 to take Part 2].

Anke-Hilse Maitland-van der Zee,
Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht University,
Pharmacogenetics Methods I

Efrosini Setakis, Division of General Practice Research Database, Medicines & Healthcare Products Regulatory Agency, UK.
Pharmacogenetic Methods II and Databases as Study Sources

Andrew Freedman, National Institutes of Health, Pharmacogenomics Translation: From Discovery to Confirmation to Clinical Utility

Stephen Kimmel, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Warfarin as a Prototype Pharmacogenetic Example

1:00-5:00pm
Introduction to Pharmacogenetics – Part 1*

Educational Objectives

- Understand the genetic and pharmacogenetic terminology and how cellular and molecular biology informs pharmacogenetic studies at analysis
- Appreciate the challenges of utilizing biospecimens
- Know the study design and methodologic approaches, their strengths and weakness used in pharmacogenetic epidemiology
- Understand statistical approaches used in Pharmacogenetics
- Understand how pharmacogenetics relates to current focus of Personalized Medicine
- Have an overview of clinical utility of pharmacogenetics and associated regulatory issues.

Co-Chairs: Geoffrey Liu & Anke-Hilse Maitland

Leah Sansbury, National Institutes of Health, Pharmacogenetic Terminology: The Basics

Geoffrey Liu, Alan Brown Chair in Molecular Genomics, CCO Chair in Population Studies and Experimental Therapeutics, University of Toronto, Biospecimen Issues for Pharmacoepidemiologists

Wei Zhou, Senior Epidemiologist, Merck Pharmaceuticals, Biospecimen Databases

5:00-7:00pm
Student Meet and Greet
(Cuban Revolution Restaurant & Grill; 50 Aborn Street)

- Organized by the ISPE Student Council

5:15-6:30pm
Literature Review Journal Club
(Room 555AB)

Panelists:
Alexander M. Walker, FISPE, World Health Information Science Consultants

Sean Hennesssey, FISPE, Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine

Stephen Evans, London School of Hygiene and Tropical Medicine

**Agenda - Sunday, August 16**

**7:30am-6:00pm**
Registration  
(Third Floor Foyer)

**8:00-5:00pm**
Speakers’ Ready Room  
(Room 553 B)

---

**8:30-Noon**

**Regulatory Epidemiology/Public Health Decision Making**  
(* Room 555B*)

**Educational Objectives**
- Understand the intent and structure of regulation to protect the Public Health
- Appreciate the challenges of decision making with weak data
- Know about practical approaches typically chosen by regulators
- Recognize the challenges epidemiology faces to provide sufficient information for public health decision making
- Have an overview of world wide challenges for drug regulatory agencies and variation in approaches
- Know about current strategies to strengthen regulation in the face of these challenges

**Chair: Gerald Dal Pan**

- Gerald Dal Pan, US FDA, Regulation & Challenges of Decision-Making with Weak Data
- June Raine, EMEA, Regulatory Decision Making Approaches in Europe
- Stephen Evans, London School of Tropical Medicine, An Epidemiologist’s View of Public Health Decision Making
- Ralph Edwards, WHO Collaborating Centre for International Drug Monitoring, Global Perspective on Regulatory Utilization of Pharmacovigilance Data

---

**8:30-Noon**

**Introduction to Drug Utilization/Health Services Research**  
(* Room 555A*)

**Educational Objectives**
- To explain the definition and scope of the eclectic discipline of Drug Utilization Research within the context of Pharmacoepidemiology.
- To motivate researchers providing international cross-national comparisons of national drug utilization data to cooperate on the collection of a minimal dataset of reliable and comparable drug utilization data in their country, in terms of volume, expenditures and quality of drug use.
- To explain the process of developing and validating prescribing quality indicators.
- To give an applied overview of methods useful for drug policy research (time series analysis)

**Co-Chairs:** Robert Vander Stichele & Julie Zito, FISPE

---

**Pre-Conference Educational Sessions (RICC)**

**8:30-Noon**

**Comparative Effectiveness Research**  
(* Ballroom D*)

**Educational Objectives**
- Identify the differences between effectiveness and efficacy research and implications for improving routine care
- Understand the basic study design issues for non-randomized data recorded in routine care settings
- Recognize the advantages and limitations of a variety of data sources for comparative effectiveness research and how combining multiple sources can enhance the utility of a given dataset
- Have an overview of methodological challenges and proposed solutions in non-randomized effectiveness research
- Learn how to create and synthesize evidence with the decision maker in mind

**Co-Chairs:** Sebastian Schneeweiss, FISPE, & Erick Johnson

- Scott Smith, AHRQ, Objectives of CER
- Eric Johnson, Kaiser, Cohort Studies
- David Magid, Kaiser, Data Sources and Implications
- Sebastian Schneeweiss, Harvard, Methodological Challenges in Non-Randomized CER
- David Atkins, Veteran’s Administration, Creating and Synthesizing Evidence with the Decision Maker in Mind

---

* NOTE FOR EDUCATIONAL SESSIONS:  
Admission by ticket only. Tickets will be included in registration materials for those who registered for this session.
8:30-Noon
Introduction to Pharmacogenetics*– Part 2 (Room 556A)
Must register for Part 1; attendance at Part 2 is optional.
- Speakers will lead small discussion groups addressing real life pharmacogenetic examples.

Co-Chairs: Geoffrey Liu & Anke-Hilde Maitland
Leah Sansbury, National Institutes of Health
Geoffrey Liu, University of Toronto
Wei Zhou, Merck Pharmaceuticals
Anke-Hilde Maitland-van der Zee, Utrecht University
Efrosini Setakis, Medicines & Healthcare Products Regulatory Agency, UK
Andrew Freedman, National Institutes of Health, USA
Stephen Kimmel, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine

8:30-12:00pm
New Course!
Introduction to Pharmacogenetics*– Part 2 (Room 556A)
Must register for Part 1; attendance at Part 2 is optional.
- Speakers will lead small discussion groups addressing real life pharmacogenetic examples.

Co-Chairs: Geoffrey Liu & Anke-Hilde Maitland
Leah Sansbury, National Institutes of Health
Geoffrey Liu, University of Toronto
Wei Zhou, Merck Pharmaceuticals
Anke-Hilde Maitland-van der Zee, Utrecht University
Efrosini Setakis, Medicines & Healthcare Products Regulatory Agency, UK
Andrew Freedman, National Institutes of Health, USA
Stephen Kimmel, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine

1:30-6:00pm
Advanced Topics in Pharmacoepidemiology* (Ballroom D)
Chair: James D. Lewis, FISPE
Sander Greenland, Bayesian Methods for Observational Research
Tom MacDonald, FISPE, Clinical Trials or Observational Studies for Drug Safety Assessment?
Joanna Haas, Unique Aspects of Studying Biologics
Daniel Heitjan, Methods for Handling Missing Data

1:30-6:00pm
Introduction to Risk Management* (Room 557)
Co-Chairs: Elizabeth Andrews, FISPE & Carla van Bennekom
Elizabeth Andrews, FISPE, Overview of Risk Management and the Role of Evaluation
Mary Willy, US Regulatory
Stella Blackburn, FISPE, EU Regulatory
Carla van Bennekom, Isotretinoin
Judith Jones, FISPE, Workshop for Participants to Develop an Evaluation Plan

6:00-7:30pm
Welcome Reception/Academic Showcase
(Rhode Island Statehouse)
- Admission by badge or ticket. Cash Bar
Welcome
Kate Lapane, FISPE, Chair, 2009 Scientific Program Committee
Miriam Sturkenboom, ISPE President

Academic Showcase
- Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine
- Center for Drug Safety, School of Pharmacy, University of Maryland
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida
- Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University
- Program in Pharmacoepidemiology and Pharmacoeconomics, College of Pharmacy, University of Rhode Island
- Program in Pharmacoepidemiology, Department of Epidemiology, UNC Gillings School of Global Public Health University of North Carolina at Chapel Hill

Noon-1:30pm
Lunch on your own.

Noon-1:30pm
Luncheon for New Members/Student Prize Winners/Scholarship Recipients
(Westin Providence Waterplace Ballroom)
- By Invitation
7:00-8:00am
ISPE Committee Meeting
- Open to all participants.
- Breakfast will be available in meeting rooms
  ■ Education Committee (Room 551B)
  ■ Finance Committee (Room 551A)

7:00-5:00pm
Speakers’ Ready Room (Room 553B)

7:00-8:00am
Poster Session A Set-up (Hall B)
Continental Breakfast (Hall B)

7:00-6:00pm
Registration (Third Floor Foyer)

8:00-6:00pm
Exhibits/Posters (Hall B)

8:00-10:00am
Opening Session (Ballroom A)
- Welcome
  Kate L. Lapane, FISPE, Chair, 2009
  Scientific Program Committee, &
  Co-Chair, 25th Anniversary Committee
  Brian J. Quilliam, Chair, 2009 Local
  Host Committee
- Presidential Address
  Miriam CJM Sturkenboom, ISPE President
- Keynote Address
  Accounting for Uncertainty About
  Investigator Bias
  Sander Greenland, Professor of
  Epidemiology, UCLA School of Public
  Health, and Professor of Statistics, UCLA
  College of Letters and Science
- Special Anniversary Presentation
  Susan Sacks, FISPE, Co-Chair,
  25th Anniversary Committee
  Thomas MacDonald, FISPE,
  ISPE Poet Laureate

10:00am -10:30am
Break/Posters/Exhibits (Hall B)

You will notice that the “ICPE 25th Anniversary” logo has been appended to selected sessions. These sessions have been selected because the topics are broad and reach into the future of our field.
Pfizer, Inc. discovers, develops, manufactures, and markets leading prescription medicines for humans and animals.

With 2008 actual spending of $7.9 billion in research & development (R&D), Pfizer has the industry's largest pharmaceutical R&D organization.

Our search for new treatments spans hundreds of research projects across fifty-six major disease groups in 10 therapeutic areas.

We build our success on the innovation, skills, and entrepreneurial spirit of each of our colleagues.

Every year we help 150 million patients, utilize the skills of medical researchers, and work in partnership with governments, individuals, and other payers for healthcare to treat and prevent illnesses – adding both years to life, and life to years.

The Epidemiology Group at Pfizer partners with development teams to bring new medicines to patients and to evaluate the safety of our medicines.

We are committed to the conduct of research meeting the highest scientific and ethical standards to assess the benefits and risks of our medicines.

Pfizer Epidemiology is proud to support the 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management and welcomes the opportunity for the open exchange of scientific ideas and research findings in order to advance the fields of pharmacoepidemiology and risk management.
Early Detection In Pharmacovigilance (Room 555AB)

Moderators: Andrej Czarnecki, FISPE, & M. Miles Braun, FISPE

10:30am
- A Comparison of MedDRA and WHOART for Signal Detection on a Database of Spontaneous Adverse Drug Reaction Reports [7]
  Richard Hill, Kristina Star, G Niklas Norén. (Sweden)

10:45am
- Using Regression To Find Otherwise Undetected Drug Safety Issues [8]
  Ola Caster, Kristina Star, Richard Hill, G Niklas Norén. (Sweden)

11:00am
- Comparison of Adverse Drug Reaction (ADR) Reports Submitted to the FDA by Consumers and Healthcare Professionals (HCPs) [9]
  Thamir M Alshammari, Syed Rizwanuddin Ahmad, Lynette Swartz, Tarek A Hammad. (United States)

11:15am
- Using the Capture-Recapture Method To Assess the Incidence of Drug-Induced Liver Injury in a French University Hospital [10]
  Neda Tavassoli, Virginie Ramillon, Pauline Calvet, Laure Pourceel, Jean Louis Montastruc, Maryse Lapeyre-Mestre. (France)

11:30am
- Evaluation of Cardiovascular Diseases (CVDs) Risk in French Patients Receiving Milnacipran (MLN) Relative to Patients Receiving Other Antidepressants Therapies [11]
  PJ Mease, MS Duh, F Vekeman, A Guérin, M Boerstoel-Streefland, W Jiang, P Lefebvre, PJ Zimetbaum. (United States)

11:45am
  WK Yih, B Fireman, N Klein, M Kulldorff, E Lewis, T Lieu, E Weintraub, R Platt. (United States)
**Effects of Cardiovascular Drugs (Room 556AB)**
Moderator: Jennifer Christian & Michael Lewis, FISPE

10:30am
- Statins, Other Antihyperlipidemic Agents, and Psoriasis [13]
  Yolanda B Brauchli, Susan S Jick, Christoph R Meier. (Switzerland)

10:45am
- Statin-CYP3A4 Inhibitor Drug Interaction Shows Differential Increased Risk for Adverse Events Depending on Statin Metabolism [14]
  Christopher G Rowan, Steven M Brunelli, James Flory, Jeffrey Munson, Warren Bilker, Brian Strom. (United States)

11:00am
- Safety and Effectiveness of Bivalirudin in Routine Care of Patients Undergoing Percutaneous Coronary Intervention [15]
  Jeremy A Rassen, Murray A Mittleman, Robert J Glynn, M Alan Brookhart, Sebastian Schneeweiss. (United States)

11:15am
- Association of Proton Pump Inhibitors with Clopidogrel Effectiveness in Elderly Stroke Patients [16]
  Mi-Sook Kim, Sun-Young Jung, Ye-Jee Kim, Nam-Kyong Choi, Byung-Joo Park. (Republic of Korea)

**Hormones/Reproductive Agents (Room 554AB)**
Moderators: Stephen Evans & Annlouise Assaf

10:30am
- Teen Pregnancy Rates Following Pharmacist-Initiated Emergency Contraceptives [19]
  Vivian WY Leung, Judith A Soon, Marc Levine, Larry D Lynd, Carlo A Marra. (Canada)

10:45am
- An Internet-Based Prospective Study of Pregravid Oral Contraceptive Use and Time to Pregnancy [20]
  Ellen M Mikkelsen, Lauren A Wise, Anders Riis, Elizabeth E Hatch, Henrik T Serensen, Kenneth J Rothman. (United States)

11:00am
- Incident Anticoagulant Use among Users of Extended-Cycle Versus Conventional Oral Contraceptives [21]
  Joshua J Gagne, Tarek A Hammad, Solomon Iyasu. (United States)

11:15am
- Extended Results on the Risk of Venous Thromboembolism (VTE), Myocardial Infarction (MI), and Stroke in Users of Transdermal Norelgestromin/Ethinyl Estradiol (Patch) [22]
  David D Dore, Heather Norman, Clorinda Hoffman, Judy Wong, John D Seeger. (United States)
10:30am
- Pregnancy Exposure Registries: Challenges in Identifying Comparison Groups [25]
  Deborah L Covington, Susan S Roberts, Jessica Albano, Laura F McKain. (United States)

10:45am
- Can the General Practice Research Database Identify a Known Teratogenic Association? [26]
  Rachel A Charlton, John G Weil, Julia M Snowball, Marianne C Cunningham, Corinne S de Vries. (United Kingdom)

11:00am
- Valproic Acid Exposure & Specific Malformations [27]
  J Jentink, MA Loane, H Dolk, JK Morris, LTW de Jong-van den Berg, EUROCAT AED Working Group. (Netherlands)

11:15am
- Effect of Correct Folic Acid Use on Spina Bifida in Pregnancies Exposed to Valproic Acid or Carbamazepine in the Netherlands [28]
  J Jentink, MK Bakker, LTW de Jong-van den Berg. (Netherlands)

11:30am
- Serotonin Reuptake Inhibitor and Pregnancy: Risk of Gestational Hypertension? [29]
  Christine Damase-Michel, Veronique Duhalde, Caroline Hurault, Robert Bourrel, Jean Louis Montastruc. (France)

11:45am
- Use of Antidepressants during Pregnancy and the Risk of Preterm Delivery and Fetal Growth Restriction [30]
  Sengwee Toh, Allen A Mitchell, Carol Louik, Martha M Werler, Christina D Chambers, Sonia Hernandez-Diaz. (United States)
12:00pm-1:30pm
Lunch/Poster Session A/Exhibits/Poster Walks (Hall B)
~Lunch Sponsored by UBC
Poster Walks/Moderators
- Pharmacovigilance, Harry Seifert & Keith Beard, FISPE
- Medicines in Pregnancy/Birth Defects, Lolkje T de Jong-van den Berg
- Drug Utilization Studies, Monique Elseviers
- Uses of Linked Databases, Matthew W. Reynolds

ISPE Committee/Council Meetings
- Open to all participants. (Lunches will be available in meeting rooms)
- Development Committee (Room 558B)
- Fellowship & Awards Committee (Room 558A)
- Public Policy Committee (Room 557)
- Student Council (Ballroom E)

1:30-3:00pm
Concurrent Sessions: Contributed Papers
Analysis Methods I (Ballroom B)
Moderators: Til Stürmer, FISPE & Marieke DeBruin
1:30pm
- Estimating Absolute Risks in the Presence of Noncompliance: An Application to a Women's Health Initiative Randomized Trial [31]
  Sengwee Toh, Sonia Hernandez-Diaz, Roger Logan, James M Robins, Miguel A Herman. (United States)
  Student Award Recipient - Best Methods Abstract

1:45pm
- Prior Event Rate Ratio Adjustment: A Magic Bullet or More of the Same? [32]
  Arlene Gallagher, Frank de Vries, Tjeerd van Staa. (Netherlands)
  Student Award Recipient - Best Drug Utilization Abstract

2:00pm
- Observed Performance of the High-Dimensional Propensity Score (hd-PS) Algorithm in Small Samples [33]
  Jeremy A Rassen, M Alan Brookhart, Sebastian Schneeweiss. (United States)

2:15pm
- Applying Propensity Scores Estimated in a Full Cohort To Achieve Balance in Subgroup Analyses [34]
  Jeremy A Rassen, M Alan Brookhart, Sebastian Schneeweiss. (United States)

2:30pm
- Bias from Excluded Event-Depleted Time in Cohort Studies [69]
  Frank Andersohn, Stefan N Willich. (Germany)

2:45pm
- Confounder Summary Scores When Comparing the Effects of Multiple Drug Exposures [36]
  Suzanne M Cadarette, Joshua J Gagne, Daniel H Solomon, Jeffrey N Katz, Til Stürmer. (Canada)
Gastrointestinal Drugs: Going Beyond the Intestine
(Room 554AB)
Moderator: Dan Mines & Mari-Ann Wallander, FISPE

1:30pm
- Prokinetic Drugs in Children; Drug Utilization and Safety [37]
  S de Bie, KMC Verhamme, SMJM Straus, G Piceli, A Ceci, MCJM Sturkenboom. (Netherlands)

1:45pm
- No Evidence for Association of Tegaserod with Adverse Cardiovascular Ischemic Events [38]
  Jeanne Loughlin, Sherry Quinn, Elena Rivero, Heather Norman, David L Earnest, Judy Wong, John D Seeger. (United States)

2:00pm
- Use of Protonpump Inhibitors and Risk of Hip Fracture [39]
  Arief Lalmohamed, Sander Pouwels, Cyrus Cooper, Tjeerd van Staa, Bert Leufkens, Anthonius de Boer, Frank de Vries. (Netherlands)

2:15pm
- The Role of Medical Comorbidities in the Association of Proton Pump Inhibitors [PPIs] and Fractures [40]
  David R Gagnon, Jennifer R Fonda, Richard Scranton, Elizabeth V Lawler. (United States)

2:30pm
- Use of Proton Pump Inhibitors and Histamine Type 2 Receptor Blockers Is Not Associated with Pneumonia Risk [41]
  Sascha Dublin, Rod L Walker, Michael L Jackson, Jennifer C Nelson, Noel S Weiss, Lisa A Jackson. (United States)

2:45pm
- Proton Pump Inhibitors and Risk for Recurrent Clostridium difficile Associated Diarrhea [42]
  Amy Linsky, Kalpana Gupta, Elizabeth Lawler, Jennifer Fonda, John Hermos. (United States)

Improving Linking Databases
(Room 555AB)
Moderators: Thomas MacDonald, FISPE, & Earl Goehring

1:30pm
- Automated Data Capture from Free Text Radiology Reports To Enhance Accuracy of Hospital Inpatient Stroke Codes [43]
  Robert Flynn, Thomas MacDonald, Gordon Murray, Alexander Doney. (United Kingdom)

1:45pm
- Linking Inpatient and Outpatient Data [44]
  Suellen Curkendall, Daniel Huse. (United States)

2:00pm
- Sensitivity and Specificity of Acute Renal Failure Medical Claims Validated against Electronic Medical Records [45]
  Marc B Rosenman, Peter M Wahl, Gregory Daniel, J Marc Overhage, Patricia McGuire, Daniel Thompson, Keith Rodgers, Louise Short, Rhonda L Bohn, William M Tierney. (United States)

2:15pm
- Effect of Extended Mortality Ascertainment in a Cohort Study of the Risk of Cancer in Regranex (Becaplermin) Users and Matched Comparators [46]
  Najat Ziyadeh, Daniel Fife, John D Seeger. (United States)

2:30pm
- Signal Detection Beyond Spontaneous Reports: An Example of Acute Adverse Event Detection in Large Claims Databases [47]
  Zhenchao Guo, Gilbert J L’Italien, Jayanti Mukherjee, Hugh Kawabata, Andres Gomez Caminero. (United States)

2:45pm
- Validation of Persistent Pulmonary Hypertension in the Newborn (PPHN) within the UK-Based General Practice Research Database (GPRD): Comparing Two Approaches [48]
  Tarek A Hammad, Carol Pamer, Susan McCune, Sigal Kaplan, Hany Aly, Solomon Iyasu. (United States)
### Personalized Medicine: Molecular and Genetic Biomarkers of Efficacy and Toxicity (Room 552AB)

**Moderator:** Frederick Nyberg & Andrew Freedman

1:30pm
- Cisplatin, Nucleotide Excision DNA Repair Pathway, and Esophageal Cancer Outcomes: A Pharmacogenetic Epidemiology Study [49]
  Penny Bradbury, Wei Zhou, Rihong Zhai, Kofi Asomaning, Li Su, David Christiani, Geoffrey Liu. (Canada)

1:45pm
- CYP2C9, CYP2C19 and ABCB1 Genotype and Hospitalization for Phenytoin Toxicity [50]
  Sean Hennessy, Charles E Leonard, Cristin M Palumbo, Joshua P Metlay, Xin Chu, Brian L Strom, Warren B Bliker. (United States)

2:00pm
- Variation in Renin-Angiotensin System and Salt Sensitivity Genes and the Risk of Diabetes Mellitus Associated with the Use of Thiazide Diuretics [51]
  Ozlem Bozkurt, Anthonius de Boer, Diederik E Grobbee, Peter W de Leeuw, Abraham A Kroon, Paul Schiessers, Olaf H Klungel. (Netherlands)

2:15pm
- Single Nucleotide Polymorphisms in Genes That Are Associated with a Modified Response to Statin Therapy: The Rotterdam Study [52]
  Catherine E de Keyser, Mark Eijgelsheim, Albert Hofman, Eric JG Sijbrands, Anke-Hilse Maitland-van der Zee, Cornelis M van Duijn, Andre G Utterlinden, Jacqueline CM Witteman, Bruno HCh Stricker. (Netherlands)

**Student Award Recipient – Best Molecular Epidemiology – Pharmacogenetics Abstract**

2:30pm
- The Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients with Atrial Fibrillation [53]
  Amanda R Patrick, Jerry Avorn, Niteesh K Choudhry. (United States)

2:45pm
- Mesothelin, a Biomarker of Pharmacologic Response in Malignant Pleural Mesothelioma, Evaluated in a Molecular Epidemiologic Study [54]
  Boming Yang, Paul Wheatley-Price, Deval Patel, Clement Ma, Natasha Leight, Ron Feld, Marc de Perrot, Geoffrey Liu. (Canada)

### Vaccines (Room 556AB)

**Moderators:** M. Miles Braun, FISPE, & Robert Chen, FISPE

1:30pm
- A Systematic Approach To Analyze Safety Data Clinical Trial Database [55]
  Caroline Legendre, Alena Khromava, Gillis Carrigan. (France)

1:45pm
- Active Safety Surveillance of DTaP Vaccines by Linkage of Immunization Registry and Claims Database in Korea [56]
  Sun-Young Jung, Nam-Kyong Choi, Byung-Joo Park. (Korea)

2:00pm
- The Risk of Seizures after Acellular Pertussis Vaccines in Early Childhood — United States, 2002-2006 [57]
  Wan-Ting Huang, Paul Gargiullo, Irene Shui, Eric Weintraub, James Baggs, Karen Broder, John Iskander. (United States)

2:15pm
- Effectiveness of the Pentavalent Rotavirus Vaccine in Preventing Gastroenteritis in the United States: A Claims-Based Analysis [58]
  Florence T Wang, T Christopher Mast, Roberta J Glass, Jeanne Loughlin, John D Seeger. (United States)

2:30pm
- Cautionary Example of Potential Exposure-Based Differential Misclassification in a Post-Marketing Vaccine Safety Study [59]
  Nancy C Santanello, Christopher Mast, Jeanne Loughlin, John Seeger. (United States)

2:45pm
- A Post-Marketing Surveillance Program for Pentavalent Rotavirus Vaccine [60]
  Jeanne Loughlin, Wang Florence, P Mona Eng, T Christopher Mast, John D Seeger. (United States)

3:00-3:30pm
Break/Posters/Exhibits (Hall B)
Concurrent Sessions: Symposia And Workshops

Automated Data Sources for Pharmacoepidemiology in Asia-Pacific Region – Updates and Perspectives [61] (Room 556AB)
- Byung Joo Park, Yea Huei Kao Yang, Libby Roughhead, Daisuke Koide, Jeff J Guo, Tomomi Kimura, Arnold K Chan, Judith K Jones, Brian L Strom. (Japan)

Can Registries Deliver? The Methods and Use of Registries for Biologics [62] (Room 555AB)
- Sponsored by the Biologics SIG
- Sean Zhao, Nancy Dreyer, Alex Cole, Annette Stemhagen, Nils Feltelius, Joanna Haas. (United States)

Confounding by Indication Studying Epoetin and Mortality [63] (Ballroom B)
- John Acquavella, Eric Weinhandl, Brian Bradbury, Alan Brookhart, Til Stürmer, Kenneth J Rothman. (United States)

Evaluating Study Designs for the Measurement of Drug Exposure in Pregnancy [64] (Room 552AB)
- Sponsored by the Medicines in Pregnancy SIG and the Teratology Society
- Elizabeth B Andrews, Lyn Colvin, Sonia Hernandez-Diaz, Lewis Holmes, Tina Chambers, Andrea Margulis, Allen Mitchell. (United States)

Pharmacoepidemiology, Medicines Policy and Health Outcomes: The Next Steps [65] (Room 551AB)
- Andrew L Gilbert, Richard Laing, Andreas Laupacis, Elizabeth Roughead, Kate L Lapane. (Australia)

The Past, Present and Future of Pharmacoepidemiology at CDER, FDA [66] (Ballroom A)
- Solomon Iyasu, Tarek A Hammad, Gerald J Dal Pan, Judy A Staff. (United States)

Is Accuracy at Odds with Privacy? Challenges and Solutions When Combining Data from Multiple Sources [285] (Room 554AB)
- Jeremy Rassen, Lang Chen, Miriam Sturkenboom, Sebastian Schneeweiss, Stephen Evans. (United States)

You will notice that the “ICPE 25th Anniversary” logo has been appended to selected sessions. These sessions have been selected because the topics are broad and reach into the future of our field.
Editor-in-Chief: Professor Ronald D. Mann

Pharmacoepidemiology & Drug Safety provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

- Free online access for ISPE members via the society website
- Latest Impact Factor: 2.516 (JCR® 2008)

A selection of the top-downloaded papers from the 2008 Volume (17)

- Reliability of the assessment of preventable adverse drug events in daily clinical practice.
  Jaspenen E. van Doormaal, Peter G. M. Mol, et al. Volume 17, Issue 7, Pages 645-54

- Association between serious ischemic cardiac outcomes and medications used to treat diabetes.
  David J. Margolis, Ole Holfstad, Brian L. Strom. Volume 17, Issue 8, Pages 753-59

  Alexander M. Walker, Carol E. Koro, Joan Landon. Volume 17, Issue 8, Pages 760-68

- A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14 237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
  Alexander Cobitz, Andrew Zambanini, et al. Volume 17, Issue 8, Pages 769-81

- The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care.

For more information on these top papers and other journal features, please visit www.interscience.wiley.com/journal/pds

Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2009 Volume: 18 • Frequency: Monthly
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-8:00am</td>
<td>Annual Roundtable Discussion/Breakfast: Centers for Education and Research on Therapeutics</td>
</tr>
<tr>
<td></td>
<td>(Room 557)</td>
</tr>
<tr>
<td></td>
<td>- Anne E Trontell, Mark Hornbrook, Stephen Crystal. (United States)</td>
</tr>
<tr>
<td>7:00-8:00am</td>
<td>Poster Session B Set-up (Hall B) Continental Breakfast (Hall B)</td>
</tr>
<tr>
<td>7:00-6:00pm</td>
<td>Registration (Third Floor Foyer)</td>
</tr>
<tr>
<td>7:30-5:00pm</td>
<td>Speakers' Ready Room (Room 553B)</td>
</tr>
<tr>
<td>8:00-6:00pm</td>
<td>Exhibits/Posters (Hall B)</td>
</tr>
<tr>
<td>8:00-9:15am</td>
<td>Invited Plenary Session</td>
</tr>
<tr>
<td></td>
<td>(Ballroom A)</td>
</tr>
<tr>
<td></td>
<td>National Pharmaceutical Policy Imperatives: Implications for Pharmacoepidemiologists</td>
</tr>
<tr>
<td></td>
<td><strong>Chair</strong>: Andrew Gilbert</td>
</tr>
<tr>
<td></td>
<td><strong>Speaker</strong>: Lloyd Sansom, Emeritus Professor; University of South Australia: Chair, Pharmaceutical Benefits Advisory Committee; Australian Government Department of Health and Aging</td>
</tr>
<tr>
<td>9:15-10:30am</td>
<td>Annual Meeting Of ISPE Members, Awards Ceremony &amp; Special Address (Ballroom A)</td>
</tr>
<tr>
<td></td>
<td>- Open to all participants.</td>
</tr>
<tr>
<td></td>
<td><strong>Annual Meeting of ISPE Members</strong></td>
</tr>
<tr>
<td></td>
<td>- Miriam CJM Sturkenboom, FISPE, ISPE President</td>
</tr>
<tr>
<td></td>
<td>- Nancy Dreyer, ISPE Vice President Finance</td>
</tr>
<tr>
<td>10:30-11:00am</td>
<td>Break/Posters/Exhibits (Hall B) -Sponsored by CSD-EPIC</td>
</tr>
</tbody>
</table>
### Concurrent Sessions – Contributed Papers

#### Anti-Infectives (Room 552B)
**Moderators:** Patricia Saddier & Kerry LaPlante

**11:00am**
- Effectiveness of an Information Technology Intervention To Improve Prophylactic Antimicrobial Use in the Post-Operative Period [227]
  Kevin Haynes, Darren Linkin, Neal Fishman, Warren Bilker, Eric Pifer, Sean Hennessy. (United States)

**11:15am**
- Effectiveness of Palivizumab in Medicaid Infants [228]
  Almut G Winterstein, Christian Hampp, Arwa Saidi. (United States)

**11:30am**
- Comparison of Infection-Related Hospitalization Risk among Patients Receiving Sargramostim, Filgrastim, and Pegfilgrastim for Chemotherapy-Induced Neutropenia [229]
  Mei Sheng Duh, Edmond L Toy, Francis Vekeman, Francois Laliberte, Bree L Dority, Daniel Perlman, Victoria Barghout, Mark L Heaney. (United States)

**11:45am**
- Is Cigarette Smoking a Risk Factor for Subsequent Use of Antibiotics? [230]
  Hege S Blix, Vidar Hjellvik, Irene Lileskare, Marit Rønning, Aage Tverdal. (Norway)

**12:00pm**
- Reporting of Hepatic Events in Patients Using Vancomycin from Clinical Studies: A Meta-Analysis [231]
  Yan Chen, Xiao Yan Yang, Michael Zeckel, Chris Killian, Kenneth Hornbuckle, Simon Voss. (United States)

**12:15pm**
- Outcomes of Antibiotic Use for Respiratory Infections [232]
  Sharon B Meropol, A Russell Localio, Joshua P Metlay. (United States)

#### Information as Basis for Risk Management (Ballroom D)
**Moderators:** Elizabeth Andrews, FISPE & Nataliya Volkova

**11:00am**
- Determinants of Metabolic Testing for Patients Treated with Second-Generation Antipsychotics after the FDA Diabetes Warning [233]
  Elaine H Morrato, Benjamin Druss, Daniel M Hartung, Robert J Valuck, Deborah Thomas, Richard Allen, Elizabeth Campagna, John W Newcomer. (United States)

**11:15am**
- Quantification of Patient Population Impact of Contra-Indications: Glaucoma Therapy [234]
  Andrew Maguire, Sharon MacLachlan (United Kingdom)

**11:30am**
- Perceptions of Older Adults Regarding Information Obtained from Pharmacists and Medication Leaflets [235]
  Roberta Goldman, Anne L Hume, Brian J Quilliam, Pedro Pichardo, Devi Ross, Kate L Lapane. (United States)

**11:45am**
- Opioid Analgesic Abuse Surveillance: Convergence of Poison Control Center Intentional Exposure Calls and Media Reports [236]
  John Brownstein, Richard Dart, Meredith Y Smith. (United States)

**12:00pm**
- Evaluation of the Infliximab (Remicade®) Pediatric Crohn’s Disease Educational Plan [237]
  Alejandro Arana, Sam Allen, Ola Ghatnekar, María T Rico, Nathalie Vanhaverbeke, Jörg Burkowitz. Charles E Wentworth, Valerio Fantoni, Max Brosa, Felix M Arellanom (Spain)

**12:15pm**
- A Comparison of Health Outcomes and Healthcare Utilization during Episodes of Modified-Release Opioid Analgesic Therapy with and without Evidence of an Alcohol-Related Disorder [238]
  Meredith Y Smith, J David Haddox, Liisa Palmer. (United States)
Measurement Methods (Ballroom B)
Moderators: Tobias Gerhard & Tamar Lasky
11:00am
- Prescription Changes and Chronic Disease Score as Predictors for Hospitalization [239]
  Carolien GM Sino, Rutger Stufken, Eibert R Heerdink, Patrick C Souverein, Marieke J Schuurmans, Antoine CG Egberts. (Netherlands)
11:15am
- Positive Predictive Value (PPV) of Commercial Health Insurance Claims Data for Identifying Acute Pancreatitis (AP) in Patients with Diabetes Mellitus (DM) [240]
  David D Dore, Clorinda Hoffman, Sherry G Quinn, Saadja Chaudhry, John D Seeger. (United States)
11:30am
- Impact of Exposure Data Sources on Risk Estimates in Etiological Studies: Application to Benzodiazepines in the Three-City (3C) Study [241]
  Fabienne Bazin, Pernelle Noize, Antoine Pariente, Nicholas Moore, Annie Fourrier-Réglat. (France)
11:45am
- The Validity of Mother-Reported Asthma and Asthma Medication Use in Children [242]
  Kari Furu, Øystein Karlstad, Svetlana Skurtveit, Siri Haaberg, Per Naftstad, Stephanie London, Wenche Nystad. (Norway)
12:00pm
- Impact of Missing Data on Potential Confounders in Perinatal Pharmacoepidemiologic Studies Using Administrative Databases [243]
  Anick Bérard, Hamid R Nakhai-Pour, Sophie Kulaga. (Canada)
12:15pm
- Risk of Hospitalization among Rheumatoid Arthritis Patients Initiating Treatment with TNFα-Inhibitors: Effect of Different Exposure Measurements and Propensity Score Estimates [244]
  Carlos Grijalva, Lisa Kaltenbach, Patrick Arbogast, Edward Mitchel, Marie Griffin. (United States)

The Spectrum of Anti-Inflammatory Therapies (Room 552A)
Moderators: Sean Hennessy, FISPE & C. Ineke Neutel, FISPE
11:00am
- The Influence of CYP2D6, CYP3A4/3A5 and UGT2B7 Genetic Polymorphisms on Prescription of Other Analgesics in Codeine Users [245]
  Monique J Bijl, Loes E Visser, Ron HN van Schaik, Mark Eijgelsheim, Albert Hofman, Andre G Uitterlinden, Arnold G Vulto, Teun van Gelder, Bruno HCh Stricker. (Netherlands)
11:15am
- Risk of Serious Infections Among Patients with Rheumatoid Arthritis Initiating Treatment with Tumor Necrosis Alpha Antagonists [246]
  Carlos Grijalva, Lisa Kaltenbach, Patrick Arbogast, Edward Mitchel, Marie Griffin. (United States)
11:30am
- Changes in Overuse and Underuse of Prophylactic Strategies with NSAID Treatment over the Past Decade [247]
  VE Valkhoff, EM van Soest, MCJM Sturkenboom, EJ Kuipers. (Netherlands)
11:45am
- Concomitant Use of Gastroprotective Agents (GPAs) among NSAID/COX-2 Selective Inhibitor Users: A Hospital Register-Based Study [248]
  Jarir Atthobari, Erna Kristin, Iwan Dwiprahasto. (Indonesia)
12:00pm
- Randomized Controlled Trials on Cox-2 Inhibitors, Changes in Comparator Dose over Time [249]
  G Stefansdottir, ML de Bruin, MJ Knol, DE Grobbee, HGM Leufkens. (Netherlands)
12:15pm
- Association between Non-Steroidal Anti-Inflammatory Drugs and Keratinocyte Cancer Prevention: VATTC Trial [250]
  Anthony P Nunes, Kate L Lapane, Martin A Weinstock. (United States)
Use and Risks of Psychotropics in Elderly Persons (Room 557)

Moderators: Vincent Mor & Lauri Daiello

11:00am
- Socioeconomic Determinants of Psychotropic Drug Use Among Elderly [251]
  Eva Lesén, Karolina Andersson, Max Petzold, Anders Carlsten. (Sweden)

11:15am
- Antipsychotics and the Risk of Hip Fracture, Pneumonia and Stroke: Self-Controlled Case Series and Instrumental Variable Analysis Results [252]
  Nicole Pratt, Elizabeth Roughhead, Philip Ryan, Robert Peck, Andrew Gilbert. (Australia)

11:30am
- Antipsychotic Use and the Risk of Hip Fracture in Nursing Home Residents with Dementia [253]
  Jessica J Jalbert, Susan C Miller, Charles B Eaton, Kate L Lapane. (United States)

11:45am
- Factors Associated with Discontinuation of Cholinesterase Inhibitors in the Netherlands [254]
  Edeltraut Kröger, Rob van Marum, Patrick Souverein, Toine Egberts. (Netherlands)

12:00pm
- Impact of Non-Persistence to Cholinesterase Inhibitor Treatments in Demented Elderly [255]
  Antoine Pariente, Annie Fourrier-Réglat, Alice Dragomir, Sylvie Perreault, Nicholas Moore, Yola Moride. (France)

12:15pm
- Risk of Upper Gastrointestinal Bleeding and Degree of Serotonin Reuptake Inhibitions among Elderly Patients in Korea [256]
  Ye-Jee Kim, Nam-Kyong Choi, Sun-Young Jung, Jong-Mi Seong, Joongyub Lee, Byung-Joo Park. (Republic of Korea)
**Agenda - Tuesday, August 18**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30-2:00pm</td>
<td>Lunch/Poster Session B/Exhibits/Poster Walks (Hall B)</td>
</tr>
<tr>
<td></td>
<td><strong>Poster Walks/Moderators</strong></td>
</tr>
<tr>
<td></td>
<td>- Pharmacovigilance</td>
</tr>
<tr>
<td></td>
<td>Harry Seibert</td>
</tr>
<tr>
<td></td>
<td>- Molecular Epidemiology/Pharmacogenetics</td>
</tr>
<tr>
<td></td>
<td>Weu Zhou &amp; David Miller</td>
</tr>
<tr>
<td></td>
<td>- Drug Utilization Studies</td>
</tr>
<tr>
<td></td>
<td>Monique Elseviers</td>
</tr>
<tr>
<td></td>
<td>- Biologics</td>
</tr>
<tr>
<td></td>
<td>Pavel Napalkov</td>
</tr>
<tr>
<td></td>
<td>- Use of Linked Database</td>
</tr>
<tr>
<td></td>
<td>Matthew R. Reynolds</td>
</tr>
<tr>
<td></td>
<td><strong>ISPE Committee/Council Meetings</strong></td>
</tr>
<tr>
<td></td>
<td>- Open to all participants. (Lunches will be</td>
</tr>
<tr>
<td></td>
<td>available in meeting rooms)</td>
</tr>
<tr>
<td></td>
<td>- Bylaws and Policies Committee (Room 558A)</td>
</tr>
<tr>
<td></td>
<td>- Global Development Committee (Room 554A)</td>
</tr>
<tr>
<td></td>
<td>- Membership Committee (Room 554B)</td>
</tr>
<tr>
<td></td>
<td>- Publications Committee (Room 558B)</td>
</tr>
<tr>
<td>1:00-2:00pm</td>
<td><strong>Public Forum on Core Competencies for Pharmacoepidemiology (Ballroom A)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Sponsored by ISPE Education Committee</strong></td>
</tr>
<tr>
<td></td>
<td>- NOTE: Eat first–lunch will not be available</td>
</tr>
<tr>
<td></td>
<td>at this session</td>
</tr>
<tr>
<td></td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td></td>
<td>- James D. Lewis, FISPE, Chair, Education</td>
</tr>
<tr>
<td></td>
<td>Committee</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator, Introduction</strong></td>
</tr>
<tr>
<td></td>
<td>- Hugh Tilson, FISPE</td>
</tr>
<tr>
<td></td>
<td><strong>Data Presentation</strong></td>
</tr>
<tr>
<td></td>
<td>- Judith Jones, FISPE</td>
</tr>
<tr>
<td></td>
<td><strong>Panel Comments</strong></td>
</tr>
<tr>
<td></td>
<td>- Jennifer Polinski, Student Council</td>
</tr>
<tr>
<td></td>
<td>- Wei Dong, Manufacturing/Service</td>
</tr>
<tr>
<td></td>
<td>Provider Council</td>
</tr>
<tr>
<td></td>
<td>- Anna Birna Almarsdóttir, Academic Council</td>
</tr>
<tr>
<td></td>
<td>- Richard Hill, Government/Regulatory Council</td>
</tr>
<tr>
<td></td>
<td><strong>Open Discussion</strong></td>
</tr>
<tr>
<td>2:00-3:30pm</td>
<td><strong>Concurrent Sessions ~ Contributed Papers</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Cancer All Over the Place! (Room 551A)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators: Annette Beiderbeck &amp; Jim Kaye</strong></td>
</tr>
<tr>
<td>2:00pm</td>
<td>- Half of Breast Cancer Patients Starting on Tamoxifen</td>
</tr>
<tr>
<td></td>
<td>Complete Five Years of Endocrine Treatment [257]</td>
</tr>
<tr>
<td></td>
<td>Myrthe PP van Herk-Sukel, Adri C Voogd, Grard AP</td>
</tr>
<tr>
<td></td>
<td>Nieuwenhuijzen, Ron MC Herings, Jan Willem W Coebergh,</td>
</tr>
<tr>
<td></td>
<td>Lonneke V van de Poll-Francse. (Netherlands)</td>
</tr>
<tr>
<td>2:15pm</td>
<td>- Dose Response of Retinol and Isotretinoin in the</td>
</tr>
<tr>
<td></td>
<td>Prevention of Non-Melanoma Skin Cancer Recurrence</td>
</tr>
<tr>
<td></td>
<td>[258] Mary C Clouser, Denise J Roe, Janet A Foote,</td>
</tr>
<tr>
<td></td>
<td>Robin B Harris. (United States)</td>
</tr>
<tr>
<td>2:30pm</td>
<td>- Incidence Rates of ARDS in Solid Tumor Cancer</td>
</tr>
<tr>
<td></td>
<td>Patients in the THIN Database [259]</td>
</tr>
<tr>
<td></td>
<td>Victor Gastanaga, Chuck Wentworth, Anthony Yeo,</td>
</tr>
<tr>
<td></td>
<td>Gail Hughes, William Haddock, Sean Zhao. (United</td>
</tr>
<tr>
<td></td>
<td>States)</td>
</tr>
<tr>
<td>2:45pm</td>
<td>- Patients (Pts) with Metastatic Renal Cell Carcinoma</td>
</tr>
<tr>
<td></td>
<td>(mRCC) Receiving Angiogenesis Inhibitor (AI)</td>
</tr>
<tr>
<td></td>
<td>Therapies: Treatment Efficacy and Safety in Clinical</td>
</tr>
<tr>
<td></td>
<td>Practice [261]</td>
</tr>
<tr>
<td></td>
<td>David McDermott, Toni K Choueiri, Jessica Clement,</td>
</tr>
<tr>
<td></td>
<td>Ashley J Brick, Christabel Kwabi, Karishma Shah,</td>
</tr>
<tr>
<td></td>
<td>Lucia Antras, Sujata S Jayawant, Si-Tien Wang,</td>
</tr>
<tr>
<td></td>
<td>Andi Luka, Mei Sheng Duh, Maureen Neary, William K</td>
</tr>
<tr>
<td></td>
<td>Oh. (United States)</td>
</tr>
<tr>
<td>3:00pm</td>
<td>- Pattern of Bevacizumab (BV) Use in 1st-Line Therapy</td>
</tr>
<tr>
<td></td>
<td>Metastatic Colorectal Cancer (mCRC) in Real-Life</td>
</tr>
<tr>
<td></td>
<td>Practice: Results of the ETNA Cohort Study [262]</td>
</tr>
<tr>
<td></td>
<td>A Fourrier-R[acutel]lat, D Smith, A Ravaud, M</td>
</tr>
<tr>
<td></td>
<td>Rouyer, A Balestra, D Jayles, N Moore, ETNA Study</td>
</tr>
<tr>
<td></td>
<td>Group.</td>
</tr>
</tbody>
</table>
Agenda - Tuesday, August 18

Cardiovascular Disease (Ballroom D)
Moderators: Annlouise Assaf & Cristina Varas

2:00pm
- Antipsychotic Use and Myocardial Infarction in Demented Patients Treated with Cholinesterase Inhibitors [263]
  Antoine Pariente, Yola Moride, Alice Dragomir, Sylvie Perreault, Nicholas Moore, Annie Fourrier-Réglat. (France)

2:15pm
- Do Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs Increase the Risk of Cardiovascular Events and Death after Intracoronary Stenting? [264]
  M Schmidt, M Maeng, L Pedersen, JF Lassen, TT Nielsen, HT Sorensen. (Denmark)

2:30pm
- Evaluation of the Level of Anticoagulation Control in Patients with Non-Valvular Atrial Fibrillation [265]
  Bill Zang, Efrosini Setakis, Tjeerd P van Staa. (United Kingdom)

2:45pm
- Non-Selective α-Blockers Decrease Thrombotic Events in Patients with Heart Failure [266]
  Olav R De Peuter, Patrick C Souverein, Olaf H Klungel, Ton de Boer, Harry R Büller, Pieter-Willem Kamphuisen. (Netherlands)

3:00pm
- Oral Bisphosphonates and the Risk of Atrial Fibrillation in a Cohort of Older Adults [267]
  Linda Lévesque, Ana Blagojevic, Mahyar Etminan, James Brophy. (Canada)

3:15pm
- Case-Control Study: Use of Oral Contraceptives Containing Dienogest and Risk of Venous Thromboembolism [268]
  Juergen C Dinger, Kristina Voigt, Sabine Moehner. (Germany)
Potpourri Session (Ballroom B)
Moderators: Gianluca Trifiro and Rene Schade

2:00pm
- Population-Based Studies of Antithyroid Drugs and Sudden Cardiac Death [609]
  Charlotte van Noord, Miriam CJM Sturkenboom, Sabine MJM Straus, Jacqueline CM Witteman, Bruno HC Stricker. (Netherlands)

Student Award Recipient - Best Abstract

2:15pm
- Outcomes Following a Hip Fracture and Length of Hospitalization: The General Practice Research Database (GPRD) [610]
  Arlene Gallagher, Frank de Vries, Rinat Ariely, Tjeerd van Staa. (United Kingdom)

2:30pm
- Polymorphisms in Two Regions of the Cyclo-Oxygenase-2 Gene Associated with Variation in Risk of Coronary Thrombosis with Cyclo-Oxygenase-2 Inhibitors [611]
  D Henry, L Lincz, J Attia, P McElduff, B Bisset, R Peel, S Hancock, K Henderson, D Whitaker, M Seldon, P McGettigan. (Canada)

2:45pm
- Human Avian Influenza: Development of a Shoe-Leather Approach to Evaluating Treatment Effectiveness [612]

3:00pm
- Gabapentin Use in the US Department of Veterans Affairs [613]
  JE Lavigne, D Ganoczy, KL Knox, M Valenstein.

3:15pm
- Changing Rate of Blood-Stream Infection across Duration of Central Venous Access [614]
  Mary Ritchey, Michele Jonsson Funk, Stephen Marshall, Danica Marinac-Dabic, William Rutala, David Weber. (United States)

Student Award Recipient - Second Best Abstract

Risk Factors, Surveillance, and Comorbidity Burden (Room 551B)
Moderators: Wei Dong & Brian J. Quilliam

2:00pm
- Validation of the National Respiratory and Enteric Virus Surveillance System for the Detection of Respiratory Syncytial Virus Seasons [269]
  Christian Hampp, Almut Winterstein. (United States)

2:15pm
- Hepatitis C Virus Genotype and Basal Viral Load Distribution in Different Regions of Mexico [270]
  Ricardo Jimenez-Mendez, Felipe Uribe-Salas, Paulo Lopez-Guillen, Gilberto Castaneda-Hernandez. (Mexico)

2:45pm
- Modifiable Risk Factors among Uninsured, Insured and Medicaid-Insured United States Adults Aged 18 to 64 Years [271]
  Margaret McDonald, Robin P Hertz, Michael B Lustik, Alan N Unger. (United States)

3:00pm
- Type 2 Diabetes and Incidence of Urinary Tract Infections (UTIs). Experience from the General Practice Research Database (GPRD) [272]
  Ishan Hirji, Zhenchao Guo, Susan Andersons, Niklas Hammar, Andres Gomez Caminero. (United States)

3:15pm
- Comorbidity in Patients with Non-Small Cell Lung Cancer (NSCLC) – The Cancer and Comorbidity (CACOM) Study [273]
  Fredrik Nyberg, Tobias Svensson, Helle Kieler, Mats Lambe, Anders Ekborn, Fredrik Granath. (Sweden)

3:30pm
- Renal Cell Carcinoma Patients Are Twice as Likely To Develop Thromboembolic Events Compared to Cancer-Free Controls [274]
  Myrthe PP van Herk-Sukel, Sumitra Shantakumar, Mariel K Casparie, Page E Abrahamson, Femie JA Penning-van Beest, Ron MC Herings. (Netherlands)
To Do No Harm....? (Room 557)
Moderators: Frank May, FISPE, & Yea-Huei Kao Yang

2:00pm
- Prevalence, Nature and Severity of Prescribing Errors in Hospital Inpatients: Prospective Study in 20 UK Hospitals [275]
  Darren M Ashcroft, Penny J Lewis, Emma Carter, David Taylor, Mary P Tully, Valerie Wass, Steven Williams, Timothy Doman. (United Kingdom)

2:15pm
- Prevalence, Clinical Profile, and Preventability of Drug-Related Hospital Admissions: Prospective Observational Study [276]
  Darren M Ashcroft, Chuenjid Kongkaew, Steven Williams, David Metcalfe, Jaydeep Mandal, Peter Noyce. (United Kingdom)

2:30pm
- Computerized Clinical Decision Support during Medication Ordering for Long-Term Care Residents with Renal Insufficiency [277]
  Terry S Field, Paula Rochon, Monica Lee, Joann L Baril, Jerry H Gurwitz. (United States)

2:45pm
- RCT of a Computer Hard Stop Order Alert vs Routine Practice To Prevent Concurrent Orders of Trimethoprim/Sulfamethoxazole and Warfarin [278]
  Brian L Strom, Rita Schinnar, Faten Aberra, Warren Bilker, Sean Hennessy, Charles E Leonard, Eric Pifer. (United States)

3:00pm
- The Effectiveness of Collaborative Medicine Reviews in Delaying Time to Next Hospitalisation for Heart Failure Patients in the Ambulatory Setting: Results of a Cohort Study [279]
  Andrew L Gilbert, Elizabeth E Roughead, John D Barratt, Emmea Ramsey, Nicole Pratt, Philip Ryan, Robert Peck, Graeme Killer. (Australia)

3:15pm
- Quality of Consumer Generated Adverse Event Reports [280]
  Rose C Plummer, Elisa F Cascade. (United States)

3:30-4:00pm
Break/Posters/Exhibits
Agenda - Tuesday, August 18

5:30-6:30pm
Special Interest Group (SIG) Meetings
• Open to all participants.
  • Biologics SIG (Room 551A)
  • Database SIG (Room 551B)
  • Drug Utilization/Health Services Research SIG (Ballroom B)
  • Medications in Pregnancy SIG (Room 552A)
  • Molecular Epidemiology/Pharmacogenetics SIG (Room 55B)

7:30-Midnight
Evening at the Waterplace Restaurant
Join your colleagues to help celebrate ISPE’s Silver Anniversary ICPE on this special evening. Brass Attack, Southern New England’s finest dance band, will provide the music. And ISPE will host a WaterFire – an award-winning sculpture by Barnaby Evans and truly an unforgettable sensory experience, at dusk.
Admission is by badge or ticket. Cash bar

Brass Attack

Water Fire
Photo credit: Providence/Warwick Convention & Visitors Bureau

The Most Trusted Epidemiology Resources

Epi Database® is a global database that provides reliable, documented, and well-researched epidemiological estimates across therapeutic areas.

- Includes over 190 indications and covers France, Germany, Italy, Spain, the United Kingdom, Japan, the United States, Brazil, Russia, India, and China
- Thoroughly researched in scientific literature, with fully documented sources that provide complete transparency
- Breakouts are provided by country, indication, and year, as well as gender, race, and age if applicable.

CancerMPact® Patient Metrics module is a comprehensive resource for historical, current, and projected cancer epidemiology and treatment estimates.

Best-in-class information and proprietary calculations provide stage specific data on:
- Incidence
- Restaged 10-year prevalence
- Active Disease
- Treated patient populations by modality
- Treated patient populations by drug regimen
- Includes analysis of 30 tumor types by country for the U.S., France, Germany, Italy, Spain, the UK, and Japan

Visit our booth for a demonstration.
info@mattsonjack.com • www.mattsonjack.com

30 August 16-19, 2009 Providence, RI ICPE 2009
Need **Evidence**?

- Patient Registries
- Safety / Surveillance
- Risk Management
- Health Outcomes
- Phase IV Studies
- Quality of Life
- Comparative Effectiveness
- Phase IIIB Expanded Access
- Quality Measurement
- Quality Improvement
- Health Interventions
- Observational Studies

**Talk to the Leader** in Real-World Research.
Visit us at the Annual ICPE Meeting in Providence.

**OUTCOME™**
real-world results™

www.outcome.com  evidence@outcome.com  617-621-1600  +41 (0) 21 321 3560

© 2009 Outcome Sciences, Inc. All Rights Reserved
7:00-8:00am
2010 ICPE Scientific Program Committee Meeting (Room 557)
• Open to interested ISPE members

7:30-8:30am
Poster Session C Set-up (Hall B)
Continental Breakfast (Hall B)

7:30-5:00pm
Registration (Third Floor Foyer)

7:30-3:30pm
Speakers’ Ready Room (Room 553B)

8:00-1:45pm
Exhibits/Posters (Hall B)

8:30-10:00am
Concurrent Sessions - Contributed Papers

Analysis Methods II (Ballroom B)
Moderators: John Seeger & Tomasz Dyszynski

8:30am
• Using Different Types of Priors in a Bayesian Hierarchical Model for the Analysis of Drug Adverse Events [438]
  David Prieto-Merino, Stephen JW Evans. (United Kingdom)

8:45am
• The Effect of Psychotropic Medication Among Children On Changes in Mental Health: A Comparison of Marginal Structural Models (MSM) with Standard Regression Adjustment [439]
  Shirley Wang. (United States)

9:00am
• Predictors of Nucleoside Reverse Transcriptase Inhibitor Use: Channeling Bias in HIV Clinical Care [440]
  Emily S Brouwer, Sonia Napravnik, Joseph J Eron Jr. (United States)

9:15am
• Hurdle or No Hurdle? Select Appropriate Statistical Methods for Modeling Rare Events [441]
  Liping Huang, George Quartey, Jamie Robinson. (United States)

9:30am
• Reporting of Case-Series in Drug Safety: A Review of Published Studies [442]
  Antoine Pariente, Claire Nour Abou Chakra, Marion Pinet, Nicola Moore, Yola Moride. (Canada)

9:45am
• Significance of Incorporating Real World Clinical Non-Adherence and Drug Adverse Events Data into Pharmacoeconomic Models: Statins Example [443]
  Pendar Farahani, Gray Ellrodt. (United States)

8:30-5:00pm
Diabetes From Legs To Death (Room 551A)
Moderators: Niklas Hammar & Andrej Czarnecki, FISPE

8:30am
• Use of Thiazolidinediones and the Risk of Fracture in Patients with Type II Diabetes in Taiwan [444]
  Churn-Shiou Gau, Yi-Shiu Lin. (Taiwan)

8:45am
• Thiazolidinediones and Fractures in Men and Women [445]
  Colin R Dormuth, Greg Camey, Bruce Carleton, Ken Bassett, James M Wright. (Canada)

9:00am
• Effect of Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors on Limb Amputation [446]
  David Margolis, Ole Hoffstad, Tim Crombleholme. (United States)

9:15am
• Incidence of Acute Pancreatitis in Exenatide Initiators Compared to Other Antidiabetic Drug Initiators: A Retrospective, Cohort Study [447]
  David Dore, Gary Bloomgren, Ruth Patterson, Sherry Quinn, Clorinda Hoffman, Saadia Chaudhry, Rebecca Noel, Daniel Braun, John Seeger. (United States)

9:30am
• Adverse Cardiovascular Events during Treatment with Pioglitazone and Rosiglitazone [448]
  David N Juurlink, Tara Gomes, Lorraine L Lipscombe, Peter C Austin, Jan E Hux, Muhammad M Mamdani. (Canada)

9:45am
• Combination Therapy of Sulfonylureas and Metformin and the Risk of Death in Patients with Type 2 Diabetes [449]
  Laurent Azoulay, Verena Schneider-Lindner, Sophie Dell’Aniello, Alicia Schiffrin, Samy Suissa. (Canada)
Drug Utilization: Session II (Room 551B)
Moderators: Andrew Gilbert & Monique Elsevier

8:30am
  V Schneider-Lindner, S Dell’Aniello, A Kezouh, C Quach, J Hanley, S Suissa. (Canada)

8:45am
- Off-Label Use of Antipsychotic Drugs in Privately and Publicly Insured Youth in the US [451]
  Stephen Crystal, Tobias Gerhard, Cecilia Huang, Mark Olfson. (United States)

9:00am
- Physician Preference Motivates Use of Anti-TNF Therapy Independent of Clinical Disease Activity [452]
  Jeffrey R Curtis, Lang Chen, Leslie Harrold, Pongthorn Narongroeknawin, George Reed, Daniel H Solomon. (United States)

9:15am
- Levetiracetam One Year Retention Rate in Real-Life Practice in France, Final Results of the EULEV Study [453]
  C Droz, C Dureau, H Vespignani, C Marchal, J Jové, N Moore, A Fourrier. (France)

9:30am
- Use of Cardioprotective Drugs in Newly Treated Individuals with Type 2 Diabetes Aged Under 65 [454]
  Anis Ben Abdeljelil, Jocelyne Moisan, Jean-Pierre Grégoire. (Canada)

9:45am
- Polypharmacy in Chronic Diseases in the Elderly: Evidence-Based or Potentially Inappropriate Prescribing? [455]
  Gillian Caughey, Agnes Vitry, Andrew Gilbert, Elizabeth Roughead. (Australia)
Medications in Pregnancy and Birth Outcomes II (Room 552A)
Moderators: Janneke Jentink & Sara A. Ephross

8:30am
- Descriptive Study of the Administration of Category X Medications during Pregnancy Using an Outpatient Electronic Health Record [456]
  Brian L Strom, Rita Schinnar, Joshua Jones, Warren Bilker, Mark Weiner, Sean Hennessy, Charles E Leonard, Peter Cronholm, Eric Pifer. (United States)

8:45am
- Trimethoprim Use Prior to Pregnancy and Risk of Congenital Malformation: A Register Based Nationwide Cohort Study [457]
  Jon T Andersen, Morten Petersen, Jeppe N Rasmussen, Nadia LT Andersen, Christian Torp-Pedersen, Henrik E Poulsen. (Denmark)

9:00am
- Linking a Pharmaceutical Claims Database with a Birth Defects Registry To Investigate Birth Defect Rates of Known Teratogens [458]
  Lyn Colvin, Linda Slack-Smith, Fiona J Stanley, Carol Bower. (Australia)

9:15am
- Maternal Use of Bupropion and Risk for Congenital Heart Defects [459]
  Sura Alwan, Jennita Reefhuis, Lorenzo Botto, Adolfo Correa, Sonja Rasmussen, Jan Friedman. (United States)

9:30am
- Early-Pregnancy Opioid Analgesic Treatment and Risk for Congenital Heart Defects [460]
  CS Broussard, SA Rasmussen, J Reefhuis, JM Friedman, MW Jann, MA Honein. (United States)

9:45am
- Does Decongestant Use during Pregnancy Reduce Preterm Delivery? [461]
  Rohini K Hernandez, Allen A Mitchell, Martha M Werler. (United States)
Agenda - Wednesday, August 19

Psychotropics II: Safety of Psychotropics (Room 552B)
Moderators: James Wilson & Jessica Jalbert

8:30am
• General Population Risk of Suicide Attempt Compared to Depressed Untreated and Antidepressant Treated Populations [462]
  Robert J Valuck, Heather D Orton, Anne M Libby. (United States)

8:45am
• Use of Antiepileptic Drugs in Epilepsy and the Risk of Self Harm and Suicidal Behaviour [463]
  Frank Andersohn, René Schade, Carlos Martinez, Stefan N Willich, Edeltraut Garbe. (Germany)

9:00am
• Use of Dopaminergic Drugs and Risk of Hip or Femur Fracture: A Population-Based Case-Control Study [464]
  Maurits Arbouw, Kris Movig, Tjeerd van Staa, Toine Egberts, Patrick Souverein, Frank de Vries. (Netherlands)

9:15am
• Renal Outcomes in People with Bipolar Disorder Treated with Lithium: A Retrospective Cohort Database Study [465]
  Joe Reilly, Helen Close, John Main, Mukesh Kripalani, Pali Hungin, Douglas Wilson, James Mason. (United Kingdom)

9:30am
• Effects of Preexisting Cardiovascular Risk Factors on Initiation of Stimulants in Adults Newly Diagnosed with ADHD [466]
  Tobias Gerhard, Almut Winterstein, Mark Olfson, Arwa Saidi, Stephen Crystal. (United States)

9:45am
• Extensive Psychotropic Drug Use among Icelandic Children: A Nationwide Population Based Study [467]
  Helga Zoega, Gísli Baldursson, Birgir Hrafnkelsson, Anna B Almarsdóttir, Unnur Vaidmarsdóttir, Matthías Halldórsson. (Iceland)

10:00-10:30am
Break/Posters/Exhibits (Hall B)

10:30-Noon
Concurrent Sessions: Symposia & Workshops

Assessment of Prenatal Exposure to Medications [616] (Room 552B)
• Lyn Colvin, Sonia Hernandez-Diaz, Elizabeth Andrews, Allen Mitchell, Tina Chambers, Pamela E Scott, Richard Hill. (United States)
  Sponsored by the Medicines in Pregnancy SIG and the Teratology Society

RMP, RiskMAP and REMS: The Challenges of Epidemiology [470] (Ballroom D)
• Patricia Saddier, Susana Perez-Gutthann, Annette Stemhagen, Rekha Garg, Stella Blackburn, Gerald Dal Pan. (United States)

Benchmarking of Healthcare Databases To Improve Harmonization [468] (Room 551A)
• Miriam Sturkenboom, Martijn Schuemie, Gianluca Trifiro, Annie Fourrier, Preciosa CoIoma, Jeffrey Brown, BJ Park, Helle Kieler, Ron Herings. (Netherlands)

Assessing the Association of Pharmacotherapeutics and Suicidal Behavior: Lessons from the Front [281] (Room 551B)
• Jamie Geier, Juhaeri Juhaeri, Daniel Mines, Andrew Mosholder, Madhukar Trivedi, Sybil Eng, Mary Lou Skovron, Paul Stang, Nataliya Volkova. (United States)

Safety Assessment and Risk Management of Biologics–Challenges and Opportunities (Biologics SIG) [471] (Ballroom B)
• Thijis J Giezen, Brigitte Keller, Anders Sundstrom, Aaron S Kesselheim, Wei Dong, Judith K Jones, Hans Petri. (Netherlands)

The Future of Epidemiology [472] (Room 557)
• Ken Rothman, Gerald Dal Pan, Stephen Evans, Paul Stang, Judith Jones, Til Sturmer. (United States)

Using Databases for both Hypothesis Generating and Hypothesis Confirmation: One Database or Two? [473] (Room 552A)
• Larry Gould, Alec Walker, Patrick Ryan, Sebastian Schneeweiss, Nancy Santanello, Susan Sacks. (United States)

You will notice that the “ICPE 25th Anniversary” logo has been appended to selected sessions. These sessions have been selected because the topics are broad and reach into the future of our field.
Agenda - Wednesday, August 19

Noon-1:30pm
Lunch/Poster Session C/Exhibits/ Poster Walks (Hall B)

Poster Walks/Moderators
- Pharmacovigilance – Harry Seifert
- Use of Linked Databases – Matthew R. Reynolds
- Biologics – Pavel Napalkov
- Drug Utilization Studies – Monique Elseviers

ISPE Board of Directors Luncheon (Room 554AB)
- Meeting open to all members; check with staff if you wish to attend

1:30-3:00pm

Invited Plenary

FDA’s Sentinel Initiative Project
(Ballroom A)

Chair: Scott Smith, Agency for Healthcare Research & Quality

Panelists:
- Richard Platt, Harvard University
- Mark McClellan, Engelberg Center for Health Care Reform, The Brookings Institution
- Invited, FDA
- Miriam CJM Sturkenboom, Erasmus University Medical Center

3:00-4:30pm

Hot Topics Session:

Clopidogrel: Has the Pharmacogenetics Era Arrived?
(Ballroom A)

Chair: Leah Sansbury, National Cancer Institute, National Institutes of Health

Panelists:
- Jessica Mega, Thrombolysis in Myocardial Infarction Study Group, Brigham and Women’s Hospital, Harvard Medical School; Clopidogrel Pharmacogenetics: Overview of The TIMI

Study Results
- O.H. Klungel, Department of Pharmaceutical Sciences, Utrecht University; Methodological Aspects of Clopidogrel Pharmacogenetics
- Alan R. Shuldiner, Professor of Medicine, University of Maryland School of Medicine; Perspective on Potential Clinical Utility of Clopidogrel Pharmacogenetics (Recent MI, Recent Stroke or Established Peripheral Arterial Disease)
- Bonny Lewis Van, Pharmacogenetic Epidemiologist; Potential Clinical Utility with Coronary Stents/ Summary Perspective of Future Direction of Pharmacogenetic Epidemiology.

4:30-5:00pm

The Final Word (Ballroom A)

Moderator
Kate L. Lapane, FISPE, Chair, 2009 Scientific Program Committee

Poster Awards
- Wei Dong, Chair, Poster Awards Committee

ICPE 2010 Brighton, England, UK
- Corinne de Vries, Chair, 2010 Scientific Program Committee

5:00pm
Adjournment of ICPE 2010
In drug safety, you need the perspective of a team with a proven track record.

Join PPD & WHISCON at ICPE.

When it comes to identifying benefits and risks in late-stage research, you need the perspective of a team of experts who has been there before. PPD, in collaboration with WHISCON, brings knowledge gained from thousands of clinical trials and hundreds of safety studies to help you confidently manage your product’s safety.

Visit PPD’s booth at ICPE to gain insight from David Brown, executive director of epidemiology at PPD, and Alec Walker and Deb Hennessey, founders of WHISCON.

Visit www.ppd.com/services/post-approval and www.WHISCON.com to learn more.

Gain insight from Alec Walker at the following events:
15 Aug: Journal Club panel
19 Aug: “Using Databases for Both Hypothesis Generating and Hypothesis Confirmation: One Database or Two?”

Helping you Advance the Science of Safety

PRECLINICAL/PHASE I > PHASE II-IIID > POST-APPROVAL > LABS

www.ppd.com

© 2009 Pharmaceutical Product Development, Inc. All Rights Reserved. PPD is a trademark of PPD. Other marks are the property of their respective owners.
Overview
Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

Poster Session
Posters will be displayed in Hall B of the Rhode Island Convention Center (RICC) August 17-19. Each day will have a separate poster session. All posters for a specific day’s session must be removed that day.
- **Monday, August 17** .......... Poster Session A
- **Tuesday, August 18** ............ Poster Session B
- **Wednesday, August 19** .......... Poster Session C

1. Set Up
- **Monday & Tuesday** .......... 7:00-8:00am
- **Wednesday** .................. 7:30-8:30am

2. Hours
- **Hall B will be open for the attendees from:**
  - 8:00am-6:00pm .......... Monday and Tuesday
  - 8:00am-1:45pm ............. Wednesday

3. Discussion Time
- **General:** Presenters should be at their posters between 12:15-1:15pm (Monday & Wednesday), and 12:45-1:45pm on Tuesday.
- **Poster Walks** – organized by the ISPE Special Interest Groups (SIG)
  - **Monday:** Pharmacovigilance; Medicines in Pregnancy/Birth Defects; Drug Utilization Studies; & Uses of Linked Database
  - **Tuesday:** Pharmacovigilance; Molecular Epidemiology/Pharmacogenetics; Drug Utilization Studies; Biologics; and Uses of Linked Database
  - **Wednesday:** Pharmacovigilance; Uses of Linked Databases; Biologics; and Drug Utilization Studies

The poster walks offer selected presenters the opportunity to present their work and to discuss their results with an audience. Participants in these categories should be at their posters between 12:15-1:15pm (Monday & Wednesday), and 12:45-1:45 (Tuesday). When the poster walk chair and audience stop at your poster, please give a brief, 3-minute, presentation and to answer questions about your research.

4. Poster Prizes
A group of judges will select the best posters of each poster walk. The best presenters will receive an invitation to display their poster for the duration of the ICPE. The best posters will be announced at The Final Word session at 4:30pm, August 19.

5. Take Down
All posters must be taken down by 6:30 pm on Monday and Tuesday; posters must be taken down by 5:00pm on Wednesday.

Numbering System
- Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster in the Final Program, which will be available at the ISPE Registration Desk (3rd Floor Foyer/RICC). The poster number is the first number listed. Please note the number may differ from that shown in the preliminary program. The abstract number, for use in locating abstracts in the Final Program and the special issue of Pharmacoepidemiology and Drug Safety, is in brackets [ ] after the title of the abstract.

Poster Specifications
1. Posters must be designed to fit a space 4 feet HIGH by 8 feet WIDE; POSTER ORIENTATION: LANDSCAPE. Business cards or small leaflet literature for distribution may be inserted in an envelope and affixed to the board.

2. Posters may be attached to the boards using Velcro. All poster presenters are encouraged to bring their own supplies.

3. Disclosure Statement
A disclosure statement must accompany each abstract submission and each presentation. This statement must list all funding sources for the current project, as well as other potentially conflicting relationships that existed at any time during the conduct of the study, or at a minimum, the 1-year period before the ICPE. Non-financial conflicts (e.g., a close relationship with, or a strong antipathy to, a person whose interests may be affected) should also be disclosed.

NOTE: ISPE and the RICC are not responsible for any poster that is left up overnight or is lost or damaged.
<table>
<thead>
<tr>
<th>Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. The Need for Right Censoring for Identification of Secondary Care Outcomes in THIN – A UK GP Database [68]</td>
</tr>
<tr>
<td>Alison Bourke, Michelle Hards, Hassy Daftani. (United Kingdom)</td>
</tr>
<tr>
<td>2. Withdrawn by author [35]</td>
</tr>
<tr>
<td>3. Absence of Evidence and Evidence of Absence in Population-Based Studies [69.5]</td>
</tr>
<tr>
<td>Zuleika Aponte, Marco Pavesi, Swati Basu. (Spain)</td>
</tr>
<tr>
<td>4. Bayesian Prescribing Model for Cox-2 Selective NSAIDS [70]</td>
</tr>
<tr>
<td>Margaret R Stedman, MA Brookhart. (United States)</td>
</tr>
<tr>
<td>5. Bridging Cardiovascular Risk from Clinical Trials to Real Life Population [71]</td>
</tr>
<tr>
<td>ASY Chain, C Vannoord, JP Dieleman, M Danhoff, MCJM Sturkenboom, O Della Pasqua. (Netherlands)</td>
</tr>
<tr>
<td>6. Validation of Ischemic Cerebrovascular Diagnoses in the Health Improvement Network (THIN) [72]</td>
</tr>
<tr>
<td>Ana Ruigómez, Elisa Martin-Merino, Luis A García Rodríguez. (Spain)</td>
</tr>
<tr>
<td>7. Automated Selection of Interaction Terms for Poisson Regression Models with Many Dichotomous Variables from Large Scale Observational Databases [73]</td>
</tr>
<tr>
<td>Alan M Hochberg. (United States)</td>
</tr>
<tr>
<td>8. Compliance Bias in a Cohort Study of Older Adults Treated with Oral Bisphosphonates [74]</td>
</tr>
<tr>
<td>Linda Lévesque, Ana Blagojevic, Mahyar Emtinan, James Brophy. (Canada)</td>
</tr>
<tr>
<td>Hoa V Le, Kathleen J Beach. (United States)</td>
</tr>
<tr>
<td>10. Data-Driven Analysis of All Recorded Comorbidities in Persons with a Diagnosis of Rheumatoid Arthritis (RA) in Marketscan US Claims Database [76]</td>
</tr>
<tr>
<td>Hans Petri, Debra Maldonato, Noah Robinson. (United Kingdom)</td>
</tr>
<tr>
<td>11. Meta-Analysis for Drug Development and Risk Management [77]</td>
</tr>
<tr>
<td>Matthew W Reynolds, Tamar Lasky, FDA Representative. (United States)</td>
</tr>
<tr>
<td>12. Comparison of Alpha-Spending Plans for Influenza Vaccine Safety Surveillance [78]</td>
</tr>
<tr>
<td>SK Sandhu, D Burwen, T Macurdy, J Gibbs, E Rusev, B Garcia, C Sholley, D Marston, K Elmo, H Izurieta, R Ball. (United States)</td>
</tr>
<tr>
<td>13. Abstract Withdrawn by Author [79]</td>
</tr>
<tr>
<td>Cancer</td>
</tr>
<tr>
<td>14. Update on the Absence of Interaction between Tamoxifen and the SSRI Citalopram with Respect to Protection Against Breast Cancer Recurrence [80]</td>
</tr>
<tr>
<td>Deirdre Cronin-Fenton, Timothy L Lash, Lars Pedersen, Thomas P Ahern, Carol L Rosenberg, Rebecca A Silliman, Kathy L Lunetta, Stephen Hamilton-Dutoit, Jens P Garner, Marianne Ewertz, Henrik T Sørensen. (Denmark)</td>
</tr>
<tr>
<td>15. Enhanced Oncology Applications of Health Insurance Claims Data through Clinical Data Linkage [81]</td>
</tr>
<tr>
<td>David Dore, Andrew T McAfee, Ruby K Woo, John D Seeger. (United States)</td>
</tr>
<tr>
<td>16. Treatment (Tx) and Dosing Patterns for Angiogenesis Inhibitor (AI) Therapies in Patients (Pts) with Metastatic Renal Cell Carcinoma (mRCC) [82]</td>
</tr>
<tr>
<td>Toni K Choueiri, Ashley J Brick, David McDermott, Jessica Clement, Christabel Kwabi, Karishma Shah, Lucia Antras, Kristina Chen, Sujata S Jayawant, Mei Sheng Duh, Andi Luka, Maureen Neary, William K Oh. (United States)</td>
</tr>
<tr>
<td>17. Completeness of Recorded Cancer Incidence in the Health Improvement Network [83]</td>
</tr>
<tr>
<td>Kevin Haynes, Kimberly Forde, Rita Schinar, Patricia Wong, Brian Strom, James Lewis. (United States)</td>
</tr>
<tr>
<td>18. Incidence of Malignancy in Patients with Rheumatoid Arthritis [84]</td>
</tr>
<tr>
<td>Helen Huang, Jamie Laudati, Zhiping Huang. (United States)</td>
</tr>
<tr>
<td>19. Abstract Withdrawn by Author [85]</td>
</tr>
<tr>
<td>20. Prenatal Exposure to Medicines and the Risk of Childhood Brain Tumor [86]</td>
</tr>
<tr>
<td>Karin Stålberg, Bengt Haglund, Helle Kieler. (Sweden)</td>
</tr>
<tr>
<td>21. An Observational Follow-Up Study of Patients Previously Enrolled in Exubera Controlled Clinical Trials (FUSE): Design and Rationale [87]</td>
</tr>
<tr>
<td>Nicole M Gatto, Daniel O Koralek, Joanna Lem, Neville Jackson. (United States)</td>
</tr>
<tr>
<td>22. Survival of Malignant Mesothelioma in a Retrospective Survey in the West Part of Japan [88]</td>
</tr>
<tr>
<td>Shuko Nojiri, Tsugumichi Sato, Takuiro Yamaguchi, Kenichi Gemba, Keisuke Aoe, Katsuya Kato, Takumi Kishimoto, Kiyoshi Kubota. (Japan)</td>
</tr>
<tr>
<td>23. Hfs 14: A Specific Quality of Life Instrument for Patients with Hand-Foot Syndrome [89]</td>
</tr>
<tr>
<td>Charles Taieb. (France)</td>
</tr>
<tr>
<td>24. The Risk of Cancer Associated with Anti-Diabetic Agents [90]</td>
</tr>
<tr>
<td>Hui-Talia Zhang, Terek A Hammad, David Christiani, Edward Giovannucci. (United States)</td>
</tr>
</tbody>
</table>
25 Suicidality in Patients Treated with Antiepileptic Drugs [91]
Alejandro Arana, Charles E Wentworth III, José Luis Ayuso-Mateos, Janet Price, Felix M Arellano. (Spain)

26 Distribution of Cases of Progressive Multifocal Leukoencephalopathy: Analysis of the French National Hospital Discharge Registry [92]
Marion Pinet, Nadia Foskett, Anthony Amey, Jamie Robinson. (United Kingdom)

27 Incidence of Progressive Multifocal Leukoencephalopathy (PML) in Patients with Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE) from MarketScan Claim Database [93]
Nadia Foskett, Liping Huang, Hans Petri, Pavel NAPALKOV, Philip Watson, Elena Fisheleva, Ravi RAO, Sophie Banzet, Noah Jamie Robinson. (United Kingdom)

28 Individual-Level Time Series Analysis of Antidepressant and Antipsychotic Drug Use Around Varenicline Initiation [94]
Joshua J Gagne, Tarek A Hammad, Solomon Iyasu. (United States)

29 Incidence of Urinary Tract Infection in Subjects with Type 2 Diabetes. Experience from Adverse Event Reporting in Diabetes Clinical Trials [95]
Niklas Hammar, Bahman Farahmand, Susan Andersson, Svante Joelson, Mikael Gran. (Sweden)

30 Exploratory Analysis of the Relationship between Antipsychotic Use and the Incidence of Seizures among Patients with Schizophrenia in the UK General Practice Research Database (GPRD) [96]
Meghan E Jones, Lamiya A Rizvi, Indiana Strombom, Frank DeLisle, Ludmila Kryzhanovskaya, Joachim Wemicke, Bruce J Kinon. (United States)

32 Antidepressant Selection Associated with Prior Use of Hypnotics/Anxiolytics in Patients with Major Depressive Disorder [98]
Xianchen Liu, Wenyu Ye, Madelaine M Wohldrech, Stacey Bledsoe. (United States)

33 Maternal Use of Antibiotics during Pregnancy and Risk of Epilepsy in Childhood: A Danish Population-Based Cohort Study [99]
Mette Nørgaard, Vera Ehrenstein, Leiv Bakkeleig, Hennik T Sørensen, Lars Pedersen. (Denmark)

Community Pharmacies Network: Results 2005-2007 of the OSIAP Europe Survey [97]
Ulf Bergman, Alfonso Carvajal, Anita Conforti, Rob Heerdink, Maryse Lapeyre-Mestre, Diego Macias, Robert Vander Stichele. (France)
### Disease Epidemiology/Burden of Illness

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>Characteristics of Patients with Diabetic Macular Edema, Retinal Vein Occlusion, and Uveitis</td>
<td>Kandace L Amend, Najat Ziyadeh, Suresh Mahabhashyam, John Seeger. (United States)</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>A Two-Stage Sampling Cohort Study on the Risk of Perinatal Mortality Associated with Asthma during Pregnancy</td>
<td>Marie-Claude Breton, Marie-France Beauchesne, Catherine Lemiere, Evelyn Rey, Amelie Forget, Lucie Blais. (Canada)</td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>Investigation of Pediatric Crohn’s Disease Burden in Multiple Data Sources</td>
<td>Kristen Butterfield, Meighan Cappello, Erica Velthuis, Margaret Richards, Joanna Haas, Melynda Holmes. (United States)</td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>Longitudinal Changes in Lower Urinary Tract Symptoms in Men Managed for Benign Prostatic Hyperplasia</td>
<td>Wendy J Carman, John Wei, Martin Miner, David Pasta, Raymond Rosen, Claus Roehrborn, Allen Seftel. (United States)</td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>The Incidence of Guillain Barre Syndrome in the United Kingdom</td>
<td>Gillis Carrigan, Germano Ferreira, Alena Khromava.</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>The Risk of Suicidal Behavior among Patients with Diabetic Peripheral Neuropathic Pain, Low Back Pain, Fibromyalgia, or Osteoarthritis</td>
<td>Yingkai Cheng, Dale Marmaduke, Antonio Crucitti, Sharon Hoog, Indiana Strombom, Kenneth Hornbuckle. (United States)</td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>Incidence Rate of Febrile Convulsions in Toddlers – A Database Study in the United Kingdom</td>
<td>Germano Ferreira, Gillis Carrigan, Alena Khromava. (France)</td>
<td></td>
</tr>
</tbody>
</table>

### Coverage Without Evidence

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>Identifying Intentional Self-Harm Hospitalizations when E-Codes Are Incompletely Recorded</td>
<td>Amanda R Patrick, Matthew Miller, Catherine W Barber, Philip S Wang, Claire F Canning, Sebastian Schneeweiss. (United States)</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>Predictors of 60 Day Mortality after Aneurysmal Subarachnoid Haemorrhage</td>
<td>R Risselada, H Lingsma, E Steyerberg, M Sturkenboom. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>The Acute Effect of Alcohol on Psychomotor Performance in Healthy Korean Men with ALDH2 Variations</td>
<td>Hee-Young Shin, Kyung-Lyung Bae, Sung-Wan Kim, Il-Seon Shin, Tak Youn, Jin-Sang Yoon. (Korea)</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>Systematic Review of Observational Research Studying Long-Term Use of Antithrombotic Medicines Following Haemorrhagic Stroke</td>
<td>Robert Flynn, Thomas MacDonald, Gordon Murray, Alexander Doney. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>Pragmatic Randomized Trial of Continuing Cholinesterase Inhibitors among Indeterminate Responders</td>
<td>Malcolm Maclure, Carolyn J Green, Claudia Jacova, Robin G-Y Hsiung. (Canada)</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Measuring the Use of Medical Devices Dispensed According to the PNPCD</td>
<td>Carolina Monteiro. (Portugal)</td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>Heart Failure, Myocardial Infarction and Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease</td>
<td>Luis A Garcia Rodriguez, Mari-Ann Wallander, Elisa Martin-Merino, Saga Johansson. (Spain)</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>Predictors of Uncontrolled Asthma in Adult and Pediatric Patients: Results from the Asthma Control Characteristics and Prevalence Survey</td>
<td>Alicia Gilsenan, Richard Stanford, Christine Bui, Ryan Ziemicki, Hector Ortega. (United States)</td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>Validation of Diabetic Macular Edema (DME) through Claims Profile Review</td>
<td>Earl L Goehring Jr, Bao-Anh Nguyen-Khoa, Winifred Werther, Judith K Jones. (United States)</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Cardiovascular Disease and Risk Factors in Patients with Ankylosing Spondylitis</td>
<td>Katherine L Gooch, David L Laitinen, Robert L Wong, Oscar A Hayes. (United States)</td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>Changes in Prevalence and Healthcare Use and Costs of Breast Cancer among 21- to 64-Year Old Female Recipients in a Fee-for-Service State Medicaid Program: 2000-2005</td>
<td>Rahul Khanna, S Suresh Madhavan, Abhijeet Bhanegaonkar. (United States)</td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>Drug-Related Poisonings in the Brazilian General Population from 1996 to 2005</td>
<td>Daniel M Mota, Jose RR Melo, Daniel RC Freitas, Márcio Machado. (Canada)</td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>Longitudinal Assessment of Smoking in the Health Improvement Network (THIN) Database</td>
<td>Aditya A Marfatia, Mary Maneno, Jie Li, Judith K Jones. (United States)</td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>Myocardial Infarction and Cerebrovascular Accident in Patients with Diabetic Macular Edema</td>
<td>Bao-Anh Nguyen-Khoa, Earl L Goehring Jr, Winifred Werther, Judith K Jones. (United States)</td>
<td></td>
</tr>
</tbody>
</table>

### Devices

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>Measuring the Use of Medical Devices Dispensed According to the PNPCD</td>
<td>Carolina Monteiro. (Portugal)</td>
<td></td>
</tr>
<tr>
<td>Poster Session A: Monday, Aug. 17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>55</strong></td>
<td>Incidence of Oropharyngeal Conditions in Patients with Influenza in the GPRD [122]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Michael M Peng, Anthony Amey, Jamie Robinson. (United States)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>56</strong></td>
<td>Treatment Patterns in Depressed Elderly and Younger Adult Patients in the U.S. [123]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thibaut Sanglier, Dominique Milea, Delphine Saragoussi, Jean-paul Auray, Marie Tournier. (France)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>57</strong></td>
<td>Characteristics of Depressed Elderly Patients Compared with Younger Depressed Adult Patients: An Assessment Based on a Large U.S. Insurance Claims Database [124]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thibaut Sanglier, Delphine Saragoussi, Dominique Milea, Jean-Paul Auray, Marie Tournier. (France)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>58</strong></td>
<td>Risk of Serious Skin Reactions Associated with Carbamazepine and Phenytoin: A Signal Detection from Thai-vigibase [125]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pakawadee Sripiriyawong, Sareeya Wechwitan. (Thailand)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>59</strong></td>
<td>Incidence of Chlamydia Diagnoses, Tests, and the Use of Antibiotics [126]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ann Vanrolleghem, Eva M van Soest, Ingrid van den Broek, Minam CJM Sturkenboom. (Netherlands)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>60</strong></td>
<td>Prescribing Guidelines Concerning Analgesics – Geographic Variations and Adherence [127]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Magnus AB Axelsson, Lena Gustafsson, Susamma M Wallerstedt. (Sweden)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>61</strong></td>
<td>Factors Associated with Changes in Management of Benign Prostatic Hyperplasia: Longitudinal Data from the BPH Registry [128]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wendy J Carman, Martin Miner, John T Wei, David J Pasta, Raymond Rosen, Claus G Roehrborn, Allen D Seltel. (United States)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>62</strong></td>
<td>Prevalence of Drug-Drug Interactions among Epileptic Patients Receiving Antiepileptic Drugs and Oral Anticancer Drugs at a Cancer Centre: A Retrospective Study [129]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yin Ting Cheung, Alexandre Chan, Wai Keung Chui. (Singapore)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>63</strong></td>
<td>Levetiracetam Effectiveness in Real-Life Practice in France, Final Results of the EULEV Study [130]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C Droz, C Dureau, A Alpérovitch, H Vespignani, C Marchal, J Jové, N Moore, A Fourrier. (France)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>64</strong></td>
<td>Trends in Outpatient Drug Utilization Patterns in the U.S. Pediatric Population: Y2002 – Y2008 [131]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patty Greene, Laura Governale, Vicky Borders-Hemphill, Hina Mehta, David Moenly. (United States)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>65</strong></td>
<td>Assessment of Orphan Drugs Developed and Drug Utilization Under the Orphan Drug Act: A Descriptive Empirical Study [132]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Erin McErlane, Jeff J Guo, Pankaj Desai, William Sietsema, Christina ML Kelton. (United States)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>66</strong></td>
<td>Treatment Status and Treatment Changes in a Dutch Type 2 Diabetes Cohort [133]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jaco Voorham, Petra Denig, Ronald P Stoik, Bruce HR Wolfenbuttel, Dick De Zeeuw, Flora M Haaijer-Ruskamp, GIANTT Group. (Netherlands)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>67</strong></td>
<td>Adherence to Pharmacotherapy Guideline in Depression and Anxiety; Preliminary Results [134]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pierre M Bet, Jacqueline G Hugtenburg, Brenda WJH Penninx, Ton van Balkom, Witte JH Hoogendijk. (Netherlands)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>68</strong></td>
<td>Lipid-Regulating Drugs in Japanese Psychotic Inpatients [135]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ataru Inagaki, Toshiaki Itoh, Kazumi Tsukada. (Japan)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>69</strong></td>
<td>Drug Concurrency Patterns among Asthma Patients Using Single-Ingredient LABA: A Claims Data Study [136]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sigal Kaplan, Yulan Ding, Andrew Mosholder. (United States)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>70</strong></td>
<td>Predictors of Treatment Failure in Trigeminal Neuralgia [137]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Joseph SHA Koopman, Jeannie P Dieleman, Frank J Huygen, Marissa de Mos, Minam CJM Sturkenboom. (Netherlands)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>71</strong></td>
<td>Increasing Prevalence and Incidence of Drug Use in Sweden – Data from the National Prescribed Drug Register [138]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Andreis Leimanis, Orjan Ericsson, Michael Forord, Niklas Hammar, Björn Wettermark. (Sweden)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>72</strong></td>
<td>Prevalence and Persistence of TNF Inhibitors in Norway 2004-2008 [139]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Milada Mahic, Svetlana Skurtveit, Randi Selmer, Kari Furu. (Norway)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>73</strong></td>
<td>Driving Impairing Medication Use in the Netherlands [140]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S Ravera, ST Visser, JJ de Gier, LTW de Jong-van den Berg. (Netherlands)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>74</strong></td>
<td>Utilization of Behavioral Medication in a Medicaid Population Pre and Post Formulary Implementation [141]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jason C Simeone, Rita M Marcoux, Brian J Quilliam. (United States)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>75</strong></td>
<td>Off-Label Use of Oncology Drugs in a Community Oncology EMR Database [142]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reejis Stephen, Kevin Knopf, Matthew Reynolds, Weixiu Luo, Kathy Fraeman. (United States)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>76</strong></td>
<td>Comparison of Outpatient Utilization of Psychopharmaceuticals between Zagreb and Scandinavian Countries (2001-2006) [143]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Danijela Stimac, Albert Cattunar, Zvonimir Šostar. (Croatia)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>77</strong></td>
<td>Adjusting the Nicotine Dose: The Key to a Successful, “Tailored” Method of Quitting Smoking [144]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Charles Taieb. (France)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Measurement Methods

78 Assessment of Drug Exposure in Etiological Studies: A Review from Pharmacoepidemiology and Drug Safety [145]
Perelle Noize, Fabienne Bazin, Antoine Pariente, Nicholas Moore, Annie Fournier-Réglat. (France)

79 Constructing Drug Treatment Episodes from Individual Dispensed Prescriptions: The Influence of the Gap-Length [147]
Helga Gardarsdottir, Elbert R Heerdink, Toine CG Egberts. (Netherlands)

80 Impact of Exposure Data Sources on Risk Estimates in Etiological Studies: Application to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Three-City (3C) Study [148]
Fabienne Bazin, Perelle Noize, Antoine Pariente, Nicholas Moore, Annie Fournier-Réglat. (France)

81 Providers’ and Administrators’ Perceived Value of the UMWA Health and Retirement Funds MineRx Program [149]
Eric P Jack, MP Powell, Jeroan J Allison, Kenneth G Saag, Norman W Weissman. (United States)

Sigal Kaplan, Lois La Grenade, Carol Pamer, Ann Corken Mackey. (United States)

83 Reliability and Convergent Validity of the Perceived Stress Scales 4 and 10 Items: Results from the Antidepressants in Pregnancy Discontinuation Study [151]
Fatiha Karam, Anick Bérard. (Canada)

84 Systematic Process for Coding Definition/Algorithm Development in Database Analyses [152]
Bob LoCasale, Vinay Mehta, Lucy Alderton, Ed Bortnichak, Matt Reynolds, Reejis Stephen, Natalie Jones, Carol Ware. (United States)

85 Comparison of Treatment Utilization of Intravenous Bisphosphonates (IVBIS) in an Electronic Medical Records (EMR) and Administrative Claims Database [153]
Vinay Mehta, Bob Locasale, Chuck Wentworth, Reejis Stephen, Beth Nordstrom, Kathy Fraeman. (United States)
<table>
<thead>
<tr>
<th>Poster Session A: Monday, Aug. 17</th>
</tr>
</thead>
</table>

| 86 | Reliability of Patients and Physicians Information on Drug Exposure: A Study in the Systematic Case-Referent PGRx Database [154]  
Lamiae Bensouda-Grimaldi, Michel Rossignol, Elodie Aubrun, Constance Charveriat, Nabil El Kermi, Richard Goudreau, Fanny Depot-Hebert, Benoît David, Lucien Abenhaim. (Canada) |

| 87 | Validation of Claims-Based Diagnostic and Procedure Codes for Serious Adverse Events in a Commercially-Insured Population [155]  
Peter M Wahl, Keith Rodgers, Sebastian Schneeweiss, Brian F Gage, Louise J Short, Rhonda L Bohn. (United States) |

Catherine J Williams, Matthew W Reynolds, Weixiu Luo, Kyle Fahrbach, Jenna Collins. (United States) |

| 89 | Medications in Pregnancy/Birth Defects  
Population-Based Surveillance System on Medicine Use during Pregnancy in Finland [157]  
Miia Artama, Mika Gissler, Annukka Ritvanen, Heli Malm. (Finland) |

| 90 | Fluoxetine Use during Pregnancy and the Risk of Major Congenital Malformations [158]  
Anick Bérard, Martin St-André. (Canada) |

| 91 | Gestational Exposure to Antidepressants and the Risk of Miscarriage: A Review [159]  
Perrine Broy, Anick Bérard. (Canada) |

| 92 | Birth Outcome in Women Exposed to Anti-Inflammatory Drugs for Ulcerative Colitis [160]  
Gabriella Brumbs, Fredrik Granath, Olof Stephansson, Helle Kieler. (Sweden) |

| 93 | Antispasmodics in Pregnancy: A Study in EFEMERIS Database [161]  
Christine Damase-Michel, Isabelle Lacroix, Caroline Hurault, Jean-Louis Montastruc. (France) |

| 94 | What Mothers Think: Trends in Perceptions of Medications as a Teratogens [162]  
LTW de Jong-van den Berg, C Louik, M Malone-Moses, AA Mitchell. (Netherlands) |

| 95 | Outcome of Infants Exposed In Utero to More Than One Antidepressant during Pregnancy: A Prospective Comparative Study [163]  
Adrienne Einarson, Jacqueline Choi, Thomas Einarsen, Gideon Koren. (Canada) |

| 96 | A Pilot Study To Investigate Drug Prescribing among Pregnant Women in Tayside, Scotland [164]  
Robert Flynn, Linda Irvine, Iain Crombie, Gillian Libby, Josie Evans. (United Kingdom) |

| 97 | Use of Opioids in Mothers and Fathers before and during Pregnancy–2004-2006 [165]  
Marte Handal, Anders Engeland, Svetlana Skurtveit, Kari Furu. (Norway) |

| 98 | Carbamazepine Exposure & Specific Malformations [166]  
J Jenink, H Dolk, MA Loane, JK Morris, LTW de Jong-van den Berg, EUROCAT AED Working Group. (Netherlands) |

| 99 | Preterm Delivery in HIV+ Pregnant Women on Protease Inhibitors [167]  
Derek Johnson, Olufemi Ogundeji, Kariyek Akharya, Bachmann Laura, Sturdevant Marsha, Mirjam Kempf. (United States) |

| 100 | Prescriptions Filled for Drugs with Embryotoxic, Feto-toxic or Teratogenic Potential during Pregnancy [168]  
Sophie N Kulaga, Amir Zargarzadeh, Anick Bérard. (Canada) |

| 101 | Benzodiazepine Use during Pregnancy and the Risk of Major Congenital Malformations [169]  
Sophie N Kulaga, Sheehy Odile, Perrine Broy, Anick Bérard. (Canada) |

| 102 | Drug Utilization of Pregnancy Category D or X Drugs among Child-Bearing Age Women with Depression or Bipolar Disorder in Medicaid [170]  
Xing Li, Jeff J Guo, Patricia R Wigle, Christina ML Kelton, Yonghua Jing. (United States) |

| 103 | Development of a Pregnancy Registry in Herceptin (H) Treated Breast Cancer (BC) Patients (pts)  
MotHER: The Herceptin Pregnancy Registry [171]  
Wang Lisa, Cochran Colette, Brannan Carol, Shing Mona, Dong Wei. (United States) |

| 104 | Use of Teratogenic Ingredients Across Different Ethnic Groups among Pregnant Women [172]  
Puball D Matteo, Somnath Pal. (United States) |

| 105 | Exposure to Hydroxyurea and Pregnancy Outcomes [173]  
William F McCarthy, Samir K Ballas, Nan Guo, Bruce A Barton. (United States) |

| 106 | Statins and Pregnancy Outcomes: A Cohort Study in the GPRD [174]  
Anita McGrogan, Julia Snowball, Corinne S de Vries. (United Kingdom) |

| 107 | Exposure to Herbal Products during Pregnancy and the Risk of Low Birth Weight [175]  
Kristel Moussaly, Gideon Koren, Anick Berard. (Canada) |

| 108 | Antihypertensive Medication Use during Pregnancy and the Risk of Major Congenital Malformations or Small-for-Gestational-Age Newborns [176]  
Hamid Reza Nakhai-Pour, Evelyne Rey, Anick Bérard. (Canada) |

| 109 | Antidepressant Medication Use during Pregnancy and the Risk of Miscarriage [177]  
Hamid Reza Nakhai-Pour, Perrine Broy, Anick Bérard. (Canada) |

| 110 | Paternal Exposures and Birth Defects: Overlooked or Unnecessary? [178]  
Susan S Roberts, Laura F McKain, Deborah L Covington, Jessica D Albano. (United States) |
111 Exposure to Anti-Infective Drugs during Pregnancy and the Risk of Prematurity [179]
   Fabiano Santos, Anick Bérard. (Canada)

112 Utilisation of Psychotropic Medicines in Pregnancy [180]
   Irini-Alexia Terzakis, Julia M Snowball, Anita McGrogan, Corinne S de Vries. (United Kingdom)

113 Abstract Withdrawn by Author [181]

114 Performance of Screening Multiple Observational Databases for Active Drug Safety Surveillance [182]
   Patrick B Ryan, Gregory E Powell, Ed N Pattishall, Kathleen J Beach. (United States)

115 Active Safety Surveillance of the Risk of Acute Pancreatitis (AP) Associated with Exenatide or Sitagliptin Compared to Metformin or Glyburide [183]
   David D Dore, John D Seeger, Kui Huang. (United States)

116 Review of Evidence Related to the Abuse of Tramadol [184]
   Edgar H Adams. (United States)

117 Reporting Rates of Hemorrhagic/Necrotizing Pancreatitis (HNP) in Association with Selected Newer Antidiabetics [185]
   Syed Rizwanuddin Ahmad, Joslyn Swann. (United States)

118 Considerations When Using FDA AERS Data for Data Mining Purposes [186]
   Keith L Altman. (United States)

119 Use of the Multi-Item Gamma Poisson Shrinker (MGPS) Algorithm in Retrospective Screening of Spontaneous Data of Withdrawn Marketed Products [187]
   Jacinta U Aniagolu. (United States)

120 Second Generation Antipsychotics and Adverse Drug Reactions – A Comparison between Children and Adults [188]
   Gertrud Brunlöf, Anders Sundström, Marie-Louise Johansson, Susanna M Wallerstedt. (Sweden)

121 Uterine Perforation in Women Using Intrauterine Devices: Interim Results from the EURAS-IUD Study [189]
   Juergen C Dinger, Anita Assmann, Mathias Altmann. (Germany)

122 Incidence Rates of Thromboembolic Events in Solid Tumor Cancer Patients in the THIN Database [190]
   Victor Gastanaga, Chuck Wentworth, Anthony Yeo, Gail Hughes, Ming Ji, Sean Zhao. (United States)

123 Does Pharmacy Students’ Education in Postmarketing Adverse Drug Reaction Reporting Influence Post-Graduate Drug Safety Surveillance Training Plans? [191]
   Jean Kim, Nicole L Perma, Yvonne Viteri, Anthony G Oladipo. (United States)

   D Layton, R Walker, E Lynn, SAW Shakir. (United Kingdom)

125 Lessons Learned from Celecoxib Familial Adenomatous Polyposis (FAP) Registry Study [193]
   Joanna Lem, Evelyn Moy, Carla Yunis, Kui Huang. (United States)

126 Case Reports of Suspected Adverse Drug Reactions: An Evaluation of the Efficiency of Search Strategies in MEDLINE and EMBASE [194]
   Shannon Michels, Alex Ward. (United States)

127 Analysis of Adverse Events Related to Ziconotide Intrathecal Administration: Utilization of the FDA AERS Database [195]
   Marie Lou Munson, Vivek Saharan, Soares George. (United States)

128 Evaluation of a Community Based Pharmacovigilance Program in Nepal [196]
   Subish Palaian, Mohamed Izham, Pranaya Mishra. (Nepal)

129 Abstract Withdrawn by Author [197]

130 Publication of Dear Doctor Letters and Reporting Patterns of the AEs of Concern [198]
   Bharat T Thakrar, Marianne Gerber, Noah Jamie Robinson. (Switzerland)

131 Selective Serotonin Reuptake Inhibitors (SSRIs) and Hyperprolactinemia [199]
   Emmanuelle Herlem, Fany Oger, Marie Laure Germain, Thierry Trenque. (France)

132 Epidemiologic Study of Antipsychotic Use and the Incidence of Suicide Events [200]
   M Ullickas Yood, G DeLorenze, C Quesenberry Jr., S Phillips, A Tsai, V Willey, S Niemcryk, K Wells, ML Skovron, M Cziraky, W Carson, S Oliveria. (United States)

133 Frequency and Characteristics of Pediatric Adverse Drug Reactions Reported to a Major Poison Control Center over a 9-Year Period [201]
   Zdravko P Vassilev, Alvin F Chu, Steven M Marcus. (United States)

134 The Risk of Institutionalization with the Concurrent Use of Cholinesterase Inhibitors (ChEIs) and Potentially Contraindicated Medications in Alzheimer’s Disease (AD) [202]
   Alison L Supina, David B Hogan, Scott B Patten, Braden J Manns, Winanne Downey, Patty Beck, Colleen J Maxwell. (Canada)

135 Utilization of Antidepressants among Young Adults in Sweden [203]
   Karolina Andersson, Mika Gissler, Max Petzold, Margda Waern. (Sweden)

136 Priapism Associated with Antipsychotics: Role of Alpha-1 Adrenoceptor Affinity [204]
   Frank Andersohn, Niklas Schmedt, Stefan Weinmann, Stefan N Willich, Edeltraut Garbe. (Germany)

137 Hepatic Events in Duloxetine Users Compared to Other Depressed and Non-Depressed Subjects [205]
   Fei Xue, Indiana Strombom, Bruce Turnbull, Shao Zhu, John D Seeger. (United States)
<table>
<thead>
<tr>
<th>Postersession</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>138</td>
<td>Patterns of Psychotropic Drug Use: A Comparative Study in Alzheimer ‘s Disease and Community-Dwelling Elderly Populations [206]</td>
<td>Sarah-G Beland, Antoine Pariente, Djamel Berbiche, Michel Previlee, Yola Moride. (Canada)</td>
<td></td>
</tr>
<tr>
<td>139</td>
<td>Association between Benzodiazepine Use and Individual Components of Sleep in the Community-Dwelling Elderly Population [207]</td>
<td>Sarah-Gabrielle Beland, Michel Preville, Marie-France Dubois, Philippe Voyer, Dominique Lorrain, Yola Moride. (Canada)</td>
<td></td>
</tr>
<tr>
<td>140</td>
<td>Effects of Cholinesterase Inhibitors on Visual Attention in Mild Alzheimer’s Disease [208]</td>
<td>Lori A Daiello, Brian R Ott, Elena K Festa, William C Heindel. (United States)</td>
<td></td>
</tr>
<tr>
<td>141</td>
<td>Factors Associated with Suboptimal Benzodiazepine Use in Older Adults [209]</td>
<td>Sascha Dublin, Tingting Li, Shelly L Gray, Jennifer C Nelson, Noel S Weiss, Eric B Larson. (United States)</td>
<td></td>
</tr>
<tr>
<td>142</td>
<td>Sickness Leave Patterns and Characteristics of Users of Antidepressants in 2004 [210]</td>
<td>Christiane Gasse, Delphine Saragoussi, Dominique Milea, Preben B Mortensen. (Denmark)</td>
<td></td>
</tr>
<tr>
<td>143</td>
<td>Analysis of Potential Drug-Drug Interaction Pairs Associated with Antipsychotics among Medicaid Patients with Schizophrenia or Bipolar Disorder [211]</td>
<td>Jeff J Guo, Nick C Patel, Yonghua Jing, Christina ML Kelton, Paul C Keck. (United States)</td>
<td></td>
</tr>
<tr>
<td>144</td>
<td>Hemoglobin A1C Level in Relation to Olanzapine, Quetiapine, and Risperidone in a Claims Database [212]</td>
<td>Zhenchao Guo, Andrei Pikalov, Edward Kim. (United States)</td>
<td></td>
</tr>
<tr>
<td>145</td>
<td>Association between Maternal Exposure to Antidepressant Drugs and Persistent Pulmonary Hypertension of the Newborn (PPHN) in the Mother-Baby Linked Records in the UK-Based General Practice Research Database (GPRD): Preliminary Results [213]</td>
<td>Tarek A Hammad, Carol Pamer, Susan McCure, Sigal Kaplan, Hany Aly, John Yap, Solomon Iyasu. (United States)</td>
<td></td>
</tr>
<tr>
<td>146</td>
<td>Suboptimal Prescribing of Antidepressants in Older Veteran Nursing Home Patients [214]</td>
<td>Joseph Hanlon, Xiaojin Wang, Nick Castle, Roslyn Stone, Steven Handler, Todd Semla, Mary Jo Pugh, Dan Berlowitz, Maurice Dysken. (United States)</td>
<td></td>
</tr>
<tr>
<td>147</td>
<td>Increasing Antidepressant Use in Older Nursing Home Patients [215]</td>
<td>Joseph Hanlon, Steven Handler, Nick Castle. (United States)</td>
<td></td>
</tr>
<tr>
<td>148</td>
<td>BZD Use in the Entire Norwegian Population According to Age, Gender and Disability Pension Status-A Register Linkage Study [216]</td>
<td>Ingeborg Hartz, Aage Tverdal, Svetlana Skurtveit. (Norway)</td>
<td></td>
</tr>
<tr>
<td>149</td>
<td>Disability Pension as Predictor of Continued Use of Benzodiazepines [217]</td>
<td>Ingeborg Hartz, Aage Tverdal, Svetlana Skurtveit. (Norway)</td>
<td></td>
</tr>
<tr>
<td>150</td>
<td>Weight Gain in Autic Children using Risperidone and Haloperidol in Thailand [218]</td>
<td>Chutima Pasook, Tita Apichathajutan, Nakarin Insonm, Penkarn Kanjanarat, Wirat Niwatpanan, Nootjarea Kamduang. (Thailand)</td>
<td></td>
</tr>
<tr>
<td>153</td>
<td>Benzodiazepine’s Utilization and Forecast in Portugal Mainland [221]</td>
<td>Mafalda Ribearinho, Carolina Monteiro, Rosária Oliveira. (Portugal)</td>
<td></td>
</tr>
<tr>
<td>154</td>
<td>Abstract Withdrawn by Author [222]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>155</td>
<td>Antidepressant Discontinuation and Risk of Suicide Attempt [223]</td>
<td>Robert J Valuck, Heather D Orton, Anne M Libby. (United States)</td>
<td></td>
</tr>
<tr>
<td>156</td>
<td>Psychiatrist’s Awareness of Schizophrenic Patients’ Weight When Prescribed Antipsychotics: The EPIONE Survey [224]</td>
<td>E Van Ganse, L Laforest, R Arnaud, JL Eyenchere, MA Geoffroy, JY Loze, A Dillenschneider, F Rouillon. (France)</td>
<td></td>
</tr>
<tr>
<td>157</td>
<td>Cardiovascular Events in Duloxetine Users Compared to Other Depressed and Non-Depressed Subjects [225]</td>
<td>Fei Xue, Indiana Strombom, Bruce Turnbull, Shao Zhu, John D Seeger. (United States)</td>
<td></td>
</tr>
<tr>
<td>158</td>
<td>Autistic Disorder and Asperger’s Disorder: Contrasting Psychotropic Patterns in U.S. Medicaid-Insured Youth [226]</td>
<td>Julie M Zito, Daniel J Safer, James J Korelitz, James F Gardner, Diane McNally. (United States)</td>
<td></td>
</tr>
</tbody>
</table>
Celgene Corporation is proud to sponsor ICPE’s 25th Anniversary event

Committed to improving the lives of patients worldwide.

Celgene shares ISPE’s dedication to enhancing public health through the creation of critical and innovative safety and risk management programs in areas of great medical need.

www.celgene.com
8 Antithrombotic Prescribing Patterns Following Intracerebral Haemorrhage in the Tayside Stroke Cohort (TSC) [294]
Robert Flynn, Thomas MacDonald, Gordon Murray, Alexander Doney.
(United Kingdom)

9 Heart Failure Medication Use in Older Home Care Clients [295]
Andrea Foebel, John Hirdes, George Heckman, Erin Tijam, Suzanne Tyas, Colleen J Maxwell. (Canada)

10 Rate of Bleeding Events and Comorbidities among Atrial Fibrillation Patients Treated with or without Warfarin [296]
S GHAte, J Biskupiak, J CASCiano, M HAGan, D Brixner. (United States)

11 Is Hyperlipidemia or its Treatment Associated with Erectile Dysfunction? Results from the Boston Area Community Health (BACH) Survey [297]
Susan A Hall, Varant Kupelian, Raymond C Rosen, Thomas G Trivison, Carol L Link, Martin M Miner, Peter Ganz, John B McKinlay. (United States)

12 Influence of Proton Pump Inhibitors on the Antplatelet Properties of Two Clopidogrel Dosing Regimens and the Role of CYP2C19 Genotype [298]
Ankie M Harmsze, Jochem W van Werkum, Vera HM Deneer, Henk J Ruven, Olaf H Klungel, Chris M Hackeng, Jurrien M Ten Berg, Antonius De Boer. (Netherlands)

13 Persistence of Antihypertensive Therapy by Socioeconomic Status [299]
Vidar Hjellvik, Randi Selmer, Hege S Blix, Solveig Sakshaug, Aage Tverdal. (Norway)

14 Persistence of Statin Treatment by Socioeconomic Status [300]
Vidar Hjellvik, Solveig Sakshaug, Randi Selmer, Hege S Blix, Aage Tverdal. (Norway)

15 Use of Spironolactone in the Treatment of Congestive Heart Failure [301]
Lachaine Jean, Beauchemin Catherine, Ramos Èlodie. (Canada)
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>More Than 50% of High Risk Patients Are Not Prescribed Statins [310]</td>
<td>Pieter van den Haak, Edith Heintjes, Arian Plat, Miriam Sturkenboom, Fernie Penning-van Beest, Ron Herings.</td>
<td>Netherlands</td>
</tr>
<tr>
<td>25</td>
<td>THE Role of LDL-Levels in Initiating Statin Treatment [311]</td>
<td>Edith Heintjes, Arian Plat, Miriam Sturkenboom, Fernie Penning-van Beest, Ron Herings.</td>
<td>Netherlands</td>
</tr>
<tr>
<td>26</td>
<td>Does Serum Potassium Monitoring Protect against Hyperkalemia? [312]</td>
<td>Marsha Raebel, Colleen Ross, Stan Xu, Craig Cheetham, Douglas Roblin, Chris Blanchette, Gwyn Saylor, David Smith.</td>
<td>United States</td>
</tr>
<tr>
<td>27</td>
<td>Abstract Withdrawn by Author [313]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>Use of Antiplatelet Drugs and Risk of Subarachnoid Hemorrhage. A Population-Based Case-Control Study [315]</td>
<td>Morten Schmidt, Martin B Johansen, Steffen Christensen, Christian F Christiansen, Henrik Toft Sørensen.</td>
<td>Denmark</td>
</tr>
<tr>
<td>31</td>
<td>Angiotensin Receptor Blockers (ARBs) and the Reduced Risk of Erectile Dysfunction [317]</td>
<td>Hong Ji Song, Hwa Jung Kim, Ju Young Kim, Sun Young Jeong, Byung-Joo Park.</td>
<td>Korea</td>
</tr>
<tr>
<td>32</td>
<td>Abstract Withdrawn by Author [318]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Drug Utilization Studies**

43 Herbal Beverages: Perceptions and Knowledge among General Public towards Its Safety and Efficacy [319]
Mohamed Azmi Ahmad Hassali, Asrul Akmal Shafie. (Malaysia)

44 Trends in Potentially Inappropriate Prescribing among the Elderly in Taiwan: Population-Based Study [320]
Chia-Hsien Chang, Yea-Huei Kao Yang. (Taiwan)

45 Prevalence of Asthma, Diabetes Mellitus and Essential Hypertension and Association of Health Insurance with Diagnosis Specific Prescribed Medication [321]
Ravi Y Dalwadi, Conrad W Dhing. (United States)

46 Levetiracetam One Year Retention Rate in Real-Life Paediatric Practice in France, the EULEVp Study [322]
C Dureau, C Droz, JM Pédespan, G Lavernhe, M Mann, J Jové, N Moore, A Fourrier. (France)

47 Differences in Drug Use by Race/Ethnicity in a Population-Based Sample [323]
Susan A Hall, Gretchen R Chiu, David W Kaufman, Judith P Kelly, Carol L Link, Varant Kupelian, John B McKinlay. (United States)

48 Effect of Health Literacy on Adherence in Heart Failure Patients [324]
Aaron J Katz, Dan Morrow, Wanzhu Tu, Jingwei Wu, Michael D Murray. (United States)

49 First Line Use of Pain Medication in Neuropathic Facial Pain [325]
Joseph SHA Koopman, Frank J Huysgen, Jeanne P Dieleman, Marissa de Mos, Miriam CJM Sturkenboom. (Netherlands)

50 The Prescribing Pattern of Bone Specific Drugs among Taiwan Elderly Women with Established Hip/Vertebral fractures [326]
Tzu-Chieh Lin, Yea-Huei Kao Yang. (Taiwan)

51 Antipsychotic Use among Nursing Home Residents [327]
Judith Lucas, John Bowblis, Tobias Gerhard, Sujoy Chakravarty, Stephen Crystal. (United States)

52 Epidemiology of Glaucoma and Drug Utilization in UK Primary Care [328]
Andrew Maguire, Mary Thompson. (United Kingdom)

53 Use of Anxiolytic and Hypnotic Drugs in Extremadura. (Spain) 2003- 2005 [329]
Nuria González-Bermejo, Diana González-Bermejo, Javier García del Pozo, Ramona Mateos-Campos. (Spain)

54 An Analysis of the Length of Hospital Stay for Patients with Potential Drug Interactions [330]
Cristiano S Moura, Francisco A Acurcio, Najara O Belo, Ludmila S Tavares, Jessica O Bomfim, Luana A Santos. (Brazil)

55 The Effect of Treatment Guidelines on the Initial Management of Idiopathic Pulmonary Fibrosis [331]
Jeffrey C Munson, Maryl Kreider, Jason D Christie, Stephen E Kimmel. (United States)

56 Age- and Sex-Related Differences in Use of Tertiary Medical Prophylaxis among Patients with Ischemic Stroke in Denmark: A Nationwide Follow-Up Study [332]
Kaare D Palnum, Grethe Andersen, Frank Mehnert, Søren P Johnsen. (Denmark)

57 Attitudes in Antibiotic Use by General Population in Greece [333]
Paraskevi Papaioannidou, Fotios Tsanakalis, Panagiotis Akritopoulos. (Greece)

58 Changing Trends in Thiazolidinedi-store Use in TRICARE [334]
Kate A Stewart, Brenda M Natzke, Thomas Williams, Elder Granger, S Ward Casscells, Thomas W Croghan. (United States)

59 Adherence to Prescription Guidelines in General Practice: Inter-Doc tor Variation and Trends over Time [335]
Lisa Van Dijk, Judith D de Jong, Peter Spreeuwenberg, Michael van den Berg, Gert P Westert, Dinny H De Bakker. (Netherlands)

60 Impact of Recent European Reforms To Encourage Prescribing of Generic Statins [336]
Björn Wettermark, Brian Godman, Jaana Martikainen, Arash Ghaffarian Samavarchi, Vera Vlahovic Palcevski. (Sweden)

**Economics**

61 Economic and Clinical Impact of Formularies on Pneumonia Admissions [337]
Godefreda V Dalmacion, Hilton Y Lam, Noel Juban, Nina C Carandang, Carlo Panelo. (Philippines)

62 Anxiety Disorders – Cost of Illness and Treatment Patterns Analysis from a Retrospective US Claims Database [338]
Clément François, Nicolas Despiégel, Khaled Maman, Delphine Saragoussi, Pascal Auquier. (France)

63 Application of Principals of Pharmacoeconomics, Clinical Pharmacology and Therapeutics in Pharmacoeconomics [339]
Pendar Farahani. (United States)

64 Impact of Adalimumab (HUMIRA®) on Work Productivity in Patients with Psoriatic Arthritis: Results from ACCLAIM [340]
Dafna D Gladman, Fotoula Psaradelis, Marie-Josee Martel, Olivier Illouz, Benoit Guerette, John S Sampalis. (Canada)

65 The Effect of an Advice To Read the Medicine/Patient Information Leaflet among Patients in Ghana: A Cross-Sectional Survey [341]
Daniel N Ankrah, Charles N Ofei. (Ghana)
66 A Systematic Review on Kushenin Versus Western Medicines for the Patients of Chronic Hepatitis B [342]
Boyang Bian, Rong Shao, Yongfa Chen, Ying Xia. (United States)

67 Effect of Compliance to Statins on the Risk of Non-Fatal Coronary Events in Primary Prevention [343]
Salvatore Mannino, Alfredo Cocci, Silvia Lucchi, Marco Villa. (Italy)

68 The Impact of Comparative Effectiveness Information on Prescribing Patterns: A Case Study [344]
Tami L Mark. (United States)

69 Safety Promoting Behaviors: An Innovative and Feasible Method To Determine the Effectiveness of a Pharmacy Benefit Management Program [345]
MP Powell, Jeroan J Allison, Kenneth G Saag, Norman W Weissman. (United States)

70 Definition of the Risk-Windor for the Outcomes of the LIVE Study by Minimization of the Mean Squared Error (MSE) of the Estimator [346]
Marco Villa, Salvatore Mannino, Silvia Lucchi, Kenneth J Rothman. (Italy)

71 Incidence of Endophthalmitis after Intravitreal Injection Procedures in the General Population of the United States of America [347]
Alejandro Arana, Felix M Arellano, Elena Rivero, Joan Fortuny, Charles W Wentworth. (Spain)

72 Prevalence of Diabetes in Hepatitis C Population [348]
Shirin Ahmed, Helen Huang, Pat Chandra. (United States)

73 Study of Hypoglycemia in Veteran Diabetes Patients [349]
Donald R Miller, Madhuri Pali-nati, Graeme Fincke, Jean-Philippe Lafrance, Cindy Christiansen. (United States)

74 Evaluation of Thiazolidinedione Related Risk of Fracture [350]
Joongyub Lee, Nam-Kyong Choi, Sun-Young Jung, Ye-Jee Kim, Jong-Mi Seong, Byung-Joo Park. (Republic of Korea)

75 A Comparison of Pioglitazone vs Rosiglitazone for Heart Failure in Elderly Type 2 Patients [351]
Jong-Mi Seong, Nam-Kyong Choi, Sun-Young Jung, Ye-Jee Kim, Joongyub Lee, Byung-Joo Phark. (Republic of Korea)

76 Predictive Value of ICD and CPT Codes for Identifying Osteonecrosis of the Jaw (ONJ) [352]
Patricia Tennis, Athanasios Zavras, Constantinos Laskarides, Hiangkiai Tan. (United States)

77 LDL-C Goal Attainment According to Prescribed Lipid-Lowering Therapy: Results from the LIPIDE European Survey [353]
Gaelle Desamericaq, Laurent Lafor-est, Marie-Sophie Schwalm, Philippe Moulin, Emilie Michel, Caroline Etete, Gabriel Coffin, Cecile Ritleng, Eric Van Gans. (France)

78 No Evidence for Association of Tegaserod with Suicide-Related Outcomes [354]
Jeanne Loughlin, Sherry Quinn, Elena Rivero, Heather Norman, David L Earnest, Judy Wong, John D Seeger. (United States)

79 Ventricular Arrhythmia and Sudden Unexpected Death and Domperi-done [355]
Charlotte van Noord, Jeanne P Dieleman, Katia Verhamme, Miriam CJM Codes for Identifying Osteonecro-

80 Abstract Withdrawn by Author [356]

81 Thiazolidinedione Use and Ulcerative Colitis-Related Flares: An Analysis of Administrative Data [357]
Jennifer L Lund, Til Stümmer, Carol Q Porter, Robert S Sandler, Michael D Kappelman. (United States)

82 Prevalence of Concomitant Proton Pump Inhibitor Prescription Medication Use in the US Population [358]
Shan Cai, Sonia Hernández-Díaz. (United States)

83 Use of Selective Serotonin Reuptake Inhibitors and Upper GI Bleeding [359]
Michael Dall, Ove B Schaffalitzky de Muckadell, Annmarie Touborg Lassen, Jane Møller Hansen, Jesper Hallas. (Denmark)

84 Association between Immune Thrombocytopenic Purpura and Vaccines, in the PGRx Database [360]
Lamiae Bensousa-Grimaldi, Michel Rossignol, Bertrand Godeau, Marc Michel, Jean Francois Viallard, Maya Hacini, Benoit David, Lucien Aben-haim. (France, Metropolitan)

85 The Effect of Increased Altitude on Achieved Hematocrit and EPO Dosing in End-Stage Renal Disease [361]
Maurice A Brookhart, Brian Bradury, Wolfgang Winkelmayer. (United States)

86 Risk of Hematological Malignancy among Persons with Chronic Idiopathic Thrombocytopenia [362]
Cheryl Enger, Dimitri Bennett, Ulla Forssen, Andrew T McAfee. (United States)

87 Factors Associated with Receipt of Splenectomy for Patients with Chronic Idiopathic Thrombocyto-

88 Validation of TTP Diagnostic Codes in a Commercially Insured Popula-

Hematological

84 Association between Immune Thrombocytopenic Purpura and Vaccines, in the PGRx Database [360]
Lamiae Bensousa-Grimaldi, Michel Rossignol, Bertrand Godeau, Marc Michel, Jean Francois Viallard, Maya Hacini, Benoit David, Lucien Aben-haim. (France, Metropolitan)

85 The Effect of Increased Altitude on Achieved Hematocrit and EPO Dosing in End-Stage Renal Disease [361]
Maurice A Brookhart, Brian Bradury, Wolfgang Winkelmayer. (United States)

86 Risk of Hematological Malignancy among Persons with Chronic Idiopathic Thrombocytopenia [362]
Cheryl Enger, Dimitri Bennett, Ulla Forssen, Andrew T McAfee. (United States)

87 Factors Associated with Receipt of Splenectomy for Patients with Chronic Idiopathic Thrombocyto-

Gastrointestinal

88 Validation of TTP Diagnostic Codes in a Commercially Insured Popula-

Abstract Withdrawn by Author [356]
**Poster Session B: Tuesday, Aug. 18**

**Hormones/Reproductive Agents**

89 The Effects of Hormone Contraceptive Use on Immune Reconstitution in HIV Positive Women on Antiviral Medication [369]
Derek Johnson, Sadeep Shrestha. (United States)

90 Results from the European Active Surveillance Study in Italy (EURAS-OC Italy) [367]
Kristina Voigt, Assmann Anita, Moehner Sabine, Dinger Juergen. (Germany)

91 Potential for Decreasing Breast Cancer with Decreasing Hormone Replacement Therapy (HRT) [368]
C Ineke Neutel, Howard Morrison. (Canada)

**Molecular Epidemiology/Pharmacogenetics**

92 CYP2D6 Genotypes, Depression, and Antidepressant Discontinuation during Pregnancy: Results from the Antidepressants in Pregnancy Discontinuation Study [369]
Anick Bérard, Fatima Karam, Andrea Gaegick, Odile Sheehy, Sylvie Perreault. (Canada)

93 Understanding the Clinical Utility and Adoption of Pharmacogenomics: A Quantitative Analysis of Patient Decision-Making [370]
Amalia M Issa, Janis Hutchinson, Waqas Tufail, Jose Tenorio. (United States)

94 CYP2C19*2 Is Associated with Increased Survival in Breast Cancer Patients Using Tamoxifen [371]
Tanneke R Ruiter, Monique J Bijl, Albert Hofman, Ron HN van Schaik, Loes E Visser, Bruno HCh Stricker. (Netherlands)

95 K-Ras Mutation among Colorectal and Non-Small Cell Lung Cancer Patients [372]
Wei Zhou, Holly Brown, Melissa Tice. (United States)

96 Interaction between the G894T eNOS Gene Variant and Calcium Antagonists on the Risk of Myocardial Infarction [373]
Diane BMA van Wieren-de Wijer, Anke Hilse Maitland-van der Zee, Antonius de Boer, Abraham A Kroon, Peter W de Leeuw, Paul Schiffers, Rob GJH Janssen, Bruce M Psaty, Cornelia M van Duijn, Bruno HCh Stricker, Olaf H Klungel. (Netherlands)

97 Pharmacogenetic Determinants for Discontinuation of Non-Ergoline Dopamine Agonists in Parkinson’s Disease [374]
Maurits Arbouw, Kris Movig, Toine Egberts, Petra Poels, Jeroen van Vugt, Judith Wessels, Tahar van der Straaten, Cees Neef, Henk-Jan Guchelaar. (Netherlands)

98 Transcription Factor 7-Like 2 (TCF7L2) Polymorphism and Retinal Vascular Signs in African American and Caucasian Adults: The Atherosclerosis Risk in Communities (ARIC) Study [375]
Yu Yan, Ronald Klein, Gerardo Heiss, Cynthia J Girman, Ethan M Lange, Barbara E Klein, Kathryn M Rose, Suzanne L West, Eric Boerwinkle, James S Pankow, Frederick L Brancati, Christine M Ballantyne, Anna Köttgen, Kari E North. (United States)

**Pharmacovigilance**

99 A Review of Amputation and Gangrene Adverse Events for Injected Promethazine [376]
Keith L Altman. (United States)

100 Performance of a Semi-Automated Process for Estimation of Risk in a Claims Database [377]
Kathleen Beach, Hoa V Le, Gregory Powell, Ed Pattishall, Patrick Ryan, Robertoino Mera. (United States)

101 Adverse Drug Reaction (ADR) Monitoring in Patient Receiving Oncologic Medications: A 3 Months Study [378]
Kanwalpreet Kaur, Pipasha N Biswas. (United Kingdom)

102 Consequences of the Exclusion of Known Adverse Drug Reactions in a Spontaneous Reporting System on the Possibility to Detect Unknown Drug/ADR Combinations [379]
Sander Borgsteede, Eugene van Puijenbroek, Kees van Grootheest. (Netherlands)

103 Variation in ICD-9 Diagnosis Coding of Potential Adverse Events [380]
Kristen Moore, Jeffrey Brown. (United States)

104 Detection of Adverse Drug Reaction Signals in the Thai FDA Database: Comparison between Reporting Odds Ratio and Bayesian Confidence Propagation Neural Network Methods [381]
Waranee Bunchuallu, Ilene H Zuckerman, Vithaya Kuksamboon, Wimon Suwanesawong. (Thailand)

105 Case-Crossover Study of PDE5 Inhibitor Exposure as a Potential “Trigger Factor” for Acute NAION [382]
Ulfka Campbell, Kenneth R Petronis, Brian J Klee, Francesca Kolitsopoulos, Alexander M Walker, Jingping Mo. (United States)

106 The Completeness of Data in the Food and Drug Administration' Adverse Event Reporting System from 1998 to 2007 [383]
Yan Chen, Alice Russell, Patrick DeLisle, Yingkai Cheng, Indiana Strombrom, Jennifer Bardsos, Stephen Motsko, Kenneth Hornbuckle. (United States)

107 The Validity of Physician-Reported Hospitalized Infections in a US Rheumatoid Arthritis Cohort [384]
Archana Jain, Nivedita Patkar, Jeffrey Greenberg, Daniel H Solomon, Jeffrey R Curtis. (United States)

108 Results from a German/Finnish Case-Control Study of Breast Cancer Risk for Levonorgestrel-Releasing Intrauterine Devices [385]
Juergen C Dinger, Sabine Moehner, Kristina Voigt, Anita Assmann. (Germany)
109 Drug-Induced Hepatic Injury in Children: Analysis of Spontaneous Adverse Event Reports of WHO Database [386]
Carmen Ferrajolo, Katia Verhamme, Martijn Schuermie, Annalisa Capuano, Francesco Rossi, Bruno Stricker, Miriam Sturkenboom. (Italy)

110 Mortality Due to Ischaemic Heart Disease in 15,659 Patients Prescribed Vardenafil in General Practice in England (2005): Results from a Prescription-Event Monitoring (PEM) Study [387]
L Hazell, V Cornelius, L Wilton, S Shakir. (United Kingdom)

111 The Impact of Patient Access Pathways on Post Marketing Drug Safety Studies Using Cancer Registry Data [388]
Kirk Midkiff, Alicia Gilsenan, Rebecca D Martin, Yun Wu, Daniel N Masica, Elizabeth B Andrews. (United States)

112 Hidden Partial Non-Compliance with Antidepressants and its Effect on Treatment Response [389]
Margareta Reis, Lars von Knorring, Ann-Charlotte Åkerblad, Lisa Ekselius. (Sweden)

113 No Evidence of a Strong Association between Orlistat and Pancreatitis. Results from a Study Using the UK General Practice Research Database (GPRD) [390]
Markus Schuerch, Noah J Robinson. (Switzerland)

114 Abstract Withdrawn by Author [391]

115 Impact of a Safety Issue on the Number and Type of Publications: The Example of Sertindole [392]
Frederieke H van der Baan, Mirjam J Knol, Marie L de Bruin, Bert GM Leufkens, Olaf H Klungel, Toine CG Egberts. (Netherlands)

116 Andrographolide: Thailand Epidemiological and Safety Profile [393]
Sareeya Wechwithan. (Thailand)

117 The Unintended Consequences of Good Intentions [394]
Edgar H Adams. (United States)

118 Abstract Withdrawn by Author [395]

119 Patterns of Reported Exposures to Cough and Cold Medications among Children Following the Release of an FDA Public Health Advisory [396]
Alvin F Chu, Zdravko P Vassilev, Steven M Marcus, Bruce Ruck. (United States)
Poster Session B: Tuesday, Aug. 18

120 Methodological and Regulatory Challenges in the Assessment of Long-Term Drug Safety [397]
Marie L De Bruin, Ingemar Persson, Sebastian Schneeweiss, Tjerd P van Staa, Hubert GM Leufkens. (Netherlands)

121 The Role of Epidemiology in New Drug Development [398]
Jeff J Guo, Christina ML Kelton. (United States)

122 Social Cost of Adherence to Philippine Generics Prescribing (PGP) [399]
Hilton Y Lam, Godofreda V Dalmacion, Noel R Juban, Nina C Carandang, Carlo A Panelo. (Philippines)

123 The Financially Tolerable Dose: A New Concept in Cancer Trial Design [400]
Sallie-Anne Pearson, Melvin Chin, Robyn Ward. (Australia)

124 Post Marketing Surveillance: What Is the Potential for Harm When Use Is Not Consistent with the Trial Population in People Receiving Cholinesterase Inhibitors for Treatment of Alzheimer’s Dementia? [401]
Ann Leverton, Debra S Rowett, Maxine Robinson, V Mabbott. (Australia)

125 Differential Effects of Drug Cost Sharing Policies on Adherence to Angiotensin Blockers in Patients with and without Heart Failure [402]
Soko Setoguchi, Amanda R Patrick, Colin Dormuth, Malcolm Maclure, Canning F Claire, Robert J Glynn, Sebastian Schneeweiss. (United States)

126 Survey on Specific Regulations and Requirements for Risk Management Plans in Countries outside the EU and the US [403]
Patrice Verpillet, Sandrine Valiere, Christine Dutar, Laurent Auclert. (France)

127 Impact of Modified-Release Versus Other Opioid Formulations on Health Outcomes during Episodes of Opioid Treatment in Patients with Alcohol-Related Disorders [404]
J David Haddox, Liisa Palmer. (United States)

128 Development of a Regulatory Post-Marketing Studies Database [405]
Martine Caron, Julie Mouchet, Marie-Pierre Emery, Juliette Longin, William C Maier. (France)

129 Atomoxetine (ATO) Use and Central Nervous System Stimulants (CNSS) Use during Physician-Office Visit for Attention Deficit/Hyperactivity Disorders (ADHD) after the Discussion on ATO Related Suicidal Risk [406]
C-Y Chen, AG Winterstein. (United States)

130 Projected Exposure to Drugs on FDA’s Watch List [407]
Suellen Curkendall, Leigh Hansen, Stella Chang, Tami L Mark. (United States)

131 Thiazolidinediones and Bone Loss: A Systematic Review [408]
Gaurav Deshpande, Sheila Weiss-Smith. (United States)

132 Evaluation of Current Risk Evaluation and Mitigation Strategies [409]
Alicia Gilsenan, Elizabeth B Andrews, Brian Calingaert, Debra Crozier, Abenah Vanderpuije. (United States)

133 Overview and Comparison of Post-Marketing Drug Safety Surveillance in Developing Countries and Other Well Developed Regions [410]
Sampada S Vaidya, Jeff J Guo, Pamela C Heaton, Michael Steinbuck. (United States)

134 Feasibility Study: Linkage of Prescribing and Dispensing Data To Generate Non-Adherence Alerts to Practitioners’ Computer Systems [411]
Jeff Harrison, Ramy Burjony, Khalid Ghanima, Sara Higgins, Ziyen Lam, Sam Pang. (New Zealand)

135 Medical Practices’ Awareness and Perceptions of the UMWA Health and Retirement Funds MineRx Program [412]
Eric P Jack, MP Powell, Jeroan J Allison, Kenneth G Saag, Norman W Weissman. (United States)

136 Implications of the Withdrawal of Exubera on the Exubera Large Simple Trial (Volume) [413]
Nicolle M Gatto, Francesca M Kolitsopoulos. (United States)

137 Patient Counseling Efforts in U.S. Community Pharmacies: Associations to Pharmacy and Personnel Attributes [414]
Stephan Linden, Carole Kimberlin, Almut G Winterstein. (United States)

138 Estimating the Magnitude of Increased False Risks Due to Stimulated Adverse Event Awareness [415]
T Christopher Mast, Nancy Santanello. (United States)

139 Changes in Topical Calcineurin Use Following Regulatory Actions in the US [416]
David Moeny, Lois La Grenade, Allen Brinker. (United States)

140 A Decade of Dear Doctor Letters. A Systematic Review [417]
Peter Mol, Sabine Straus, Jonie de Vries, Menno van der Elst, Fakhredin Tabatabaei, Pieter de Graeff, Flora Haaijer-Ruskamp. (Netherlands)

141 Metabolic Risk Mitigation in Children Receiving Antipsychotics [418]
Elaine H Morrato, Ginger Nicol, Benjamin Druss, Daniel M Hartung, Robert J Valuck, Richard Allen, Elizabeth Campagna, John W Newcomer. (United States)

142 Low Birth Weight Paradox in Districto Federal (DF), Brazil, 2005 [419]
Aline Silva, Larissa Naves, Elisa Araujo, Elisabete Duarte. (Brazil)

143 Emergency Department Visits Associated with Nonmedical Use of Hydrocodone/Acetaminophen: 2004-2007 [420]
Meredith Y Smith, Andrea Best, Rita Jain. (United States)
### Use of Linked Databases

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>144</td>
<td>Usefulness of Consumer Medication Information (CMI) [421]</td>
<td>Almut G Winterstein, Stephan Linden, Erica Fernandez, Abigail Lee, Carole Kimberlin</td>
<td>United States</td>
</tr>
<tr>
<td>145</td>
<td>Assessment of Data Quality in Health Care Databases [422]</td>
<td>Piotr Jusczak, Tim Williams, Tjeerd van Staa</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>146</td>
<td>Combining Data from Healthcare Databases in Europe: A Study of Dopamine Agonists [423]</td>
<td>Cynthia de Luise, Gianluca Trifirò, Ron Herings, Jeanne Dieleman, Eva van Soest, Katia Verhamme, Giampiero Mazzaglia, Miriam Sturkenboom</td>
<td>United States</td>
</tr>
<tr>
<td>148</td>
<td>An Audit of Completeness of Recording over Time of Key Variables in THIN – A UK General Practice Database [425]</td>
<td>Alison Bourke, Mary Thompson, Fiona Hill</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>149</td>
<td>The Use of Prescribed Medications among Residents of Quebec Covered by a Private Drug Insurance Plan: Results from the reMed Pilot Study [426]</td>
<td>Marie-Christyne Cyr, Lucie Blais, Marie-France Beauchesne, Lyne Lalonde, Jocelyne Moisan, Sylvie Perreault, Elham Rahme</td>
<td>Canada</td>
</tr>
<tr>
<td>150</td>
<td>Innovative Data Tools and Techniques That Combine Claims and EMR-Based Data Sources [428]</td>
<td>Vik Kherterpal, Stella Chang, Stacey Long</td>
<td>United States</td>
</tr>
<tr>
<td>151</td>
<td>Are the Prescription Claims Data Reliable Despite the Over-the-Counter Drug Usage in Dealing with Misclassification Bias? [429]</td>
<td>Hwa J Kim, Moo-song Lee, Seolyoung Kil, Hong-ji Song, Byoung-joo Park</td>
<td>Republic of Korea</td>
</tr>
</tbody>
</table>

---

**THE DEGGE GROUP, LTD.**

*Drug Safety Research and Information*

- Risk Management
- Program Evaluation
- Registries (Drug, Disease, AE)
- Natural History of Disease
- Phase IV Studies
- CRO Oversight
- Scientific Advisory Panel
- adjudication panel management

Stop by our Booth to find out how we may help you, or visit our website: [www.deggegroup.com](http://www.deggegroup.com)

We are proud to announce the re-launch of DGI, Inc.'s
**B.R.I.D.G.E. TO DATA**

Your connection to healthcare databases worldwide

www.bridgetodata.org
| Poster Session B: Tuesday, Aug. 18 |

| 152 | Assessing the Feasibility of Applying a Validated ICD-9-CM Coding Algorithm To Identify Hypoglycemic Events in Hospitalized Pediatric Patients with Diabetes [430]  
Zhiwen Liu, Cynthia J Girman. (United States) |
| 153 | The Workplace Burden of Smoking in the United States [431]  
Tami L Mark, Zhun Cao, Stephen Johnston. (United States) |
| 154 | Outpatient Continuation of Inpatient Antipsychotic Prescriptions: A Linked Data Analysis [432]  
Tami L Mark, Stella Chang. (United States) |
Marie Lou G Munson, Vivek Saharan. (United States) |
| 156 | COPD Classification Based on Medical Codes and Spirometry — A Comparison [434]  
Robert Y Suruki, Hana Muellerova, Richard Baxter, Kourtney J Davis. (United States) |
| 157 | Availability of Spirometry Records in Patients with COPD in the General Practice Research Database [435]  
Robert Y Suruki, Hana Muellerova, Richard Baxter, Kourtney J Davis. (United States) |
| 158 | Predictive Value of Coding of Diagnoses in the Charlson Comorbidity Index in the Danish National Registry of Patients [436]  
Sandra K Thygesen, Christian F Christiansen, Timothy L Lash, Steffen Christensen, Henrik T Sorensen. (Denmark) |
| 159 | New Opportunities for Drug Outcomes Research in Cancer Patients: The Linkage of the Eindhoven Cancer Registry and the PHARMO Network [437]  
Myrthe PP van Herk-Sukel, Lonneke V van de Poll-Franse, Valery EPP Lemmens, Gerard Vreugdenhil, Johannes FM Pruijt, Jan Willem W Coebergh, Ron MC Herings. (Netherlands) |

**End Session B**
Poster Session C: Wednesday, Aug. 19
8:30am–2:00pm

Analgesics/Anti-Inflammatory Agents

1 Survival Analysis of Australian Veterans using COX-2 Selective or Non-Selective NSAIDs [474]
   Stephen J Kerr, Geoffrey P Sayer, Susan D Whicker, Debra S Rowett, Andrea Mant. (Australia)

2 Analgesic/Antipyretic Use of Children and Adolescents in Germany – Results of the KiGGS-Study [475]
   Hildtraud C Knopf, Yong Du. (Germany)

3 The SOS Project: Cardiovascular and Gastrointestinal Safety of NSAIDs. Preliminary Results of a Systematic Review of Epidemiological Studies [476]
   Nuria Riera-Guardia, Ceri Hirst, Jordi Castellsague, Cristina Varas-Lorenzo, Antonio Pariente, Miriam CJM Sturkenboom, Susana Perez-Gutthann. (Spain)

4 The SOS Project (Safety of NSAIDs): Preliminary Results of Published Meta-Analyses Review [477]
   Francesco Salvo, Antoine Pariente, Sinem E Gulmez, Yannick Guillaume, Castellsague Jordi, Miriam C Sturkenboom, Mendel Haag, Nicholas Moore, Annie Fourrier-Reglat. (France)

5 Dose Variations in NSAID Prescriptions for Children – An Analysis of Electronic Patient Records [478]
   Kristina Star, Andrew Bate, Ola Caster, Ralph Edwards. (Sweden)

Analysis Methods

6 Validation of Claims Databases for the Ascertainment of Adverse Events: From Descriptive to Predictive Methodologies [479]
   Claire N Abou Chakra, Yola Moride, Brain Greenfield, Larry Lynd, Colleen Metge, Marie Tournier. (Canada)

7 Spontaneous Report Safety Signals Profile and Comparative Bayesian Analysis of ADHD Medication in Children in the UK [480]
   Raphaëlle Beau, Ian Douglas, Liam Smyth, Stephen JW Evans. (United Kingdom)

8 The Pattern of Risk of Myocardial Infarction in Patients Taking Asthma Medication: A Study with the UK General Practice Research Database (GPRD) [481]
   Bill Zhang, Frank de Vries, Efrosini Setakis, Tjeerd-Pieter van Staa. (United Kingdom)

9 Medical Record Abstraction To Supplement Covariate Data in Health Insurance Claims: The Case of Diabetes and Acute Pancreatitis (AP) [482]
   David D Dore, Saadia Chaudhry, Sherry G Quinn, John D Seeger. (United States)

10 Length of Follow-up Periods in Safety Studies Can Affect Findings [483]
    Xiaoming Li, Ivan SF Chan, Bruce H Fireman, Lawrence A Gould, Eric Maiese, Roger Baxter, Patricia Saddler. (United States)

11 Implications of Censoring in Studies of Medication Adherence [484]
   Amanda R Patrick, M Alan Brookhart. (United States)

12 Effects of Different Groupings of Drug Adverse Events in the Detection of Signals Using Bayesian Analyses [485]
   David Prieto-Merino, Stephen JW Evans. (United Kingdom)

13 Dealing with Unmeasured Confounding Using Instrumental Variables [486]
   George Quarfey, Loic Yengo, Liping Huang, John Weil. (United Kingdom)

14 Data Mining on Electronic Health Record Databases for Signal Detection in Pharmacovigilance: Which Events To Monitor? [487]
   Gianluca Trifirò, Antoine Pariente, Preciosa M Coloma, Jan A Kors, Giovanni Polimeni, Ghada Miremont-Salamé, Maria Antonietta Catania, Francesco Salvo, Anaelle David, Nicholas Moore, Achille P Caputi, Miriam Sturkenboom, Mariam Molokhia, Julia Hippisley Cox, Carlos Diaz, Johan van der Lei, Annie Fourrier-Reglat. (Netherlands)

15 The Risk of Hospitalization or Emergency Care Following Outpatient Treatment of Community-Acquired Pneumonia (CAP) with Levofloxacin Versus Moxifloxacin [488]
   James E Signorovitch, Anna Gu, Anirban Sengupta, Monika Raut, Samir H Mody, Richard Grant, Jeff Schein, Alan C Fisher, Daniel Ng, Mei Sheng Duh. (United States)

16 Effectiveness of Linezolid among a National Cohort of Patients Infected with Methicillin-Resistant Staphylococcus aureus (MRSA) [489]
   Aisling R Caffrey, Brian J Quilliam, Kerry L LaPlante. (United States)

17 Daily Practice of Oral Antibiotic Therapy: Problems in at Least 30% of the Children [490]
   Josta de Jong, Mirthe L Niehoff, Tjalling W de Vries, Lolkje TW deJong-van den Berg. (Netherlands)

18 Antibiotic Usage, Dosage and Course Length in Children between 0 and 4 Years [491]
   Josta de Jong, Paul B van den Berg, Sipke T Visser, Tjalling W de Vries, Lolkje TW de Jong-van den Berg. (Netherlands)

19 Evolution of Hospital Prescriptions of Antibiotics Dispensed in Community Pharmacies in 2006-2007 in France [492]
   Adeline Gallini, Maryse Lapeyre-Mestre, Florence Taboulet. (France)

20 Differences in Pharmacotherapy Adherence on Weekends Versus Weekdays [493]
   Marcus Bachhuber, Warren B Bilker, Hao Wang, Robert Gross. (United States)

21 Misuse of Antibiotics among Non-Prescription Dispensing [494]
   Rajesh Kumar. (India)

22 An Updated Cohort Study on the Risk of Cholestatic Liver Disease and Flucloxacillin Using Data from the UK General Practice Research Database [495]
   Lin Li, Hershel Jick, Susan S Jick. (United States)
23 Comparison of Fluoroquinolone and Macrolide Resistance in Campylobacter from Retail Chicken Meat in Pennsylvania with National Data [496]
Nkuchia M Mikanatha, Sonya Bodeis-Jones, Ebbing Lautenbach, Shaohua Zhao, Jason P Folster, Felicita M Medalla, A Russell Localio, Anthony T Russo, Stanley Reynolds, Patrick F McDermott. (United States)

24 Differences in Risk of ST Segment Elevation Myocardial Infarction (STEMI) or Non STEMI Associated with NSAIDs Use. A Study with the PGRx Database [497]
Lamiae Bensouda-Grimaldi, Michel Rossignol, Nicolas Danchin, Jean Da longeville, Gabriel Ph Steg, Sandra Da Cruz, Benoit David, Lucien Abenhaim. (France, Metropolitan)

Jennifer B Christian, Nancy E Bourgeois. (United States)

26 Risk of Thromboembolic Events among Persons with Chronic Idiopathic Thrombocytopaenia Purpura [499]
Cheryl Enger, Dimitri Bennett, Ulla Forssen, Andrew T McAfee. (United States)

27 Abstract Withdrawn by Author [500]

28 First-Listed Diagnostic Codes Functioned Well To Identify Hospitalization and Emergency Department Treatment for Outpatient-Originating Sudden Cardiac Death and Ventricular Arrhythmia in Medicaid and Medicare Data [501]
Sean Hennessy, Charles E Leonard, Cristin M Palumbo, Rajat Deo, Craig Newcomb, Stephen E Kimmel, Warren B Bilker. (United States)

29 Antidepressants and the Risk of Emergency Department or Inpatient Admission for Sudden Cardiac Death and Ventricular Arrhythmia [502]
Sean Hennessy, Charles E Leonard, Craig Newcomb, Stephen E Kimmel, Warren B Bilker. (United States)

30 Atomoxetine and Cerebrovascular Outcomes in Adults [503]
Crystal N Holick, Bruce R Tumbull, Meghan E Jones, Saadia Chaudhry, Mark E Bangs, John D Seeger. (United States)

31 Risk of Valvular Heart Disease in Patients Treated with Dopamine Agonists in Japan: A Study Using Spontaneous Reports [504]
Kiyoshi Kubota, Hikaru Watanabe, Tsugumichi Sato. (Japan)

32 Comorbid Conditions among Patients with Acute Coronary Syndrome [505]
Jamie Laudati, Helen Huang, Shirin Ahmed. (United States)

33 The Relationship between the Length of Oral Anticoagulation and Recurrence of Venous Thromboembolism in Taiwan – A Nationwide Population-Based Study [506]
Cheng-Han Lee, Yea-Huei Kao Yang, Li-Jen Lin, Ching-Lan Cheng. (Taiwan)

34 Atrial Fibrillation in US Veteran Fracture Patients Treated with Bisphosphonates [507]
Jay R McDonald, Cory Pittman, Angelique L Zeringue, Seth A Eisen, Fran Cunningham, Kent Wehmeier, Liron Caplan. (United States)

35 The Secondary Prevention of Hypertensive Patients with Cerebrovascular Diseases [508]
Zulfi T Radjapolova, Aymagul S Djumagulova, Andrew G Polupanov. (Kyrgyzstan)

36 Risks of Mortality and Stroke Associated with Suboptimally Anticoagulated Atrial Fibrillation Patients [509]
Efrosini Setakis, Bill Zhang, Tjard P van Staa. (United Kingdom)

37 Statins and Total (not LDL) Cholesterol Concentration and Outcome of Myocardial Infarction: Results from a Meta-Analysis and Observational Study [510]
Xia Sheng, Li Wei, Michael J Murphy, Thomas M MacDonald. (United Kingdom)

38 Recent Use of Bisphosphonates is Associated with Atrial Fibrillation [512]
Charlotte van Noord, Miriam CJM Sturkenboom, Sabine MJM Straus, Jacqueline CM Witteman, Bruno HC Stricker. (Netherlands)

Anna L Lamberg, Erzsebet Horvath-Puho, Steffen Christensen, Cathy Critchlow, Jon Frysek, Henrik T Sorensen. (Denmark)

40 Validation of Serious Ventricular Arrhythmias in an Administrative Database [514]
Cristina Varas-Lorenzo, Catherine Johannes, Lisa McQuay, Kirk Midkiff, Mary Rose Stang, Daniel Fife. (Spain)

41 Incidence of Vaginitis and Balanitis among Type 2 Diabetes Patients. Experience from the General Practice Research Database (GPRD) [515]
Ishan Hirji, Zhenchao Guo, Susan Andersson, Niklas Hammar, Andres Gomez Caminero. (United States)


43 Deprivation and Prevalence of Risk Factors and Chronic Diseases – Is There a Trend? [517]
Betina T Blak, Yingfen Hsia, Michelle Hards. (United Kingdom)

44 Estimation of the Incidence and Prevalence of Hodgkin’s Disease in the EU Pediatric Population for Pediatric Investigational Plans [518]
Carles Blanch, Katarzyna Sablinska. (Spain)
<table>
<thead>
<tr>
<th>Poster Session C: Wednesday, Aug. 19</th>
</tr>
</thead>
</table>
| **45** Neuronopathic Gaucher Disease: Demographics, Clinical Features in 131 Patients Enrolled in the ICGG Neurological Outcomes Subregistry [519]  
Anna Tylki-Szymanska, Ashok Vellodi, Amal El-Beshlawy, J Alexander Cole, Edwin Kolodny. (United States) |
| **46** Avascular Necrosis in Type 1 Gaucher Disease: Impact of Imiglucerase Therapy, Its Timing and Associated Factors [520]  
Pramod K Mistry, Patrick Deegan, Ashok Vellodi, J Alexander Cole, Michael Yeh, Neal J Weinreb. (United States) |
| **47** A Report from the International Collaborative Gaucher Group (ICGG) Gaucher Registry [521]  
Stephan vom Dahl, J Alexander Cole, Neal J Weinreb. (United States) |
| **48** Incidence, Survival and Initial Treatment in Adults Diagnosed with Glioblastoma 1981-2005 in the US [522]  
Wei Dong, Laura Chu, Asha Das, Meghna K Samant, Michael Taylor. (United States) |
| **49** A Region-Wide Database To Study the Therapeutic Management of Stroke Patients Using Hospital Inpatient Admission Data, Death Certificates and Radiology Reports [523]  
Robert Flynn, Thomas MacDonald, Gordon Murray, Alexander Doney. (United States) |
| **51** Epidemiological & Resource Utilization Trends of HIV/AIDS Patients in Unique Care Model in WNY [525]  
Amy Hayward, Christopher Purdy, Raf Magar, Brian Hargrave, Christopher Voltz. (United States) |
| **52** The Risk of Depression in Patients with Psoriasis [526]  
Shanu K Kurd, Andrea B Troxel, Joel M Gelfand. (United States) |
| **53** Prevalence of Diabetes among Female Breast Cancer Patients: A Systematic Review [527]  
Sonia S Maruti, Nadia Foskett, Noah Jamie Robinson. (United States) |
| **54** Economic Burden of Managing Adverse Drug Reactions in Children in Lagos, Nigeria [528]  
Kazeem A Oshikoya, Idowu O Senbanjo, Olisamedua F Njokanma, Ayodele I Solie. (United States) |

Genentech is a leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. We commit ourselves to high standards of integrity in contributing to the best interests of patients, the medical profession, our employees and our communities, and to seeking significant returns to our stockholders, based on the continual pursuit of scientific and operational excellence. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science.

**Epidemiology**

The Genentech Epidemiology group provides evidence-based epidemiology strategy, expertise and data to optimize Genentech’s therapeutic molecule selection, development, and commercialization. Our activities range from estimating disease incidence and prevalence, describing clinical course of disease and real world treatment practices and providing epidemiological context for adverse events, to collaborating in the design, analysis, and reporting of observational studies and patient registries.

CONTACT INFORMATION - Genentech, Inc. – 1 DNA Way, South San Francisco, CA 94080-4990  
Phone: (650) 225-1000 – www.gene.com
Drug Utilization Studies

55 Psychiatric Comorbidities in New Users of Antiepileptic Medications [529]
   Elisabetta Patorno, Amanda Patrick, Rhonda Bohn, Peter Wahl, Sebastian Schneeweiss. (United States)

56 Epidemiology of Cataract in Europe [530]
   Elena Prokofjeva, Robert Wilke, Eberhart Zrenner. (Germany)

57 Head and Neck Cancer Patients at Increased Risk of Comorbidity Compared to Cancer-Free Controls [531]

58 Epidemiology of Hyponatremia in the US Hospitalized Patients [532]
   Lili Wang, Wanju Dai. (United States)

59 Defining Mild Cognitive Impairment: Disparity of Incidence and Prevalence Estimates with Variable Operationalized Definitions [533]
   Alex Ward, Shannon L Michels, Jesse Cedarbaum, H Michael Arrighi. (United States)

60 Abstract Withdrawn by Author [534]

61 Adherence to the Pentavalent Rotavirus Vaccine Dosing Schedule in the US: 2006-2007 [535]
   Jeanne Loughlin, Florence Wang, El Khoury Antoine, Michael Doherty, T Christopher Mast, John D Seeger. (United States)

62 Unused Drugs in Iceland — Value of and Reasons for Disposal [536]
   Anna Birna Almarsdóttir, Árni Gunnar Ásgeirsson. (Iceland)

63 Analysis of Angiotensin-Converting-Enzyme Inhibitors in the US Medicaid Program from 1991 to 2007 [537]
   Boyang Bian, Jeff J Guo, Christina ML Kelton, Yonghua Jing, Xing Li. (United States)

64 Drug Information from the Pharmaceutical Industry in Primary Health Care Settings and Prescribing of Drugs [538]
   Daniel Carzon, Lena Gustafsson, Anna L Erikkson, Karin Rignér, Susanna M Wallerstedt. (Sweden)

65 New Antifungal Medication Impact on Traditional Agent Utilization and Charges in a Single Healthcare System [539]
   Teresa M Cavanaugh, Jeff J Guo, Jill E Martin-Boone, Kevin Enzscheifer, Michelle Wiest. (United States)

   Helene M Devold, Man Duong, Aage Tverdal, Kari Furu, Haakon E Meyer, Jan A Falch, Anne Johanne Sogaard. (Norway)

67 Patients’ Knowledge about Their Chronic Medication [541]
   Monique M Elseviers, Bart Van Rompaey. (Belgium)

68 Drug Treatment of Urologic Symptoms: Estimating the Magnitude of Unmet Need in the Community [542]
   Susan A Hall, Carol L Link, Jim C Hu, Paul W Eggers, John B McKinlay. (United States)

69 Abstract Withdrawn by Author [543]

70 Factors Associated with Increase of Benzodiazepine Dose in a Cohort of New-Onset Benzodiazepine Use Community-Dwelling Elderly [544]
   Brice Kitto, Patrice Dosquet. (France)

71 Long Term Use of Benzodiazepine in French Elderly: Longitudinal Patterns of Use in New Benzodiazepine Users [545]
   Brice Kitto, Patrice Dosquet. (France)

72 The Effect of Adolescent Smoking on Opioid Use – A Prospective Population Based Cohort Study [546]
   Tomas Log, Svetlana Skurtveit, Ingeborg Hartz, Aage Tverdal, Marte Handal, Kari Furu. (Norway)

73 Use of Antidepressant Drugs in Extrémadura (Spain) 2003-2005 [547]
   Nuria González-Bermejo, Diana González-Bermejo, Javier García del Pozo, Ramona Mateos-Campos. (Spain)

74 Drug Persistence with Cholinesterase Inhibitors for Elderly Patients with Alzheimer’s Disease in Korea [548]
   So-Hyon Ahn, Ye-Jee Kim, Sun-Young Jung, Nam-Kyong Choi, Ju-Young Shin, Byung-Joo Park. (Republic of Korea)

75 Abstract Withdrawn by Author [549]

76 Drug Utilization Patterns in a Community Oncology Electronic Medical Record (EMR) Database in Response to Clinical Trial Evidence and Drug Availability [550]
   Reejs Stephen, Joyce George, Kevin Knopf, Natalie Jones, Matthew Reynolds. (United States)

77 Spatial Variation in Off-Label Quetiapine Use among Alcohol Dependent Patients in the Veteran’s Health Administration [551]
   Shirley Wang, Vincent Mor, David Dore, Robert Swift. (United States)

78 Substantial Differences in Utilization and Expenditures of PPI across Europe [552]
   Brian Godman, Vera Vlahovic-Palecevski, Arash Ghaffarian Samavarchi, Ulf Bergman, Björn Wettermark. (Sweden)

79 Research on Asian Psychotropic Prescription Patterns for Antipsychotics III (REAP-AP3)—Taiwan Results [553]
   Shu-yu Yang, Shih-ku Lin, Lih-chi Chen, Chen-pang Wang, Tzu-ting Chen, Ming-chao Chen, Chi-fa Hung, Chieh-hsin Chang, Chun-chieh Fan, Tung-ping Su, Man-yoon Chong. (Taiwan)
Economics

80 Inpatient Costs Associated with 6 Months of Care Post Acute Rejection Events in Renal Transplant Patients: A Single Center Retrospective Analysis [554]
   Teresa M Cavanaugh, Jill E Martin-Boone, Pamela Heaton, Mark Eckman, Paul Succop, Paul Volek, Gautham Mogilishetty. (United States)

81 Estimation of the Cost of a Half-Day of Hospitalization among Patients with Community Acquired Pneumonia [555]
   Michael Dickson, Chris M Kozma, Daniel B Ng, Monika K Raut, Samir H Mody, Alan Fisher, Jeff Schein. (United States)

Error Prevention/ Patient Safety

82 Nurses and Medication Errors: Factors Contributing to Medication Errors [556]
   Monica GE Bergqvist, Eva Andersén Karlsson, Sara Eklöf, Johanna Ulfvarson. (Sweden)

83 Using Electronic Medical Records To Study the Safety of Psychiatric Medications Used in Pediatric Patients [557]
   Cynthia de Luise, John S March, Kenneth R Gersing, Guy Cohen, Carolyn Sikes. (United States)

84 Preventable Fatal Adverse Drug Reactions and Drug Intoxications in a Swedish Population [558]
   Katja ME Hakkarainen, Anna K Jönsson, Olav Spigset, Henrik Druid, Anne Hiselius, Staffan Hägg. (Sweden)

85 Self-Reported Knowledge of Prescription Cardiovascular Medications among Older Adults in the US [559]
   Katherine E Kelley, Judith P Kelly, David W Kaufman, Lynn Rosenberg, Allen A Mitchell. (United States)

86 Pharmacists’ Intervention in Oncology Ward: A Study from Nepal [560]
   Saval Khanal, Arjun Poudel, Krishna Sharan, Subish Palaian. (Nepal)

87 Assessment of Cardiovascular (CV) Comorbidity in Patients with Overactive Bladder (OAB) [561]
   JaeWhan Kim, Carl Asche, Kristijan Kahler, Amit Kulkarni, Karl-Eric Andersson. (United States)

88 How Drug-Drug Interactions Related to Serotonin Reuptake Inhibitors Affect Drug Dispensing: A Population-Based Study [562]
   Buster Mannheimer, Björn Wettermark, Michael Lundberg, Hans Pettersson, Christer von Bahr, Erik Eliasson. (Sweden)

89 Drug-Drug Interactions among Elderly Patients with Diabetes [563]
   Arpit Misra, Leigh G Hansen, Stella Chang. (United States)

90 Comparing Methods To Identify Patients at Risk of Medication Related Harm [564]
   Jasperien van Doormaal, Mirjam Rommers, Jos Kosterink, Irene Tsee-Tei-Tsui, Flora Haaijer-Ruskamp, Peter Mol. (Netherlands)

91 The ASPOC Project in Orthopedics Surgery: Preliminary Results from 3 European Countries [565]
   Paraskevi Papaioannidou, Vera Vlahovic-Palcevski, Giuseppina M Benoni, Branko Sestan, Fares Saieh, Laura Cuzzolin, Panagiotis Akritopoulos, George Kapetanos, Giampaolo Velo. (Greece)

92 The ASPOC Project in Obstetrics and Gynecology: Preliminary Results from 5 European Countries [566]
   P Papaioannidou, A Sabo, V Vlahovic-Palcevski, R Benko, G Velo, D Vavilis, B Tatlatzis. (Greece)

93 The ASPOC Project in Neurosurgery: Preliminary Results from 6 European Countries [567]
   P Papaioannidou, K Nanassis, A Sabo, V Vlahovic-Palcevski, MP Stojiljkovic, L Pejakov, O Horvat, GM Benoni, L Cuzzolin, Z Tomic, G Velo. (Greece)

94 Acute Drug Poisoning Attributed to Doctor Shopping among Korea Elderly Patients [568]
   Ju-Young Shin, Nam-Kyong Cho, Sun-Young Jung, Joongyub Lee, Jong-Mi Seong, Ye-Jee Kim, Byung-Joo Park. (Republic of Korea)

95 Evaluation of Medication Safety in Medical Inpatients with Three Different Prescription Support Solutions [569]
   Daniela Fritz, Alessandro Ceschi, Ivanka Curkovic, Martin Huber, Marco Eegbring, Gerd A Kullak-Ublick, Stefan Russmann. (Switzerland)

96 Common Types of Medication Errors of Outpatient Service in Pediatric Psychiatry Care [570]
   Samai Sirihongthavorn, Assawin Narkpongphun, Nootjaree Kamduang, Pinyo Isarapongs, Penkarn Kanjanarat. (Thailand)

97 Nicotine Dependence Predicts Problematic Use of Prescribed Opioids. Prospective Population Based Cohort Study [571]
   Svetlana Skurtveit, Kari Furu, Randi Selmer, Marte Handal, Aage Tverdal. (Norway)

98 Abstract Withdrawn by Author [572]

99 Comparison of Potential Determinants of Medication Errors with and without Patient Harm [573]
   Rianne J Zaal, Jasperien E van Doormaal, Bertil W Lenderink, Peter GM Mol, Jos GW Kosterink, Flora M Haaijer-Ruskamp, Patricia MLA van den Bernt. (Netherlands)

100 Data Mining in Monitoring Medical Device Safety: Are We There Yet? [574]
   Baoguang Wang, Yan Bai, Wanju Dai. (United States)

101 Prospective Observational Epidemiologic Study of Maraviroc’s Safety (POEM): Design and Rationale [575]
   Quazi Atather, Srinivas R Valluri, Hernan Valdez, Joseph Massaro. (United States)
102 A Study of Adverse Drug Reactions in an Intensive Care Unit (ICU) of a Major Hospital in India [576]
Vishudha M Kaushal, Pipasha N Biswas. (United Kingdom)

103 Comparison of Patient Information Leaflet (PIL) of CNS Drugs Marketed by Indian Companies with the Original SmPC [577]
Uday Pratap Singh, Pipasha N Biswas. (United Kingdom)

104 Interim Results of a Modified Prescription Event Monitoring Study on Atomoxetine: Reports of Suicide Related Behaviour [578]
M Davies, L Wilton, D Layton, C Fogg, SAW Shakir. (United Kingdom)

105 Differences in Demographics and Cardiovascular Risk Factors in European and US Users of Oral Contraceptives [579]
Juergen C Dinger, Kristina Voigt, Anita Assmann. (Germany)

Elisabet Ekman, Martin Bäckström. (Sweden)

107 Monoclonal Antibody Use and Risk of QT Prolongation: A Disproportionality Analysis of the FDA AERS Database [581]
E Dawn Flick, Victor V Gogolak, Colette F Saccomanno, Andrew Erdman, Pavel Napalkov. (United States)

108 Renal Impairment among Adult ITP Patients: Use of GPRD for Proactive Safety Surveillance [582]
Victor Gastanaga, Chuck Wentworth, Anthony Yeo, Gail Hughes, Steven Cha, Sean Zhao. (United States)

109 Signal Detection using a Global Database of Reports of Suspected Adverse Drug Reactions [583]
Richard Hill, Maria Tengstrand, Jeanette Johansson, Helena Sköld, Monica Plöen. (Sweden)

110 Effects of a One Page ADR Information Letter on the Reporting Rate and the Information Value of ADR Reports [584]
Marie-Louise Johansson, Gertrud Brunlöf, Staffan Hägg, Susanna M Wallerstedt. (Sweden)

111 Analysis of Adverse Drug Reaction Collected by the Electronic Reporting System in a Single Hospital [585]
Hye-Ryun Kang, Ji-Min Cheon, Yong-II Hwang. (Korea)

112 Descriptive Analysis of Progressive Multifocal Leukoencephalopathy (PML) within the FDA Adverse Event Reporting System [586]
Bao-Anh Nguyen-Khoa, Earl L Goehring Jr, Kimberly Alexander, Pavel K Napalkov, Robin L Seitzman, Judith K Jones. (United States)

113 Abstract Withdrawn by Author [587]

114 Use of Selected “Control Events” in Signal Detection Methodology [588]
Nobuhiro Ooba, Kiyoshi Kubota. (Japan)

115 Execution Benchmark Results of Large-Scale Safety Analyses Utilizing Disparate Observational Databases [589]
Stephanie Reisinger, Donald O’Hara, Gregory Powell. (United States)

116 Do Pregnancy Prevention Programs Work in Dutch Female Isotretinoin Users of Reproductive Age? [590]
Martina Teichert, Loes E Visser, Mark Dufour, Bruno HCh Stricker. (Netherlands)

117 Abstract Withdrawn by Author [591]

118 Trends in Long-Acting Beta Agonist Prescription Patterns among Patients with Asthma [592]
Kandace L Amend, Shuhua Su, Kourtney J Davis, John Seeger. (United States)

119 Antibiotic Effectiveness To Prevent New Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Current Medical Practice [593]
P Blin, S Lignot, S Lamarche, R Lasalle, D Guillemot, C Mayaud, M Molimard, N Moore. (France)

120 Long-Acting beta2-Agonists in Adult Asthma and the Pattern of Risk of Death and Severe Asthma Outcomes: A Study with the UK General Practice Research Database (GPRD) [594]
Bill Zhang, Frank de Vries, Efrosini Setakis, Tjeerd-Pieter van Staa. (United Kingdom)

121 The Direct Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Review of the Literature [595]
Edmond L Toy, Kevin F Gallagher, Elizabeth L Stanley, Mei Sheng Duh. (United States)

122 Treatment Patterns and Persistence in Asthma Therapy—A Population Based Study [596]
Joerg Hasford, Julia Uricher, Martin Tauscher, Peter Bramlage, Johann Christian Virchow. (Germany)

123 Patterns of Asthma Medication Use in the First 8 Years of Life [597]
Ellen S Koster, Alet Wyga, Jan AM Raaymakers, Henriette A Smit, Anke-Hilse Mailand-vd Zee. (Netherlands)

124 Asthma and Proactive Risk of Anaphylaxis in a Large Integrated Health Care Delivery System [598]
Carlos Irinbanen, Irina V Tolstykh, Mary K Miller, Mark D Eisner. (United States)

125 SERETIDE and Risk of Incident Non-Vertebral Fractures among COPD Patients in the UK [599]
David P Miller, Kourtney J Davis. (United States)

126 Twelve-Month Persistence of COPD Therapy after Initiation in Patients Aged 50 and Over: Results from an Observational Survey [600]
Laurent Laforest, Cecile Ritleng, Gaëlle Desamerq, Eric Van Ganse. (France)
Use of Indicators

<table>
<thead>
<tr>
<th>Use of Indicators</th>
<th>Quality of Life, Patient’s Perceptions</th>
<th>Improvements in Quality of Life</th>
</tr>
</thead>
<tbody>
<tr>
<td>127</td>
<td><strong>Functional Status in Patients with Psoriatic Arthritis Receiving Anti-TNF Therapies: Analysis of the BSR Biologics Register (BSRBR)</strong> [601] Amr A Saad, Darren M Ashcroft, Kath D Watson, Deborah P Symmons, Kimme L Hyrich. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>128</td>
<td><strong>Description of Drug Use According To Interview and Reimbursement Data in Repeated Cross-Sectional Cohort Studies: Data from the Three-City (3C) Study</strong> [602] Pernelle Noize, Fabienne Bazin, Antoine Pariente, Nicholas Moore, Annie Fournier-Réglat. (France)</td>
<td></td>
</tr>
<tr>
<td>129</td>
<td><strong>Life Quality and Quality of Drug Treatment in Elderly Patients</strong> [603] Inger Nordin Olsson, Peter Engfeldt. (Sweden)</td>
<td></td>
</tr>
<tr>
<td>131</td>
<td><strong>Reliability and Validity of the Work Limitations Questionnaire in Patients with Psoriatic Arthritis: Results from ACCLAIM</strong> [605] John S Sampalis, Dafna D Gladman, Marie-Josée Martel, Kathy L Gooch, Robert L Wong, Benoit Guerette. (Canada)</td>
<td></td>
</tr>
<tr>
<td>132</td>
<td><strong>Assessment of the Quality of Life in Women with Venous Disease</strong> [606] Charles Taieb. (France)</td>
<td></td>
</tr>
<tr>
<td>133</td>
<td><strong>Improving the Quality and Efficiency of Drug Prescribing in Primary Care by Means of Financial Incentives</strong> [607] Björn Wettermark, Åke Pehrsson, Maria Juhasz-Haverinen, Aniko Veg, Maria Edler, Gunilla Törnwall-Bergendahl, Henrik Almkvist, Brian Godman, Ulf Bergman. (Sweden)</td>
<td></td>
</tr>
</tbody>
</table>

End Session C
# Abstract Index—Final Program

## Oral

- **Abstract #**
- **Presentation Time**
- **Room**
- **Format**
- **Abstract #**
- **Presentation Time**
- **Room**
- **Format**

### Monday, August 17

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>10:30am</td>
<td>552AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>10:45am</td>
<td>552AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>11:00am</td>
<td>552AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>11:15am</td>
<td>552AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>11:30am</td>
<td>552AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>11:45am</td>
<td>552AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>10:30am</td>
<td>555AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>10:45am</td>
<td>555AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>11:00am</td>
<td>555AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>11:15am</td>
<td>555AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>11:30am</td>
<td>555AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>11:45am</td>
<td>555AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>10:30am</td>
<td>556AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>10:45am</td>
<td>556AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>11:00am</td>
<td>556AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>11:15am</td>
<td>556AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>11:30am</td>
<td>556AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>11:45am</td>
<td>556AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>10:30am</td>
<td>554AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>10:45am</td>
<td>554AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>11:00am</td>
<td>554AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>11:15am</td>
<td>554AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>11:30am</td>
<td>554AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>11:45am</td>
<td>554AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>10:30am</td>
<td>Ballroom B</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>10:45am</td>
<td>Ballroom B</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>11:00am</td>
<td>Ballroom B</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>11:15am</td>
<td>Ballroom B</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>11:30am</td>
<td>Ballroom B</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>11:45am</td>
<td>Ballroom B</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>1:30pm</td>
<td>Ballroom B</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>1:45pm</td>
<td>Ballroom B</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>2:00pm</td>
<td>Ballroom B</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>2:15pm</td>
<td>Ballroom B</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>2:30pm</td>
<td>Ballroom B</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>2:45pm</td>
<td>Ballroom B</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>1:30pm</td>
<td>554AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>1:45pm</td>
<td>554AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>2:00pm</td>
<td>554AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>2:15pm</td>
<td>554AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>2:30pm</td>
<td>554AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>2:45pm</td>
<td>554AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>1:30pm</td>
<td>555AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>1:45pm</td>
<td>555AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>2:00pm</td>
<td>555AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>2:15pm</td>
<td>555AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>2:30pm</td>
<td>555AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>2:45pm</td>
<td>555AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>1:30pm</td>
<td>552AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>1:45pm</td>
<td>552AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>2:00pm</td>
<td>552AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>2:15pm</td>
<td>552AB</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>2:30pm</td>
<td>552AB</td>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

## Poster Session A

### Analysis Methods

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>68</td>
<td>1</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>2</td>
<td>Abstract Withdrawn by Author</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>69.5</td>
<td>3</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>70</td>
<td>4</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>71</td>
<td>5</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>72</td>
<td>6</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>73</td>
<td>7</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>74</td>
<td>8</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>75</td>
<td>9</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>76</td>
<td>10</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>77</td>
<td>11</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>78</td>
<td>12</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>79</td>
<td>13</td>
<td>Abstract Withdrawn by Author</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

### Cancer

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>80</td>
<td>14</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>81</td>
<td>15</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>82</td>
<td>16</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>83</td>
<td>17</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>84</td>
<td>18</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>85</td>
<td>19</td>
<td>Abstract Withdrawn by Author</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>86</td>
<td>20</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>87</td>
<td>21</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>88</td>
<td>22</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>89</td>
<td>23</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>24</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

### CNS/Neurological

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>91</td>
<td>25</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>92</td>
<td>26</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>93</td>
<td>27</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>94</td>
<td>28</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>29</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>30</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>97</td>
<td>31</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>98</td>
<td>32</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>33</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>
# Abstract Index – Final Program

## Monday, August 17 (Cont.)

### Disease Epidemiology/Burden of Illness
- **Abstract # 100**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 101**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 102**
  - Poster
  - **Time:** 8:30am–6:00pm

### Devices
- **Abstract # 103**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 104**
  - Poster
  - **Time:** 8:30am–6:00pm

### Drug Utilization Studies
- **Abstract # 105**
  - Poster
  - **Time:** 8:30am–6:00pm

## Monday, August 17 (Cont.)

### Measurement Methods
- **Abstract # 145**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 147**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 148**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 149**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 150**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 151**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 152**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 153**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 154**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 155**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 156**
  - Poster
  - **Time:** 8:30am–6:00pm

### Medications in Pregnancy/Birth Defects
- **Abstract # 157**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 158**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 159**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 160**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 161**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 162**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 163**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 164**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 165**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 166**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 167**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 168**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 169**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 170**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 171**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 172**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 173**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 174**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 175**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 176**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 177**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 178**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 179**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 180**
  - Poster
  - **Time:** 8:30am–6:00pm

### Pharmacovigilance
- **Abstract # 181**
  - Abstract Withdrown by Author
  - **Time:** 8:30am–6:00pm
- **Abstract # 182**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 183**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 184**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 185**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 186**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 187**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 188**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 189**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 190**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 191**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 192**
  - Poster
  - **Time:** 8:30am–6:00pm
- **Abstract # 193**
  - Poster
  - **Time:** 8:30am–6:00pm

## August 16-19, 2009 Providence, RI
Abstract Index – Final Program

**Monday, August 17 (Cont.)**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>194</td>
<td>126</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>195</td>
<td>127</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>196</td>
<td>128</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>197</td>
<td>129</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>198</td>
<td>130</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>199</td>
<td>131</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>200</td>
<td>132</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>201</td>
<td>133</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Psychotropics**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>202</td>
<td>134</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>203</td>
<td>135</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>204</td>
<td>136</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>205</td>
<td>137</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>206</td>
<td>138</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>207</td>
<td>139</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>208</td>
<td>140</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>209</td>
<td>141</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>210</td>
<td>142</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>211</td>
<td>143</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>212</td>
<td>144</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>213</td>
<td>145</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>214</td>
<td>146</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>215</td>
<td>147</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>216</td>
<td>148</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>217</td>
<td>149</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>218</td>
<td>150</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>219</td>
<td>151</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>220</td>
<td>152</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>221</td>
<td>153</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>222</td>
<td>154</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>223</td>
<td>155</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>224</td>
<td>156</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>225</td>
<td>157</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>226</td>
<td>158</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Tuesday, August 18 (Cont.)**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>240</td>
<td></td>
<td>11:15am</td>
<td>Ballroom B</td>
<td>Oral</td>
</tr>
<tr>
<td>241</td>
<td></td>
<td>11:30am</td>
<td>Ballroom B</td>
<td>Oral</td>
</tr>
<tr>
<td>242</td>
<td></td>
<td>11:45am</td>
<td>Ballroom B</td>
<td>Oral</td>
</tr>
<tr>
<td>243</td>
<td></td>
<td>12:00pm</td>
<td>Ballroom B</td>
<td>Oral</td>
</tr>
<tr>
<td>244</td>
<td></td>
<td>12:15pm</td>
<td>Ballroom B</td>
<td>Oral</td>
</tr>
<tr>
<td>245</td>
<td></td>
<td>11:00am</td>
<td>552A</td>
<td>Oral</td>
</tr>
<tr>
<td>246</td>
<td></td>
<td>11:15am</td>
<td>552A</td>
<td>Oral</td>
</tr>
<tr>
<td>247</td>
<td></td>
<td>11:30am</td>
<td>552A</td>
<td>Oral</td>
</tr>
<tr>
<td>248</td>
<td></td>
<td>11:45am</td>
<td>552A</td>
<td>Oral</td>
</tr>
<tr>
<td>249</td>
<td></td>
<td>12:00pm</td>
<td>552A</td>
<td>Oral</td>
</tr>
<tr>
<td>250</td>
<td></td>
<td>12:15pm</td>
<td>552A</td>
<td>Oral</td>
</tr>
<tr>
<td>251</td>
<td></td>
<td>11:00am</td>
<td>557</td>
<td>Oral</td>
</tr>
<tr>
<td>252</td>
<td></td>
<td>11:15am</td>
<td>557</td>
<td>Oral</td>
</tr>
<tr>
<td>253</td>
<td></td>
<td>11:30am</td>
<td>557</td>
<td>Oral</td>
</tr>
<tr>
<td>254</td>
<td></td>
<td>11:45am</td>
<td>557</td>
<td>Oral</td>
</tr>
<tr>
<td>255</td>
<td></td>
<td>12:00pm</td>
<td>557</td>
<td>Oral</td>
</tr>
<tr>
<td>256</td>
<td></td>
<td>12:15pm</td>
<td>557</td>
<td>Oral</td>
</tr>
<tr>
<td>257</td>
<td></td>
<td>2:00pm</td>
<td>551A</td>
<td>Oral</td>
</tr>
<tr>
<td>258</td>
<td></td>
<td>2:15pm</td>
<td>551A</td>
<td>Oral</td>
</tr>
<tr>
<td>259</td>
<td></td>
<td>2:30pm</td>
<td>551A</td>
<td>Oral</td>
</tr>
<tr>
<td>260</td>
<td></td>
<td>2:45pm</td>
<td>551A</td>
<td>Oral</td>
</tr>
<tr>
<td>261</td>
<td></td>
<td>3:00pm</td>
<td>551A</td>
<td>Oral</td>
</tr>
<tr>
<td>262</td>
<td></td>
<td>2:00pm</td>
<td>Ballroom D</td>
<td>Oral</td>
</tr>
<tr>
<td>263</td>
<td></td>
<td>2:15pm</td>
<td>Ballroom D</td>
<td>Oral</td>
</tr>
<tr>
<td>264</td>
<td></td>
<td>2:30pm</td>
<td>Ballroom D</td>
<td>Oral</td>
</tr>
<tr>
<td>265</td>
<td></td>
<td>2:45pm</td>
<td>Ballroom D</td>
<td>Oral</td>
</tr>
<tr>
<td>266</td>
<td></td>
<td>3:00pm</td>
<td>Ballroom D</td>
<td>Oral</td>
</tr>
<tr>
<td>267</td>
<td></td>
<td>3:15pm</td>
<td>Ballroom D</td>
<td>Oral</td>
</tr>
<tr>
<td>268</td>
<td></td>
<td>2:00pm</td>
<td>Ballroom B</td>
<td>Oral</td>
</tr>
<tr>
<td>269</td>
<td></td>
<td>1:15pm</td>
<td>Ballroom B</td>
<td>Oral</td>
</tr>
<tr>
<td>270</td>
<td></td>
<td>2:30pm</td>
<td>Ballroom B</td>
<td>Oral</td>
</tr>
<tr>
<td>271</td>
<td></td>
<td>2:45pm</td>
<td>Ballroom B</td>
<td>Oral</td>
</tr>
<tr>
<td>272</td>
<td></td>
<td>3:00pm</td>
<td>Ballroom B</td>
<td>Oral</td>
</tr>
<tr>
<td>273</td>
<td></td>
<td>3:15pm</td>
<td>Ballroom B</td>
<td>Oral</td>
</tr>
<tr>
<td>274</td>
<td></td>
<td>2:00pm</td>
<td>551B</td>
<td>Oral</td>
</tr>
<tr>
<td>275</td>
<td></td>
<td>2:15pm</td>
<td>551B</td>
<td>Oral</td>
</tr>
<tr>
<td>276</td>
<td></td>
<td>2:30pm</td>
<td>551B</td>
<td>Oral</td>
</tr>
<tr>
<td>277</td>
<td></td>
<td>2:45pm</td>
<td>551B</td>
<td>Oral</td>
</tr>
<tr>
<td>278</td>
<td></td>
<td>3:00pm</td>
<td>551B</td>
<td>Oral</td>
</tr>
<tr>
<td>279</td>
<td></td>
<td>3:15pm</td>
<td>551B</td>
<td>Oral</td>
</tr>
<tr>
<td>280</td>
<td></td>
<td>4:00pm</td>
<td>557</td>
<td>Oral</td>
</tr>
<tr>
<td>469</td>
<td></td>
<td>4:00pm</td>
<td>557</td>
<td>Sympos.</td>
</tr>
<tr>
<td>67</td>
<td></td>
<td>4:00pm</td>
<td>552B</td>
<td>Sympos.</td>
</tr>
<tr>
<td>282</td>
<td></td>
<td>4:00pm</td>
<td>552A</td>
<td>Sympos.</td>
</tr>
<tr>
<td>283</td>
<td></td>
<td>4:00pm</td>
<td>Ballroom B</td>
<td>Sympos.</td>
</tr>
<tr>
<td>284</td>
<td></td>
<td>4:00pm</td>
<td>Ballroom D</td>
<td>Sympos.</td>
</tr>
<tr>
<td>286</td>
<td></td>
<td>4:00pm</td>
<td>Ballroom A</td>
<td>Sympos.</td>
</tr>
</tbody>
</table>

**Tuesday, August 18**

<table>
<thead>
<tr>
<th>#</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>608</td>
<td>7:00am</td>
<td>557</td>
<td>Sympos.</td>
</tr>
<tr>
<td>227</td>
<td>11:00am</td>
<td>552B</td>
<td>Oral</td>
</tr>
<tr>
<td>228</td>
<td>11:15am</td>
<td>552B</td>
<td>Oral</td>
</tr>
<tr>
<td>229</td>
<td>11:30am</td>
<td>552B</td>
<td>Oral</td>
</tr>
<tr>
<td>230</td>
<td>11:45am</td>
<td>552B</td>
<td>Oral</td>
</tr>
<tr>
<td>231</td>
<td>12:00pm</td>
<td>552B</td>
<td>Oral</td>
</tr>
<tr>
<td>232</td>
<td>12:15pm</td>
<td>552B</td>
<td>Oral</td>
</tr>
<tr>
<td>233</td>
<td>11:00am</td>
<td>Ballroom D</td>
<td>Oral</td>
</tr>
<tr>
<td>234</td>
<td>11:15am</td>
<td>Ballroom D</td>
<td>Oral</td>
</tr>
<tr>
<td>235</td>
<td>11:30am</td>
<td>Ballroom D</td>
<td>Oral</td>
</tr>
<tr>
<td>236</td>
<td>11:45am</td>
<td>Ballroom D</td>
<td>Oral</td>
</tr>
<tr>
<td>237</td>
<td>12:00pm</td>
<td>Ballroom D</td>
<td>Oral</td>
</tr>
<tr>
<td>238</td>
<td>12:15pm</td>
<td>Ballroom D</td>
<td>Oral</td>
</tr>
<tr>
<td>239</td>
<td>11:00am</td>
<td>Ballroom B</td>
<td>Oral</td>
</tr>
</tbody>
</table>

*Abstract Withdrawn by Author*
<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>287</td>
<td>1</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>288</td>
<td>2</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>289</td>
<td>3</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>290</td>
<td>4</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>291</td>
<td>5</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>292</td>
<td>6</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>293</td>
<td>7</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>294</td>
<td>8</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>295</td>
<td>9</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>296</td>
<td>10</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>297</td>
<td>11</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>298</td>
<td>12</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>299</td>
<td>13</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>300</td>
<td>14</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>301</td>
<td>15</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>302</td>
<td>16</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>303</td>
<td>17</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>304</td>
<td>18</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>305</td>
<td>19</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>306</td>
<td>20</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>307</td>
<td>21</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>308</td>
<td>22</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>309</td>
<td>23</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>310</td>
<td>24</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>311</td>
<td>25</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>312</td>
<td>26</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>313</td>
<td>27</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>314</td>
<td>28</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>315</td>
<td>29</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>316</td>
<td>30</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>317</td>
<td>31</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>318</td>
<td>32</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Drug Utilization Studies**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>319</td>
<td>43</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>320</td>
<td>44</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>321</td>
<td>45</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>322</td>
<td>46</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>323</td>
<td>47</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>324</td>
<td>48</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>325</td>
<td>49</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>326</td>
<td>50</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>327</td>
<td>51</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>328</td>
<td>52</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>329</td>
<td>53</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>330</td>
<td>54</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>331</td>
<td>55</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>332</td>
<td>56</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>333</td>
<td>57</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>334</td>
<td>58</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>335</td>
<td>59</td>
<td>8:30am–6:00pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Tuesday, August 18 (Cont.)**

**Poster Session B**

**Cardiovascular Drugs**

- Abstract 287-298
- Abstract 301-302
- Abstract 303-307
- Abstract 309-310
- Abstract 313-314
- Abstract 316-317
- Abstract 318

**Economics**

- Abstract 336
- Abstract 337-340

**Effectiveness Research**

- Abstract 341-352

**Emerging Epidemics**

- Abstract 353-355

**Endocrine/Diabetes**

- Abstract 357-359

**Gastrointestinal**

- Abstract 360-362
- Abstract 366-367

**Hematological**

- Abstract 368

**Hormones/Reproductive Agents**

- Abstract 370-373

**Molecular Epidemiology/Pharmacogenetics**

- Abstract 374-375
## Pharmacovigilance

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>376</td>
<td>99</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>377</td>
<td>100</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>378</td>
<td>101</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>379</td>
<td>102</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>380</td>
<td>103</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>381</td>
<td>104</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>382</td>
<td>105</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>383</td>
<td>106</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>384</td>
<td>107</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>385</td>
<td>108</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>386</td>
<td>109</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>387</td>
<td>110</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>388</td>
<td>111</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>389</td>
<td>112</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>390</td>
<td>113</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>391</td>
<td>114</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>392</td>
<td>115</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>393</td>
<td>116</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

*Abstract Withdrawn by Author*

## Regulatory Issues/Drug Policy

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>394</td>
<td>117</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>395</td>
<td>118</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>396</td>
<td>119</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>397</td>
<td>120</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>398</td>
<td>121</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>399</td>
<td>122</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>400</td>
<td>123</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>401</td>
<td>124</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>402</td>
<td>125</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

*Abstract Withdrawn by Author*

## Risk Management/Communication

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>403</td>
<td>126</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>404</td>
<td>127</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>405</td>
<td>128</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>406</td>
<td>129</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>407</td>
<td>130</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>408</td>
<td>131</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>409</td>
<td>132</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>410</td>
<td>133</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>411</td>
<td>134</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>412</td>
<td>135</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>413</td>
<td>136</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>414</td>
<td>137</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>415</td>
<td>138</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>416</td>
<td>139</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>417</td>
<td>140</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>418</td>
<td>141</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>419</td>
<td>142</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>420</td>
<td>143</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>421</td>
<td>144</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

## Use of Linked Databases

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>422</td>
<td>145</td>
<td>8:30am–6:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

---

**Tuesday, August 18 (Cont.)**

**Wednesday, August 19**
## Abstract Index – Final Program

### Wednesday, August 19 (Cont.)

#### Poster Session C

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>474</td>
<td>1</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>475</td>
<td>2</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>476</td>
<td>3</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>477</td>
<td>4</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>478</td>
<td>5</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Analysis Methods

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>479</td>
<td>6</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>480</td>
<td>7</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>481</td>
<td>8</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>482</td>
<td>9</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>483</td>
<td>10</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>484</td>
<td>11</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>485</td>
<td>12</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>486</td>
<td>13</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>487</td>
<td>14</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Cardiovascular Disease

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>497</td>
<td>24</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>498</td>
<td>25</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>499</td>
<td>26</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>500</td>
<td>27</td>
<td>Abstract Withdrawn by Author</td>
<td>Poster</td>
<td>Poster</td>
</tr>
<tr>
<td>501</td>
<td>28</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>502</td>
<td>29</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>503</td>
<td>30</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>504</td>
<td>31</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>505</td>
<td>32</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>506</td>
<td>33</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>507</td>
<td>34</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>508</td>
<td>35</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>509</td>
<td>36</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>510</td>
<td>37</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>512</td>
<td>38</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>513</td>
<td>39</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>514</td>
<td>40</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Disease Epidemiology/Burden of Illness

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>515</td>
<td>41</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>516</td>
<td>42</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>517</td>
<td>43</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>518</td>
<td>44</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Drug Utilization Studies

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>536</td>
<td>62</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>537</td>
<td>63</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>538</td>
<td>64</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>539</td>
<td>65</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>540</td>
<td>66</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>541</td>
<td>67</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>542</td>
<td>68</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>543</td>
<td>69</td>
<td>Abstract Withdrawn by Author</td>
<td>Poster</td>
<td>Poster</td>
</tr>
<tr>
<td>544</td>
<td>70</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>545</td>
<td>71</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>546</td>
<td>72</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>547</td>
<td>73</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>548</td>
<td>74</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>549</td>
<td>75</td>
<td>Abstract Withdrawn by Author</td>
<td>Poster</td>
<td>Poster</td>
</tr>
<tr>
<td>550</td>
<td>76</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>551</td>
<td>77</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>552</td>
<td>78</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>553</td>
<td>79</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Economics

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>554</td>
<td>80</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>555</td>
<td>81</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Error Prevention/Patient Safety

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>556</td>
<td>82</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>557</td>
<td>83</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>558</td>
<td>84</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>559</td>
<td>85</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>560</td>
<td>86</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>561</td>
<td>87</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>562</td>
<td>88</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>563</td>
<td>89</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>564</td>
<td>90</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>565</td>
<td>91</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>566</td>
<td>92</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>
### Abstract Index – Final Program

**Wednesday, August 19 (Cont.)**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>567</td>
<td>93</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>568</td>
<td>94</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>569</td>
<td>95</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>570</td>
<td>96</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>571</td>
<td>97</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>572</td>
<td>98</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>573</td>
<td>99</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>574</td>
<td>100</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Pharmacovigilance**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>575</td>
<td>101</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>576</td>
<td>102</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>577</td>
<td>103</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>578</td>
<td>104</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>579</td>
<td>105</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>580</td>
<td>106</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>581</td>
<td>107</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>582</td>
<td>108</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>583</td>
<td>109</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>584</td>
<td>110</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>585</td>
<td>111</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>586</td>
<td>112</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>587</td>
<td>113</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>588</td>
<td>114</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>589</td>
<td>115</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>590</td>
<td>116</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>591</td>
<td>117</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Pulmonary/Respiratory**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>592</td>
<td>118</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>593</td>
<td>119</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>594</td>
<td>120</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>595</td>
<td>121</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>596</td>
<td>122</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>597</td>
<td>123</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>598</td>
<td>124</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>599</td>
<td>125</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>600</td>
<td>126</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Use of Indicators**

*(Quality of Life, Patient's Perceptions)*

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>601</td>
<td>127</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>602</td>
<td>128</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>603</td>
<td>129</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>604</td>
<td>130</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>605</td>
<td>131</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>606</td>
<td>132</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>607</td>
<td>133</td>
<td>8:30am–2:00pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

---

**Advertisers Index**

- Amgen .................. 40
- Celgene ................. 47
- Covance ................ 14
- Degge .................... 55
- Eli Lilly .................. 63
- Genetech ................. 59
- GSK ......................... 56
- Healthcare ............... 49
- i3 Drug Safety ........... 16
- IMS ......................... 43
- Mattson Jack ............. 30
- Outcome ................... 31
- Pfizer ..................... 13
- Phase Forward ............ 53
- PPD ......................... 37
- Registrat•Mapi .......... 25
- Roche ....................... 33
- RTI-HS ..................... 8
- Prosanos ................. 34
- UBC ......................... 27
- Wiley-Blackwell .......... 21